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Summary 
Radiation therapy is a cornerstone in the management of cancer with 
approximately half of all newly diagnosed cancer patients receiving 
radiotherapy at some point in the treatment of their disease. Although the 
irradiation techniques have improved considerably over the years, 
normal tissue toxicity still occurs and varies widely from patient to 
patient. As the number of long-term cancer survivors increases, 
preventing or reducing late side effects has become a priority. The 
development of an in vitro assay capable to predict individual 
radiosensitivity prior to radiotherapy would enable the individualization 
of treatment schemes. As a consequence, radiation induced normal tissue 
toxicity could be minimized. 
Gynecologic cancers account for an important percentage of cancers in 
women worldwide. Most gynecologic malignancies, particularly cervical 
and endometrial cancers, are treated surgically followed by radiotherapy. 
In the framework of the scientific work for this thesis, a patient group 
consisting of women with cervical or endometrial cancer who received 
radiotherapy was followed for late radiation toxicity. 
During the past few decades, several in vitro assays have been developed 
in order to predict normal tissue reactions after radiotherapy. In the first 
part of this thesis, the value of the cytogenetic G2 assay on peripheral 
blood lymphocytes in predicting late clinical radiosensitivity was 
assessed. With this test, the mean number of chromatid breaks per cell 
was found to be significantly higher in patients with late normal tissue 
reactions than in patients without normal tissue reactions. However, the 
G2 assay lacked sensitivity to identify high-risk patients at the individual 
level. This leads to the conclusion that the G2 assay has limited use in the 
clinical screening for individual radiosensitivity. 
Currently, normal tissue radiosensitivity is considered as an inherited 
complex trait dependent on the interaction of multiple genes or gene 
products. As a result, it is assumed that normal tissue reactions could be 
predicted from individual genetic profiles. Because of the importance of 
DNA repair in cell and tissue response to radiation, the association 
x 
between eight single nucleotide polymorphisms (SNPs) in the DNA 
repair genes XRCC1, XRCC3 and OGG1 and the development of late 
radiotherapy reactions was investigated. The selection of these SNPs was 
based on literature data regarding a possible involvement in cancer 
predisposition and radiosensitivity. This study showed that the XRCC3 
IVS5-14 polymorphism is significantly associated with the risk of 
developing late radiation injury. The remaining individual SNPs could 
not be linked to an increased radiation toxicity, but it was shown that 
clinical radiosensitivity is significantly associated with a combination of 
different SNPs in XRCC1 and XRCC3 applying a risk allele analysis. 
In the second part of this thesis, the involvement of three microsatellite 
polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 in 
late clinical radiosensitivity was studied. This study was started because 
of promising results reported in the literature on the association between 
clinical radiosensitivity and rare microsatellites. Although no significant 
association was found between the repeat length at any of the 
microsatellites and the incidence of late radiotherapy complications, the 
possible involvement of small and large XRCC1 repeats in clinical 
radiosensitivity could not be completely ruled out. 
Over the years, it has become clear that normal tissue radiosensitivity is 
not exclusively caused by cell killing, but is the result of multicellular 
interactions between various cell types within a specific tissue or organ. 
The early activation of cytokine cascades after radiation exposure 
strongly affects the normal tissue response, and the profibrotic cytokine 
TGFβ1 plays a crucial role in the development of radiation induced late 
normal tissue reactions. Therefore, in the last part of this thesis, the 
association between six TGFβ1 polymorphisms and the occurrence of late 
normal tissue reactions was investigated. This study showed that the -
1.552delAGG, the -509C>T and the Leu10Pro polymorphisms are tightly 
linked, and that the risk of late radiation toxicity may be modulated by 
these polymorphisms. 
In conclusion, the studies performed for this thesis contribute to the 
ongoing research aiming at the identification of genetic profiles 
associated with normal tissue radiosensitivity. Indications have been 
provided that polymorphisms in the XRCC1 and XRCC3 DNA repair 
genes and in the cytokine TGFβ1 may be involved in the development of 
late radiation complications. The fact that similar associations for TGFβ1 
SNPs have also been reported by other independent studies, supports the 
possible involvement of these TGFβ1 SNPs in late radiotherapy toxicity. 
However, to achieve a comprehensive understanding of the genetic basis 
underlying clinical normal tissue radiosensitivity and in order to use 
xi 
genotype data for clinical radiosensitivity screening, large scale 
investigations making use of high-throughput technologies in a 
multicenter setting are required. 
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Samenvatting 
Radiotherapie wordt toegepast bij ongeveer de helft van alle 
kankerpatiënten en vormt bijgevolg één van de belangrijkste 
behandelingsmethoden tegen kanker. Niettegenstaande de 
bestralingstechnieken de laatste jaren veel verbeterd zijn, treedt schade 
aan normale weefsels nog steeds op. Bovendien variëren deze 
stralingsgeïnduceerde complicaties sterk van patiënt tot patiënt. Door de 
stijgende overlevingsgraad van kankerpatiënten is de preventie of 
reductie van late neveneffecten ten gevolge van radiotherapie een 
prioriteit geworden. Met een in vitro test die de individuele 
radiosensitiviteit kan voorspellen vóór de radiotherapiebehandeling, 
zouden de behandelingsschema’s verder kunnen aangepast worden 
zodat stralingsgeïnduceerde toxiciteit aan normale weesfels tot een 
absoluut minimum beperkt wordt. 
Gynaecologische tumoren maken een groot deel uit van het aantal 
kankers in vrouwen over de hele wereld. De meeste van deze 
maligniteiten, in het bijzonder cervix- en endometriumkanker, worden 
operatief behandeld gevolgd door radiotherapie. Voor deze thesis werd 
een patiëntengroep bestaande uit vrouwen behandeld voor cervix- of 
endometriumkanker opgevolgd voor late stralingstoxiciteit. 
De laatste 10-tallen jaren werden verschillende in vitro testen ontwikkeld 
teneinde schade aan normale weefsels ten gevolge van radiotherapie te 
voorspellen. In het eerste deel van deze thesis werd de toepasbaarheid 
nagegaan van de cytogenetische G2 test op perifere bloedlymfocyten als 
biomerker voor late klinische radiosensitiviteit. Er kon aangetoond 
worden dat het gemiddeld aantal chromatidbreuken per cel significant 
hoger is in patiënten met late normale weefselreacties dan in patiënten 
zonder deze reacties. De G2 test miste echter sensitiviteit om individuele 
patiënten met een verhoogd risico te identificeren. Bijgevolg heeft de G2 
test een beperkte bruikbaarheid bij de klinische screening voor 
individuele radiosensitiviteit. 
Momenteel wordt radiosensitiviteit van normale weefsels beschouwd als 
een overerfbare complexe aandoening die bepaald wordt door de 
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interactie tussen verschillende genen of genproducten. Er wordt bijgevolg 
verondersteld dat klinische radiosensitiviteit voorspeld kan worden van 
individuele genetische profielen. DNA herstel is één van de belangrijkste 
mechanismen van cellen en weefsels als respons op straling. Daarom 
werd de associatie bestudeerd tussen acht single nucleotide 
polymorfismen (SNPs) in de DNA herstelgenen XRCC1, XRCC3 en OGG1 
en de ontwikkeling van laattijdige radiotherapiereacties. De selectie van 
deze SNPs was gebaseerd op literatuurdata betreffende de mogelijke 
betrokkenheid van deze SNPs in kankerpredispositie en 
radiosensitiviteit. In dit werk werd aangetoond dat het XRCC3 IVS5-14 
polymorfisme significant geassocieerd is met het risico op de 
ontwikkeling van laattijdige radiotherapiereacties. De overige individuele 
SNPs konden echter niet geassocieerd worden met een verhoogde 
stralingstoxiciteit. Klinische radiosensitiviteit bleek wel significant 
geassocieerd met een combinatie van verschillende SNPs in XRCC1 en 
XRCC3 op basis van een risico-allel analyse. 
In het tweede deel van deze thesis werd de betrokkenheid bestudeerd 
van drie microsatelliet polymorfismen in de DNA herstelgenen XRCC1, 
XRCC3 en XRCC5 bij late klinische radiosensitiviteit. Deze studie werd 
uitgevoerd uitgaande van veelbelovende literatuurdata die wijzen op de 
associatie tussen klinische radiosensitiviteit en zeldzame microsatellieten. 
Hoewel geen significante associatie gevonden werd tussen de lengte van 
één van de microsatellieten en het voorkomen van laattijdige 
radiotherapiereacties, kon de mogelijke betrokkenheid van korte en lange 
XRCC1 herhalingen niet uitgesloten worden. 
De laatste jaren is het duidelijk geworden dat radiosensitiviteit van 
normale weefsels niet enkel veroorzaakt wordt door celdood, maar het 
resultaat is van multicellulaire interacties tussen verscheidene celtypes in 
een specifiek weefsel of orgaan. De vroege activatie van cytokine 
cascades na stralingsblootstelling heeft een grote invloed op de respons 
van normale weefsels. Het profibrotische cytokine TGFβ1 speelt een 
cruciale rol in de ontwikkeling van stralingsgeïnduceerde late 
weefselreacties. Bijgevolg werd in het laatste deel van deze thesis de 
associatie nagegaan tussen zes polymorfismen in TGFβ1 en het 
voorkomen van late toxiciteit van normale weefsels. Deze studie toonde 
aan dat het -1.552delAGG, het -509C>T en het Leu10Pro polymorfisme 
sterk met elkaar geassocieerd zijn, en dat het risico op late 
stralingstoxiciteit gemoduleerd kan worden door deze polymorfismen. 
De studies uitgevoerd in deze thesis hebben bijgedragen tot het lopende 
onderzoek met als doel genetische profielen te identificeren die 
geassocieerd zijn met radiosensitiviteit van normale weefsels. Er werden 
xv 
indicaties gegeven dat polymorfismen in de XRCC1 en XRCC3 DNA 
herstelgenen en in het cytokine TGFβ1 betrokken kunnen zijn in de 
ontwikkeling van late radiotherapiereacties. Gelijkaardige associaties 
voor de TGFβ1 SNPs werden ook reeds gerapporteerd in andere 
onafhankelijke studies. Dit ondersteunt de mogelijke betrokkenheid van 
deze TGFβ1 SNPs in laattijdige radiotherapiereacties. Om tot een volledig 
begrip van de genetische basis van klinische radiosensitiviteit te komen 
en om genetische data aan te wenden in de screening naar klinische 
radiosensitiviteit, zijn echter grootschalige studies noodzakelijk die 
gebruik maken van high-troughput technologieën in een multicenter 
setting. 
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Résumé 
Presque de la moitié des patients atteints de cancer sont traité par 
radiothérapie, montrant que la radiothérapie est un des plus importants 
traitements contre le cancer. Bien que les techniques d’irradiations soient 
améliorées considérablement les dernières années, du dommage aux 
tissus se présente encore. En outre les complications induites par 
l’irradiation varient de patient à patient. Comme le nombre de survivants 
au cancer augmente, la prévention ou la réduction d’effets secondaires 
tardifs à cause de la radiothérapie est devenue une priorité. La mise au 
point d’un test in vitro capable de prévoir la radiosensibilité 
préalablement à la radiothérapie permettrait d’individualiser le schèmes 
de traitement, de telle sorte que la toxicité induite par l’irradiation aux 
tissus normaux est réduite au maximum. 
Les cancers gynécologiques représentent un pourcentage important des 
cancers chez les femmes dans le monde entier. La plupart de ces 
malignités, en particulier les cancers cervicaux et endométriaux, sont 
traités chirurgicalement suivi par la radiothérapie. Pour cette thèse un 
groupe de patients composé de femmes atteintes d’un cancer du cervix 
ou de l’endométre, traitées par radiothérapie a été suivi pour la toxicité 
tardive d’irradiation. 
Au court des dernières décennies, plusieurs testes in vitro ont été mis au 
point à fin de prédire le dommage des tissus à la suite de la radiothérapie. 
Dans la première partie de cette thèse, la pertinence du test cytogénétique 
G2 sur des lymphocytes du sang périphérique, pour prévoir la 
radiosensibilité clinique tardive a été examiné. Ce test a démontré que le 
nombre moyen de cassures chromatides par cellule est significativement 
élevé chez des patients avec des réactions des tissus normaux par rapport 
à ceux sans réactions. Néanmoins, le teste G2 manque de sensibilité pour 
identifier les patients à haut risque au niveau individuel. Par conséquent 
le teste G2 n’a qu’une valeur restreinte en cas de screening clinique pour 
la radiosensibilité individuelle. 
xviii 
Actuellement, la radiosensibilité de tissus normaux est considérée comme 
une affection génétique héritée complexe, dépendant de l’interaction de 
gènes multiples ou de produits de gènes. Ainsi, il est supposé que les 
réactions de tissus normaux pourraient être prédit, se basant sur les 
profils individuels génétiques. Le mécanisme le plus important dans les 
cellules et dans les tissus, qui répond à l’irradiation est la réparation de 
l’ADN. Pour cette raison l’association entre huit single nucleotide 
polymorphismes (SNPs) dans des gènes de réparation de l’ADN XRCC1, 
XRCC3 et OGG1, et l’apparition de réactions tardives de radiothérapie 
ont été examinées. Les SNPs ont été sélectés à base d’information déjà 
publiée concernant leur implication dans la prédisposition au cancer et à 
la radiosensibilité. Cette étude a démontré que le polymorphisme XRCC3 
IVS5-14 est significativement associé avec le risque de développer des 
réactions tardives à l’irradiation. Les autres SNPs individuels ne 
pouvaient pas être mis en rapport avec une radiosensibilité élevée, mais 
la radiosensibilité clinique s’est avérée associée avec une combinaison de 
différents SNPs dans XRCC1 et XRCC3 en appliquant l’analyse d’allèle de 
risque. 
Dans la deuxième partie de cette thèse, l’implication de trois 
polymorphismes microsatellite dans les gènes de réparation d’ADN 
notamment XRCC1, XRCC3 et XRCC5 est examiné. Cette étude a été 
réalisée en raison de résultats prometteurs qui ont été publié concernant 
l’association entre la radiosensibilité clinique et des microsatellites peu 
fréquents. Bien qu’aucune association significative n’ait été trouvée entre 
la longueur de la répétition des microsatellites et l’incidence des 
complications tardives dues à la radiothérapie, l’implication possible de 
répétitions courtes et longues de XRCC1 dans la radiosensibilité clinique 
ne peut pas être complètement exclue. 
Au fil des années, il est apparu clairement que la radiosensibilité de tissus 
normaux n’est pas uniquement causée par la mort cellulaire, mais qu’elle 
est le résultat d’interactions multicellulaires entre différents types de 
cellules dans un tissu en particulier ou un organe. L’activation précoce 
des cascades de cytokines après l’exposition à l’irradiation, influence 
fortement la réaction des tissus normaux. La cytokine profibrotique 
TGFβ1 joue un rôle crucial dans le développement de réactions tardives 
de tissus normaux. Par conséquent, dans la dernière partie de cette thèse, 
l’association entre six polymorphismes de TGFβ1 et la présence de 
réactions tardives de tissus normaux ont été examinées. Cette étude a 
démontré que les polymorphismes -1.552del AGG, -509C>T et Leu10Pro 
sont étroitement liés, et que le risque de toxicité tardive peut être 
modulée par ces polymorphismes. 
xix 
En conclusion, les études réalisées pour cette thèse contribuent à la 
recherche en cours qui tache d’identifier des profiles génétiques liés à la 
radiosensibilité de tissus normaux. Des indications sont fournies que les 
polymorphismes dans les gènes réparateurs XRCC1 et XRCC3 et la 
cytokine TGFβ1 puissent être impliqués dans le développement de 
complications tardive dues à la radiothérapie. Le fait que des associations 
semblables à propos des SNPs TGFβ1 ont été rapportées par d’autres 
études indépendantes, soutient l’implication éventuelle de ces SNPs 
TGFβ1 dans les réactions tardives de tissus normaux. Pour obtenir une 
compréhension complète de la base génétique sous la radiosensibilité 
clinique de tissus normaux et pour appliquer les données génétiques 
dans le dépistage de la radiosensibilité clinique, des études multicentres à 
grande échelle utilisant des technologies à haut débit sont nécessaires.
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Chapter  1  
Introduction 
1.1 The biology of radiotherapy 
Radiation therapy uses ionizing radiation in the treatment of patients 
with malignant diseases. While in the past radiotherapy used  Cobalt-60 
gamma rays, contemporary radiotherapy is based on high-energy X-rays 
and electrons generated by linear accelerators. The aim of radiation 
therapy is to deliver a precisely measured dose of radiation to a defined 
tumor volume with as minimal damage as possible to surrounding 
healthy tissues, resulting in eradication of the tumor, a high quality of life 
and prolongation of survival. 
 
1.1.1 Mechanism of cell killing by ionizing radiation  
Ionizing radiation results in at random excitations and ionizations within 
the material of interaction. Depending on the localization of these 
interactions in the cellular environment, the effect is classified as direct or 
indirect (figure 1.1). The direct effect occurs when radiation deposits its 
energy directly into critical biological molecules (e.g. DNA), resulting in 
ionization of this target. In the indirect effect, the damage to the target is 
caused by reactive species produced by ionizations elsewhere in the cell. 
These indirect effects result mainly from the ionization of water 
molecules, leading to the formation of highly reactive free radicals 
(reactive oxygen species or ROS) which cause most of the damage in the 
cell (1). 
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Figure 1.1. Direct and indirect effects of ionizing radiation on DNA. Modified from 
Vanmarcke et al. (2). 
 
The main biological effect of radiation is a result of damage to DNA, 
which is the principal target of ionizing radiation within the cell. The 
produced lesions include base or sugar damage, DNA single-strand and 
double-strand breaks, DNA-protein crosslinks and DNA-DNA crosslinks. 
These different types of DNA damage can occur separately or together 
and result in complex damaged sites. Base damage and DNA single-
strand breaks are of little consequence to cancer treatment by ionizing 
radiation because cells have evolved efficient error-free DNA repair 
mechanisms to repair this type of damage. However, if the density of 
ionizations (dose) is high enough, two single-strand breaks can be close 
together and result in a double-strand break. Induction of DNA double-
strand breaks is the dominant mechanism of cell killing by ionizing 
radiation. Together with complex damaged sites they are often 
unrepaired or misrepaired, resulting in stable or unstable chromosomal 
aberrations. Unstable chromosome aberrations can result in mitotic cell 
death, whereas stable chromosome aberrations can lead to mutations and 
altered gene expression. Apart from mitotic cell death following DNA 
damage, irradiation can also lead to cell death via apoptosis and necrosis. 
Apoptosis is a process of active cell death resulting from DNA or cell 
membrane damage. The process consists of sequential stages of nuclear 
condensation, fragmentation, phagocytosis and degradation. Necrosis is a 
passive form of cell death and is characterized by an early loss of 
membrane permeability (1,3).                                                                                                             
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1.1.2 Cellular response to ionizing radiation damage 
Radiation induced DNA damage initiates a complex series of cellular 
responses. As shown in figure 1.2, these responses occur after a cascade of 
reactions in which the DNA damage is detected by sensor proteins that 
trigger the activation of transducer proteins which amplify and diversify 
the signal by targeting specific downstream effectors. The outcome of this 
dynamic cascade includes cell cycle control, DNA damage repair, 
apoptosis, and cytokine transcription. Multiple proteins, including 
poly(ADP-ribose)polymerase (PARP), DNA-dependent protein kinases 
(DNA-PKcs) and Ku70/80, are involved in the sensor phase. Ataxia 
telangiectasia mutated gene (ATM), ataxia telangiectasia-related gene 
(ATR) and p53 play a central role in the transducer phase (4,5). Non-DNA 
lesions can also stimulate various signal transduction pathways, as the 
ceramide and the protein kinase C (PKC) pathway, leading to cellular 
responses including apoptosis and altered cytokine transcription (1). 
 
 
Figure 1.2. General cascade of cellular responses to radiation induced DNA damage. 
Modified from Jackson et al. (5). 
 
1.1.2.1 Cell cycle control 
Cell cycle progression is monitored by cell cycle checkpoints which 
represent intracellular signalling pathways leading to cell cycle delay. 
The delay allows cells to initiate an event only when all conditions for 
successful completion of this event are fulfilled. DNA damage can lead to 
activation of cell cycle checkpoints at G1, S and G2 allowing actively 
dividing cells to arrest and repair DNA damage before initiating or 
continuing replication of their genome, or before segregating the 
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replicated genome into daughter cells. Depending on the complexity of 
the DNA damage and on the efficiency of the DNA repair mechanisms, 
cells will either resume cycling or undergo apoptosis (1). Key players in 
DNA damage induced checkpoint responses are ATM, cell cycle 
checkpoint kinase-1/2 (CHK1/2), p53, and cell division cycle-25 (CDC25) 
family proteins (6). 
 
1.1.2.2 Repair of DNA damage 
Cells respond to DNA damage by activating DNA repair mechanisms 
which can be divided in error-free, where the DNA is repaired correctly, 
or error-prone mechanisms, which can result in misrepair. Depending on 
the type of DNA damage, specific pathways are recruited. The five major, 
partly overlapping DNA damage repair pathways are base excision 
repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), 
homologous recombination (HR) and non-homologous end joining 
(NHEJ) (7). 
BER repairs non-bulky lesions such as small chemical base alterations and 
DNA single-strand breaks caused by ionizing radiation or oxidative 
damage. The intact complementary strand is used as template which 
results in a mainly error-free repair. In the case of base damage, BER 
starts with the recruitment of specific DNA glycosylases (e.g. 8-
oxoguanine DNA glycosylase or OGG1), which bind to and release the 
modified base resulting in an apurinic/apyrimidinic (AP) site. An AP site 
can also occur spontaneously by hydrolysis. Bi-functional glycosylases 
further cleave the sugar-phosphate backbone, whereas repair initiated by 
mono-functional glycosylases requires the activity of AP endonucleases 
(e.g. APE1) to incise the sugar-phosphate backbone. In the case of single-
strand breaks, the reaction is initiated by the recruitment of PARP and 
polynucleotide kinase (PNK) to protect and prepare the ends for repair. 
The short-patch pathway is the dominant mode for the remainder of the 
reaction. DNA polymerase-β incorporates a nucleotide and removes the 
abasic residue, ligation is performed by the ligase3/x-ray repair cross-
complementing group 1 (XRCC1) complex. The XRCC1 scaffold protein 
interacts with most of the above BER core components and is therefore 
crucial in protein exchange. A subpathway of BER, the long-patch repair, 
results in the replacement of several nucleotides and is used in the 
presence of modified AP sites which can not be excised by DNA 
polymerase-β. This pathway involves DNA polymerase-β, polymerase-
δ/ε and proliferating cell nuclear antigen (PCNA) for repair synthesis, as 
well as the flap structure-specific endonuclease-1 (FEN1) to remove the 
displaced DNA flap and ligase1 for sealing (7,8,9). Both pathways are 
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illustrated in figure 1.3. No human diseases are currently known to be 
associated with a defect in BER, which may be due to embryonic lethality 
or functional redundancy (8). However, it has recently been suggested 
that ataxia-oculomotor apraxia 1 (AOA1), which is caused by aprataxin 
gene mutations, may be a novel DNA damage response-defective disease 
as aprataxin physically interacts with XRCC1 and as cells deficient in 
aprataxin are defective in DNA single-strand break repair (10). In contrast 
to the BER pathway, which requires a number of proteins, some small 
chemical base alterations such as O-alkylated bases can also be repaired 
by the action of a single protein which directly removes the damage. An 
example is O6-methylguanine which is repaired by O6-methylguanine-
DNA methyltransferase (MGMT) (8). 
 
 
Figure 1.3. Mechanism for base excision repair. Modified from Hoeijmakers et al. (7). 
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NER and MMR are less important to repair DNA damage induced by 
ionizing radiation. NER is able to detect a variety of bulky DNA lesions 
including DNA adducts and cross-links induced by UV light. Two NER 
subpathways exist: global genome NER which surveys the entire genome 
for damage, and transcription-coupled NER which focuses on damage 
that blocks transcription. Both NER mechanisms involve damage 
recognition and assembly of the incision complex, dual DNA incision and 
damage excision, DNA repair synthesis and ligation. More than 25 
proteins, including the XP(A-G) proteins, participate in the NER 
pathway. The human syndrome xeroderma pigmentosum (XP), which is 
characterized by extreme photosensitivity and an increased incidence of 
sunlight-induced skin cancer, is caused by genetic defects in this pathway 
(11). MMR removes nucleotides misrepaired by DNA polymerases and 
insertion/deletion loops that result from slippage during replication of 
repetitive sequences or during recombination. MMR proceeds via 
mismatch recognition, identification of the wrong strand, degradation 
past the mismatch, resynthesis of the excised fragment, and ligation. 
These processes involve multi-member families of the MSH2 and MLH1 
proteins. Defects in the MMR system dramatically increase mutation rates 
and are associated with hereditary non-polyposis colorectal cancer 
(HNPCC) (7). 
DNA double-strand breaks, the dominant type of DNA damage by 
ionizing radiation, can be repaired by HR or NHEJ. HR uses a 
homologous DNA template and is highly accurate, whereas NHEJ rejoins 
the broken ends without using a template, which often results in the loss 
of a few nucleotides. NHEJ is the main pathway to repair double-strand 
breaks in mammals and is more active in the G1 cell cycle phase. HR acts 
mainly during S and G2 phases using the undamaged sister chromatid or 
the homologous chromosome as template (8). The two pathways are well 
described in literature and are presented in figure 1.4. HR starts with 
nucleolytic resection of the double-strand break by the 
MRE11/Rad50/NBS1 complex, forming single-stranded DNA fragments 
which are bound by replication protein A (RPA). Next, a Rad51 
nucleoprotein filament, including Rad51-related proteins XRCC2, XRCC3 
and Rad51B-D, is assembled stimulated by Rad52. The Rad51 filament 
catalyzes, facilitated by Rad54, strand invasion into a homologous DNA 
duplex. Subsequently, the strand is extended by DNA polymerase, the 
ends are ligated by DNA ligase1, and DNA crossovers (Holiday 
junctions) are resolved by resolvases (5,7,8). The NHEJ pathway is 
initiated by binding of the Ku70/Ku80 complex to the free DNA ends, 
followed by recruitment of DNA-PKcs. Double-strand breaks that are not 
suitable for direct ligation may be processed by the MRE11/Rad50/NBS1 
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complex and other nucleases, such as FEN1. In addition, a DNA 
polymerase may be required. Finally, the DNA ends are rejoined by the 
ligase4/XRCC4 complex (5,7). Defective repair of DNA double-strand 
breaks can result in genomic instability or mutations. A number of 
human syndromes, such as ataxia telangiectasia (AT) and Nijmegen 
breakage syndrome (NBS), as well as breast and ovarian cancer caused by 
BCRA1/2 mutations, are associated with defects in the regulation of 
double-strand break repair (8). 
 
 
Figure 1.4. Mechanism of homologous recombination and non-homologous end joining. 
Modified from Hoeijmakers et al. (7). 
 
1.1.2.3 Apoptosis 
Apoptosis or programmed cell death is a precisely regulated, complex 
cascade of molecular events to eliminate individual cells. The process can 
be considered as a protective mechanism of the cell since it removes 
highly damaged cells. The occurrence of radiation induced apoptosis 
depends on the cell type, cell cycle phase, dose rate and dose 
fractionation. The triggers for apoptosis include signals in the nucleus, as 
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well as in the cell membrane, where the ceramide pathway is initiated. 
Apoptosis is regulated by a number of proteins including p53, ATM, c-
myc, B-cell CLL/lymphoma (BCL2) and BCL2-associated X protein 
(BAX), and can be mediated by p53-dependent and p53-independent 
pathways (1,12). 
 
1.1.2.4 Cytokine transcription 
Radiation mediated gene expression also results in the induction and 
release of cytokines and growth factors by many cell types including 
macrophages, epithelial cells and fibroblasts (13). These proteins 
influence the communication between cells and allow a signalling cell to 
transfer and amplify the radiation damage response to other exposed and 
non-exposed cells (14). Examples of radiation induced cytokines are 
tumor necrosis factor-α (TNFα), interleukin-1 (IL1) and IL6. Radiation 
inducible growth factors include transforming growth factor-β (TGFβ) 
and platelet-derived growth factor (PDGF). Cytokines can provoke an 
inflammatory response and contribute, together with growth factors 
which stimulate the expression of extracellular matrix proteins, to the 
pathogenesis of tissue damage (15). 
 
1.1.3 Tissue response to ionizing radiation – adverse radiation 
effects 
The pathological processes of tissue response to radiation start 
immediately after exposure, but the clinical and histological features may 
not become visible for weeks, months or even years after treatment. 
Radiation responses are generally classified as acute, consequential or late 
effects according to the time of appearance of symptoms. Acute (or early) 
effects are observed during treatment or within a few weeks after 
treatment. Consequential effects, or consequential late effects, appear 
later and are caused by persistent acute damage. Late effects emerge 
typically after latency periods of months to years (16). The terms acute 
and late have been used for convenience in radiation therapy, but because 
the underlying molecular and cellular processes are complex and lead to 
a range of events, the definitions may be more operational than 
mechanistic (17). 
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1.1.3.1 Acute effects 
Acute radiation damage is most prominent in tissues with rapidly 
proliferating cells, such as epithelial surfaces of the skin or gastro-
intestinal tract and red bone marrow. Radiation effects occur when 
functional cells are lost as part of normal tissue turnover and are not 
replaced because of damage to the stem cell compartment. Compensatory 
proliferation within the stem cells, followed by replacement of functional 
cells may lead to rapid recovery of the injury (18). Although cell killing is 
a critical part of the etiology of tissue response after radiation, not all 
acute tissue responses can be explained by parenchymal cell death. 
Radiation induced inflammatory responses, vascular injury and wound-
healing processes may be involved in the development of acute radiation 
effects such as skin edema and erythema (19). 
 
1.1.3.2 Late effects 
Late effects tend to occur in tissues with a slow turnover of cells, such as 
subcutaneous tissue, muscle, kidney, and liver, and in sites of slow 
turnover within tissues that contain rapidly proliferating cells, such as the 
wall of the intestine (18). For many years, cell depletion and the long cell 
cycle time of the target cells has been considered to be responsible for late 
radiation injury (20). However, is has become clear that late radiation 
effects are not exclusively caused by parenchymal or vascular cell killing, 
but develop through interactions between multiple cell types within a 
particular organ (21). The radiation induced acute inflammatory response 
is followed by an aberrant chronic inflammatory/wound-healing 
response that develops over months to years and leads, together with cell 
loss, to cellular infiltration of e.g. macrophages and fibroblasts, fibrin 
leakage, collagen deposition and dysregulated cellular interactions 
(figure 1.5) (19,22). 
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Figure 1.5. Scheme of the tissue response after radiation exposure. From Stone et al. (18). 
 
Generally, vascular and parenchymal cell dysfunction and cell loss, 
associated with chronic overproduction of cytokines and growth factors, 
results in fibrosis, necrosis, atrophy and/or vascular damage, depending 
on the involved organ (23,24). The response may be perpetuated by post-
radiation tissue hypoxia, since hypoxia can generate ROS, promote 
inflammation and collagen formation, increase vascular permeability and 
activate profibrotic cytokines (25). The multifunctional cytokine TGFβ 
plays a significant role in late tissue reactions, particularly in fibrosis, via 
the induction and deposition of extracellular matrix proteins (e.g. 
collagen), inhibition of proteases involved in the degradation of the 
extracellular matrix, growth stimulation of fibroblasts and inhibition of 
endothelial cell proliferation. TGFβ is secreted as an inactive latent 
complex and can be activated by radiation and ROS (24,26). 
 
1.1.3.3 Consequential late effects 
Acute reactions which fail to heal completely can persist into the late 
period and add to the overall damage. The resulting chronic lesions are 
termed consequential late effects. Because of the introduction of 
unconventional aggressive treatment regimens with combined 
modalities, consequential late effects are increasingly observed. These 
effects are mainly found in organ systems where the acute response (of 
the epithelial lining) is associated with an impairment of the barrier 
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against mechanical or chemical stress, which may cause additional 
trauma to the underlying tissues. Therefore urinary and intestinal 
systems, mucosa, and skin are most susceptible. One prominent example 
is acute, confluent oral mucositis in head and neck tumour patients, 
which may result in chronic, non-healing ulcers and necrosis (27,28). 
 
1.1.3.4 Treatment related factors 
The risk, severity and type of early, consequential and late tissue 
reactions depend on several factors. Radiation related treatment factors 
include total dose, dose per fraction and treatment schedule. Due to the 
observations that late effects are less severe and better local tumor control 
rates can be achieved with multiple small radiation fractions than with 
one or a few large fractions, fractionated radiotherapy treatments are 
currently being used. Late effects are generally more sensitive to changes 
in fraction size, and less sensitive to changes in overall treatment time 
than early responses (29,30). The use of chemotherapy can intensify the 
reactions (31). The volume of normal tissue receiving high radiation doses 
is also important, with larger volumes carrying higher risk of functional 
damage (32). Additionally, the functional reserve and structural 
organization of normal tissue may determine the tolerance of the tissue. 
For example, the lung is able to tolerate a high dose in a small volume, 
but is less able to tolerate a low dose to the whole lung. On the other 
hand, a high dose to a small volume of the spinal cord can be dangerous, 
whereas a low dose to a large area can be harmless (33). 
 
1.1.3.5 Patient related factors   
Patient related factors in normal tissue response after radiotherapy 
treatment include trauma or surgery in irradiated sites and coexisting 
morbidities such as diabetes or hypertension (34,35). Age and lifestyle 
related factors (e.g. smoking, nutrional status) may also be associated 
factors (36). Studies from intra- and inter-patient variability in radiation 
response indicate the existence of a genetic or physiological factor that 
alters the expression of a specific type of normal tissue reaction after 
radiotherapy, and the probability that this factor is differentially 
expressed in various cells or tissues (37-40). The hypothesis that genetic 
variations are involved in radiosensitivity has found support in the 
observed hyper-radiosensitivity associated with rare genetic syndromes 
such as AT or NBS, which both result from rare, highly penetrant germ-
line mutations in DNA repair genes (41). Despite the fact that these 
disease causing mutations provide the proof of principle for the link 
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between genetic factors and radiosensitivity, they do not seem to be 
responsible for the patient-to-patient variability observed in individuals 
receiving radiotherapy (42-44). Further evidence for a genetic basis of 
radiosensitivity came from the observation that certain strains of mice 
have a greater genetic predisposition to develop radiation reactions (45). 
 
1.1.3.6 The role of the tumor 
Since tumors have the ability to change their surroundings, the presence 
of the tumor may affect normal tissue injury. Tumors physically modify 
normal tissue architecture resulting in defects that can add to damage 
produced by therapy (46,47). Moreover, tumors release proteolytic 
enzymes that facilitate cell invasion and metastasis (48). Tumor vessels 
leak fibrinogen, which is converted to fibrin, resulting in collagen 
deposition and fibrosis (49). Loss of heterozygosity in genes has been 
observed in tissues adjacent to breast and bladder tumors, and in a gene, 
possibly affecting bio-availability of proinflammatory and profibrotic 
cytokines, in tumor cells of lung cancer patients (50,51). 
 
1.1.3.7 Assessing normal tissue responses 
Multiple scoring systems have been developed for the grading of adverse 
effects after cancer treatment. The most widely used systems over the last 
20 years are the Radiation Therapy Oncology Group/European 
Organization for Research and Treatment of Cancer (RTOG/EORTC) 
scoring system for assessing acute and late radiotherapy effects, the Late 
Effects Normal Tissue/Subjective Objective Management Analytical 
(LENT/SOMA) scoring system for evaluating late radiotherapy effects 
and the Common Toxicity Criteria v2.0 (CTCv2.0) scoring system for 
assessing acute radiotherapy and chemotherapy effects (52-54). Recently, 
the Common Terminology Criteria for Adverse Events v3.0 (CTCAEv3.0) 
scoring system was developed from the CTCv2.0 scale and the 
LENT/SOMA scale (55). The merged scoring system includes early and 
late responses, and is applicable to radiotherapy, chemotherapy, surgery, 
other treatment modalities, and combinations of therapies. The scale is 
adequate for all organs and displays grades 1 through 5 with unique 
clinical descriptions of severity for each adverse effect (56). For example, 
radiation associated skin dermatitis is described as faint erythema or dry 
desquamation (grade 1), as moderate erythema, moist desquamation 
mostly confined to skin folds and moderate edema (grade 2), as moist 
desquamation outside skin folds and bleeding induced by minor trauma 
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or abrasion (grade 3), as skin necrosis or ulceration and spontaneous 
bleeding (grade 4) and as death (grade 5). 
 
1.1.4 Tumor response to ionizing radiation 
Tumors are composed of proliferative cells, resting cells, differentiated 
cells and dead or dying cells. The tumor growth rate is determined by the 
cell cycle time, the growth fraction and the rate of cell loss, and can vary 
widely among tumors of the same histological type (57). Radiation 
therapy aims at killing the clonogenic cells leading to tumor cure. The 
response of a tumor to radiation is seen by regression and is determined 
by tumor hypoxia, proportion of clonogenic cells, inherent 
radiosensitivity of tumor cells, and repair of radiation damage. 
Accelerated repopulation and the tumor-bed effect are other important 
processes in tumor radiobiology (58). Cytokine alterations in immune, 
inflammatory and angiogenic regulatory routes within the tumor 
microenvironment may also play a critical role in tumor response to 
radiation therapy (59). 
 
1.1.5 Tumor control probability and normal tissue complication 
probability 
Whereas the probability of killing the last surviving clonogenic cell in a 
tumor is expressed as tumor control probability (TCP), the probability to 
produce damage to normal tissues is defined as normal tissue 
complication probability (NTCP). The relationship between both 
probabilities and dose is threshold-sigmoid (figure 1.6). Above a certain 
threshold, tumor control and complication rates increase steeply. Curves 
for normal tissue complications are less well-defined than tumor control 
curves. However, it is likely that they are steeper than tumor control 
curves, reflecting less heterogeneity in the biology of normal tissues than 
of tumors. Thus, in practice, the TCP curve is always likely to be 
shallower than that for complication and may actually cross it. 
Radiotherapy treatment aims at maximal TCP, which increases with 
increasing dose, but which is restricted by NTCP. The therapeutic ratio of 
the treatment increases with a greater shift of the NTCP to the right. This 
displacement can be achieved by other treatment modalities like surgery 
or chemotherapy, or dose fractionation or dose rate effects (60). 
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Figure 1.6. Dose response curves for tumor control probability and normal tissue 
complications. A, B and C illustrate doses yielding different ratios of tumor control to normal 
tissue complications. From Withers (60). 
 
1.1.6 Dose fractionation 
The total dose in radiotherapy is almost always given as a series of 
fractions, commonly once a day, five days a week. In curative therapy, 
doses of 1.8-2 Gy per fraction are most often used. Each equal dose-
fraction kills the same proportion of cells, resulting in a logarithmic 
decrease in the number of surviving cells. Consequently, small 
differences in survival from each dose-fraction amplify into large 
differences after 25-35 fractions. The biologic basis of dose fractionation 
can be considered in terms of the 4Rs: repair of cellular damage, 
repopulation by surviving viable cells, redistribution within the mitotic 
cycle and reoxygenation in tumors (3,61). 
 
1.1.6.1 Repair  
Repair of sublethal cellular injury following irradiation is completed in a 
few hours and the degree and the rate varies among tissues. In general, 
slowly proliferating tissues are capable of greater repair than highly 
proliferating normal tissues and most malignant tumors. Thus, by using a 
large number of small dose fractions spaced by at least six hours, the 
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greater recovery in late responding normal tissues is exploited. This leads 
to relatively higher survival of cells in those tissues compared to tumor 
cells, and an exponential increase in therapeutic differential. 
 
1.1.6.2 Repopulation  
Following irradiation of normal and malignant tissues, dead cells are 
replaced by recruitment of resting cells into the cell cycle. This is a rapid 
process in highly proliferative normal tissues and in malignant tumors. 
As a result, such tissues can tolerate higher doses if treatment duration is 
extended. In both normal tissues and tumors, repopulation is preceded 
by a lag period of varying length during which there is no evidence of 
regeneration. In general, the lag period is shorter and repopulation is 
faster in highly proliferative normal tissues than in tumors. 
Consequently, the therapeutic differential between these tissues and 
tumors is usually enhanced by prolongation of the overall duration of 
radiation therapy. Nevertheless, the enhancement varies with the kinetic 
profile of the tumor and the possibility of accelerated repopulation in 
treated tumors should be taken into consideration. In those cases the 
radiation dose should be delivered in the shortest possible time within 
the limits of acute radiation tolerance. Cells in slowly proliferating 
normal tissues do not repopulate within the time course of radiotherapy 
and are not influenced by a prolonged course of radiotherapy. 
 
1.1.6.3 Redistribution  
The radiation sensitivity of cells varies according to the cell cycle phase 
they are in at the time of radiation exposure. In general, cells are most 
resistant in the S phase and most sensitive in the late G2 and M phases. 
When a proliferative tissue such as a tumor is exposed to small doses, the 
radiosensitive subpopulations are affected more than cells in the 
radioresistant phases of the cell cycle. Fractionation of the radiotherapy 
treatment allows the surviving, relatively radioresistant cells to progress 
towards more radiosensitive cell cycle phases. Highly proliferating 
normal tissues will also undergo the self-sensitizing effect of cell cycle 
redistribution between dose fractions. In contrast, for slowly proliferating 
normal tissues, redistribution has a neutral effect since cells in these 
tissues are static within the relatively radioresistant G0 phase. Radiation 
induced cell cycle delay also influences the process of redistribution. 
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1.1.6.4 Reoxygenation  
As solid tumors grow, their increased demand for nutrients can often not 
be met by their vascular supply. As a result, poorly vascularised tumors 
develop areas of hypoxia and necrosis. Hypoxic cells are known to be 2-3 
times more radioresistant than well oxygenated cells. The oxygen effect 
occurs because oxygen expands the damage by producing free radicals. 
The existence of hypoxia in tumors is a potential cause of treatment 
failure in radiation therapy. If a large single dose is replaced by multiple 
small fractional doses, the influence of hypoxic cells can be reduced or 
eliminated by a process of reoxygenation during the interfraction 
intervals. Reoxygenation of hypoxic cells can occur by recirculation of 
blood through vessels that were temporarily closed, or by reduced 
metabolic activity of sterilized cells. Other possible mechanisms include 
removal of sterilized cells which permits better access to oxygen, and a 
reduction in intercapillary distances allowing oxygen to reach the 
hypoxic cells. Furthermore, reoxygenation of hypoxic tumor cells leads to 
DNA damage resulting in cell death. 
 
1.1.7 Dose rate effect - brachytherapy 
The dose rate at which irradiation is delivered influences the biologic 
response to a given dose. The dose rate effect is most apparent between 6 
Gy/hr and 60 Gy/hr. External beam radiotherapy uses dose rates in the 
range of 60-300 Gy/hr (1-5 Gy/min). As the dose rate is lowered, the time 
to deliver a certain radiation dose increases and biologic processes that 
modify radiation response can take place during irradiation. The same 
processes (repair, repopulation, redistribution, reoxygenation) that apply 
to dose fractionation, are involved in low dose rate continuous 
irradiation. Continuous low dose rate irradiation is particularly applied 
in interstitial or intracavitary radiotherapy (brachytherapy), delivering 
doses at the rate of 0.4 to 2 Gy/h. An additional physical dose effect 
appears after irradiation from an implanted source within a tumor. The 
rapid decline of dose with distance results in a high dose rate and 
subsequently a high degree of cell killing close to the irradiation source, 
and a lower dose rate and less cell killing further away from the 
irradiation source ensuring sparing of surrounding normal tissues. At 
present, the brachytherapy dose is often delivered in a series of pulses 
(pulsed dose rate) where every pulse delivers approximately 0.5 Gy per 
10-minute exposure every hour (62,63). 
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1.2 Gynecologic cancer 
1.2.1 Overview 
Cancers of the female genital tract account for an important proportion of 
cancers in women. The global cancer statistics from the International 
Agency for Research on Cancer (IARC) indicate that gynecologic cancers 
accounted for 19% of the 5.1 million estimated new cancer cases, 2.9 
million cancer deaths and 13 million 5-year prevalent cancer cases among 
women in the world in 2002. Cervical cancer accounted for 493.000 new 
cases and 273.000 deaths; ovarian cancer1 for 204.000 new cases and 
125.000 deaths; endometrium cancer for 199.000 new cases and 50.000 
deaths; cancers of the vulva, vagina and choriocarcinoma together 
constituted 45.900 cases. More than 80% of the cervical cancer cases 
occurred in developing countries and two-thirds of endometrium cancer 
cases occurred in the developed world (64). 
 
1.2.1.1 Cancer of the cervix 
Cancer of the cervix is the second most common life-threatening cancer in 
women worldwide (65). This cancer is more frequent in women who had 
intercourse at early age, have a history of sexual promiscuity, or had a 
large number of pregnancies. Epidemiological and clinical data indicate 
that human papillomaviruses (HPV), especially HPV-16 and HPV-18, 
play a major role in the etiology of cervical cancer. Other factors, such as 
herpex simplex virus type 2 infections, cigarette smoking, vaginal 
douching, nutrition, and use of oral contraceptives, have been proposed 
as contributing factors. Cervical cytology screening programs have led to 
a reduction in the incidence and mortality in the developed world. 
Prophylactic HPV vaccines protect against persistent infection in fully 
vaccinated women, but are unfortunately not available in the developing 
world (65-67). Different types of treatment are available for patients with 
cervical cancer. These comprise surgery, external beam radiotherapy, 
brachytherapy, chemotherapy or a combination of these treatments. After 
cervical cancer therapy, patients can be treated with replacement 
hormones (66). 
 
                                              
1 Ovarian cancers together with fallopian tube cancers and extraovarian primary peritoneal 
cancers 
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1.2.1.2 Cancer of the ovary 
Ovarian cancer is the most lethal gynecologic malignancy. The high 
mortality can be attributed to the lack of symptoms related to the disease. 
As a result, most cases are diagnosed at an advanced stage. Ovarian 
cancer is a disease of older women, with a peak incidence in the 50- to 70-
year age group. Endocrine, genetic and environmental factors have been 
identified in the carcinogenesis of ovarian cancer. Although the majority 
of ovarian cancer cases are sporadic, family history of the disease is the 
strongest risk factor. The risk is also increased in women with a history of 
breast cancer and in BRCA1/2 mutation carriers. Furthermore, ovarian 
cancer is part of the phenotype of the HNPCC syndrome. The incidence is 
reduced by pregnancy, lactation, the oral contraceptive pill and tubal 
ligation (68-70). Fallopian tube cancer is a very rare female genital tract 
malignancy and is considered along with ovarian cancers because the two 
diseases often have analogous histological, biological and clinical 
characteristics (64). Treatment of ovarian cancer is dependent on clinical 
stage, but most patients will require pelvic clearance and adjuvant 
chemotherapy. For a minority of patients hormonal therapy is a 
therapeutic option (68). 
 
1.2.1.3 Cancer of the endometrium 
Endometrial cancer, cancer of the lining of the uterus, is the most 
common gynecologic malignancy in the developed world. The peak 
incidence occurs in postmenopausal women between 50 to 70 years old. 
Mortality rates for endometrial cancer are relatively low because early-
stage localized disease usually leads to abnormal uterine bleeding 
resulting in early detection. Many of the risk factors for development of 
endometrial cancer have been identified, and most relate to estrogen 
levels. Obesity, hypertension and diabetes also predispose women to 
development of endometrial cancer. A small increase in risk is found in 
women with a family history of endometrial cancer and the malignancy 
can also be part of the HNPCC syndrome (71-73). The basic treatment for 
patients with endometrial cancer is radical surgery, postoperative 
external beam pelvic irradiation and vaginal brachytherapy. A number of 
patients will benefit from additional chemotherapy treatment. Many 
reports have documented that progestational agents are effective in 
selected patients with endometrial cancer (71). 
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1.2.1.4 Cancer of the vulva, vagina and choriocarcinoma 
Cancer of the vulva and the vagina are relatively rare malignancies, 
accounting respectively for approximately 3% and 2% of all primary 
genital cancers. Both are mainly diseases of women beyond the 
menopause. Choriocarcinoma is the rarest genital tract carcinoma 
constituting 0.6% of all gynecologic cancers (64). Epidemiological studies 
have identified sexual factors, particularly HPV infection, as increasing 
risk for vulvar cancer. Smoking also increases the risk by interacting 
synergistically with HPV infection. No apparent cause or associated 
factors that predispose women to vaginal cancer have been found. The 
standard treatment for cancer of the vulva and vagina is radical surgery 
and radiotherapy. Choriocarcinomas are usually treated by surgical 
removal of the tumor and chemotherapy (74,75). 
 
1.2.2 Radiotherapy for gynecologic cancer 
Radiotherapy is essential in the management of gynecologic 
malignancies. It is the definitive treatment modality for locally advanced 
cervical carcinomas, for most cases of vaginal cancer, as an organ-sparing 
approach in locally advanced vulvar cancer, and for inoperable 
endometrial cancer. Radiotherapy is also beneficial as an adjuvant 
treatment after hysterectomy for cervical cancer with high-risk features 
(positive margins, involved parametrium2, positive nodes, deep stromal 
invasion) or for high-risk endometrial cancer (high grade, deep 
myometrial3 invasion). It also prevents relapse of excised vulvar cancer, 
and it improves survival in vulvar cancer patients with more than one 
positive inguinal node. Radiotherapy remains the primary method to 
cure endometrial or cervical cancer that recurs after surgery. It is also 
useful for palliation of local symptoms due to metastatic disease (76). 
 
1.2.2.1 External beam radiotherapy 
External beam radiation can be administered by conventional external 
beam radiotherapy, by three dimensional conformal radiotherapy 
(3DCRT) or by intensity modulated radiotherapy (IMRT). In the past, 
pelvic malignancies were most often treated with conventional external 
                                              
2 The connective tissue of the pelvic floor 
3 The muscular outer layer of the uterus 
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beam radiotherapy. Three dimensional conformal planning has 
contributed in reducing the radiation dose to normal tissues, but the 
treatment of patients with gynecologic malignancies also requires treating 
the regional nodes which still results in a large volume of small bowel 
and rectum being irradiated. In contrast to conventional external beam 
radiotherapy and 3DCRT, where the radiation intensity is generally 
uniform within the radiation field, IMRT can vary the dose intensity 
within a field. Pelvic IMRT can be used to deliver a specified dose to the 
pelvic lymph node, the vaginal vault, and the paracervical and upper 
paravaginal tissue, while reducing the dose and the dose per fraction to 
rectum, bladder, and small bowel. The radiation therapy is typically 
administered 5 days per week for 5-6 weeks up to a total dose of 50 Gy 
via parallel and opposed anterior and posterior portals and lateral fields 
(76,77). 
 
1.2.2.2 Brachytherapy 
Brachytherapy is an important component in the radiation treatment of 
gynecologic malignancies and uses small sealed γ-ray sources to irradiate 
tissues from inside. Intracavitary therapy applies sources which are 
arranged in a suitable applicator to irradiate the walls of a body cavity. 
The most commonly used device is the Fletcher-Suit application created 
by an intra-uterine tandem and vaginal ovoids. Given at low dose rates, 
this type of irradiation takes several days and can be used for many 
anatomic sites, the most common being the uterine cervix. Interstitial 
therapy uses sources which are implanted directly into the diseased 
tissues. The most widely used radionuclide in both techniques is 192Ir. 
While intracavitary brachytherapy is the standard technique, interstitial 
brachytherapy is usually applied for more complicated clinical scenarios. 
Dose specification of intracavitary brachytherapy is based on the location 
of the ureter and the pelvic lymph nodes. The brachytherapy dose 
depends largely on the tumor stage but also on the prescription of the 
department, and is defined in accordance with the whole-pelvis external 
radiation dose and the parametrial dose. Doses ranging from 20 to 35 Gy 
at dose-maximum points are most often used (77,78). 
 
1.2.3 Pelvic normal tissue adverse effects 
The dose that can be administered by radiotherapy is limited by the 
tolerance dose (TD) of the surrounding normal tissues for late effects. 
Tolerance doses are commonly reported as TD5/5, defined as the average 
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dose that causes 5% complication risk within 5 years. The radiation 
tolerance of pelvic organs is considerably variable. The uterus, cervix and 
upper vagina can tolerate very high doses of radiation, while the colon, 
rectum and especially the small intestine are much more susceptible to 
radiation injury. As a consequence, the latter are the dose-limiting organs 
during pelvic and abdominal radiation therapy (77,79). Acute reactions of 
pelvic radiotherapy result from inflammation of the small intestine 
(enteritis), the rectum (proctitis), the bladder (cystitis), the vagina 
(vaginitis) and the skin (dermatitis). The symptoms are abdominal pain, 
diarrhea, increased secretion of mucus, rectal bleeding, dysuria, 
pollakiuria, hematuria, erythema, edema or desquamation. These effects 
are usually reversible and manageable with medical support. The most 
common late rectal effects include increased stool frequency, spotting of 
blood, and partial incontinence. Less common are mucosal ulceration, 
severe bleeding, pain, stricture, severe incontinence, and fistula. Fibrosis 
and ischemia in the submucosa and muscularis are largely responsible for 
these effects, accompanied by telangiectasia and other vascular 
abnormalities, mucosal congestion, collagen deposition and abnormal 
fibroblasts. Late radiation damage to the urinary tract, the vagina and the 
bones include, respectively, hemorrhagic radiocystitis and ureteric 
stricture, vaginal atrophy with telangiectasia and adhesions, and edema, 
pelvic fibrosis and sacrum fracture (osteoradionecrosis). Late effects are 
generally irreversible and progressive (18,76,79-81). Because of large 
differences in applied treatment schedules, length of follow-up and used 
scoring system, late complication rates vary considerably among studies. 
As a consequence, late complication rates of 7-28% have been reported in 
patients treated with radiotherapy for cervix cancer (82). More 
homogeneous studies have indicated that approximately 2-9% of the 
patients develop severe late gastrointestinal toxicity after pelvic external 
beam radiotherapy using total doses of 45-55 Gy with conventional 
fractionations (83,84). 
1.3 Radiosensitivity assays 
For a long time, many research groups have tried to develop an in vitro 
radiosensitivity assay capable of predicting the extent of normal tissue 
damage in radiotherapy patients. Despite limited success, the effort to 
achieve this objective continues because an assay capable of predicting 
susceptibility for the development of adverse radiation effects would 
allow individualization of radiotherapy schemes. It has been estimated 
that personalized radiotherapy protocols could result in a significant 
improvement in the therapeutic index (85,86). Numerous assays have 
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been proposed to predict the outcome after irradiation, but none have 
become established in daily practice. The assays can be grouped in 
cellular radiosensitivity assays and molecular radiosensitivity assays. 
 
1.3.1 Cellular radiosensitivity assays 
Different cell functions, such as cell survival, formation of chromosome 
aberrations and/or micronuclei, DNA repair capacity, and apoptosis are 
affected by individual radiosensitivity. In vitro assays using these 
endpoints have been applied in different test systems to estimate 
individual radiosensitivity (87). 
 
1.3.1.1 Clonogenic assays 
The clonogenic assay has often been employed to measure cell survival 
after in vitro or in vivo irradiation of cells. In this assay, the capacity of 
single cells to multiply and form a colony or clone after irradiation is 
measured. The fraction of colony-forming cells as a function of radiation 
dose is graphically displayed by the cell survival curve and cellular 
radiosensitivity is estimated as the surviving fraction (SF) at a certain 
dose (e.g. at 2 Gy, SF2). The formation of a clone from a single cell 
requires sustained cell division and is the ultimate proof of reproductive 
integrity. Consequently, the colony forming assay measures the end 
result of a combination of several cellular responses to irradiation 
including reproductive cell death, death by apoptosis, accelerated 
differentiation and senescence. Fibroblasts are the most common type of 
cells used in clonogenic assays (88). Early studies with a limited number 
of patients showed a moderate correlation between the in vitro 
radiosensitivity of normal human skin fibroblasts and late radiotherapy 
side effects using the clonogenic assay, but larger scaled studies did not 
find significant correlations between clonogenic in vitro radiosensitivity 
and clinical response (89-94). On the other hand, a relatively large study, 
using an alternative clonogenic assay on lymphocytes, showed a 
significant correlation between lymphocyte radiosensitivity and late 
normal tissue toxicity after radiotherapy (95). 
 
1.3.1.2 Cytogenetic assays 
During the last few years the suitability of cytogenetic assays, such as the 
G2 assay, the dicentrics assay and the micronucleus assay, have been 
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investigated as candidate biomarkers for predicting radiation sensitivity. 
The assays measure the capacity of cells to repair radiation induced 
chromosomal damage. All assays can be applied for any dividing cell 
population, but are most often used to measure the frequency of 
chromatid aberrations, chromosome aberrations or micronuclei in 
stimulated peripheral blood lymphocytes (88). In the G2 assay, 
lymphocytes are irradiated in vitro during the G2 phase of the cell cycle to 
induce DNA damage (typical dose: 0.4 Gy or 0.5 Gy). Subsequently, cells 
are allowed to progress to metaphase where chromatid breaks can be 
observed and scored (96). Figure 1.7 shows an example of a metaphase 
cell comprising chromatid breaks. 
 
 
Figure 1.7. Pictures of a metaphase cell with chromatid breaks. Chromatid breaks are 
indicated by arrows. 
 
The dicentrics assay and the micronucleus assay involve in vitro 
irradiation of lymphocytes during the G0 phase of the cell cycle. In both 
assays, irradiation doses ranging from 2 to 5 Gy are most often used. In 
the dicentrics assay, cells are blocked in metaphase and unstable 
chromosome aberrations, such as dicentric chromosomes and acentric 
fragments, can be detected in metaphase cells. In the micronucleus assay, 
micronuclei, composed of acentric fragments, whole chromosomes and 
complex chromosomal fragments, can be scored in binucleated cells after 
cytokinesis blocking (97). Up to now, only a few studies investigated the 
predictive value of the G2 assay (98,99), and in one of the studies the 
number of chromatid breaks was found to be highly correlative with the 
occurrence of acute skin reactions (98). The usefulness of the 
micronucleus assay in predicting clinical radiosensitivity seems to be 
limited since contradictory results have been obtained in different studies 
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(98,100-103). The dicentrics assay generally showed positive correlations 
between the number of dicentrics and acute and late normal tissue injury 
after radiotherapy treatment (104-106). 
 
1.3.1.3 Assays evaluating the DNA repair capacity 
The comet assay or single-cell gel electrophoresis (SCGE) assay is a rapid 
and sensitive fluorescent microscopic method to examine DNA damage 
and repair in individual cells. The principle of the assay is based upon the 
ability of denatured, cleaved DNA fragments to migrate out of the cell 
under the influence of an electric field, whereas undamaged DNA 
migrates slower and remains within the confines of the nucleus when a 
potential is applied. Evaluation of the DNA ‘comet’ tail content and 
length allows for assessment of DNA damage. By performing the comet 
assay at several time points after in vitro irradiation of cells (typical dose: 
2-5 Gy), the DNA repair kinetics can be analyzed. In the alkaline comet 
assay, cell lysis and electrophoresis is performed under alkaline 
conditions, whereas in the neutral comet assay these steps are done under 
neutral conditions. As a consequence, the alkaline comet assay measures 
the induction and repair of various types of DNA damage (e.g. single- 
and double-strand breaks, alkali labile sites) and can be seen as a test to 
evaluate the ‘global repair phenotype’. On the other hand, the neutral 
comet assay allows to quantify induction and repair of double-strand 
breaks only. The assay can be applied on several cell types of which 
lymphocytes are most applicable (107). Initially, the alkaline comet 
seemed to be a valuable technique for predicting acute clinical 
radiosensitivity (108,109), but larger scaled studies could not support the 
predicting capacities of the assay (110). 
Pulsed field gel electrophoresis (PFGE) is a technique for separating large 
DNA fragments and analyzing induction and repair of DNA double-
strand breaks following irradiation. The test operates by alternating 
electric fields to run DNA through an agarose gel. Quantification of 
double-strand breaks is determined from DNA smears on the gel after 
electrophoresis. The DNA repair kinetics can be investigated by varying 
the post-irradiation time. Fibroblasts are the most common type of cells 
used in PFGE assays and the applied doses range from to 5 Gy up to 150 
Gy (111). In the past, the assay has not been used frequently to predict 
clinical radiosensitivity and although a strong correlation has been found 
between residual DNA damage and late normal tissue response when 
fibroblast were used, this correlation was not found when keratinocytes 
were applied (112,113). Moreover, contradictory results between the 
initial number of DNA double-strand breaks and acute normal tissue 
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reactions have recently been reported in studies applying the PFGE assay 
on lymphocytes (114,115). 
 
1.3.1.4 Assays evaluating apoptosis 
The detection of apoptosis is frequently used as a parameter for radiation 
induced DNA damage. Various techniques are available to detect 
apoptotic cells, e.g. electron microscopy, fluorescence nuclear staining 
with propidium iodide, annexin V labeling, observation of 
oligonucleosomal DNA fragments by DNA laddering in agarose gels (87). 
Doses used to measure apoptosis range from 2 to 8 Gy. Recently, it has 
been shown that an assay of intrinsic radiosensitivity based on apoptosis 
in CD4 and CD8 lymphocytes is able to significantly predict radiation 
induced late toxicity (116). 
 
1.3.2 Molecular radiosensitivity assays 
Since today normal tissue radiosensitivity is considered as a complex trait 
dependent on the interaction of multiple genes or gene products, 
molecular techniques are now also being used to predict normal tissue 
radiosensitivity. The techniques allow the study of relevant target genes 
at the DNA, RNA or protein level. 
 
1.3.2.1 Assays at the DNA level - Radiogenomics 
Radiogenomics is the study of genetic variations in relation to inter-
individual differences in radiotherapy response. Most of the research so 
far has concentrated on single nucleotide polymorphisms (SNPs) in 
candidate genes (24). SNPs represent the most abundant type of sequence 
variation in the human genome and are thought to be the genetic basis for 
most genetic diseases. Currently, more then 9 million SNPs are available 
in the public SNP databases (117,118). A SNP is defined as a single base 
alteration in genomic DNA found in at least 1% of the population. The 
mechanisms by which they affect phenotype and influence complex 
diseases vary according to their genomic location. Substitutions in coding 
regions may affect the amino acid sequence of predicted proteins, 
reducing or abolishing functions like DNA binding, catalytic activity and 
receptor-ligand contact. SNPs may interrupt the initiation or the 
termination codon, or introduce errors in the reading frameshift, all with 
consequences for insufficient or prematurely truncated peptides. SNPs 
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located in regulatory regions may influence gene expression, whereas 
SNPs in non-coding sequences may affect splicing or RNA cleavage, 
stability and export (119). Apart from SNPs, other genetic variations such 
as deletions, insertions and repeats (mini- or microsatellites) can also be 
studied to identify individual genetic profiles which may predict normal 
tissue radiosensitivity. Approaches for detecting DNA variability include 
DNA sequencing, single-strand conformation polymorphism (SSCP) 
analysis, denaturing gradient gel electrophoresis (DGGE), denaturing 
high-performance liquid chromatography (DHPLC), restriction fragment 
length polymorphism (RFLP) analysis, single base extension technique 
(SNapShot®), arrayed primer extension (APEX) technique, and a number 
of high-throughput SNP genotyping platforms such as the TaqMan® SNP 
genotyping assay and the SNPlexTM genotyping system (120,121). Over 
the last few years, several studies have investigated possible associations 
between SNPs in selected candidate genes and the risk of developing 
various normal tissue complications. The results of these studies will be 
handled in the discussion section of this thesis. 
 
1.3.2.2 Assays at the RNA and protein level 
Variations in gene expression at the RNA and protein levels have also 
been evaluated as prognostic factors for complex diseases such as clinical 
radiosensitivity. Techniques to measure RNA expression are in situ 
hybridization, reverse transcription PCR methods and micro-arrays. 
Assays for detecting protein levels include immunohistochemistry, flow 
cytometry, Western blots and various proteomic methods, generally 
using mass spectrometry or antibody arrays (122,123). The transcriptional 
response of normal cells and tissues to radiation has been investigated in 
several studies using cDNA micro-arrays and many genes that could be 
relevant for predicting radiation induced morbidity have been identified 
from these studies (124-128). Studies investigating the utility of protein 
levels in tissues and blood serum as markers for the development of 
adverse radiation reactions also highlighted a number of possibly related 
proteins, of which TGFβ1 seemed to be the most promising (129-134). 
1.4 References 
1. Pouget JP, Mather SJ. General aspects of the cellular response to 
low- and high-LET radiation. Eur J Nucl Med 2001;28:541-561. 
 27
2. Vanmarcke H, Baugnet-Mahieu L, Culot JP et al. Ioniserende 
straling – Effecten van lage dossissen. 1st ed. Mol (Belgium): 
Minon, 1996. 
3. Tobias JS, Thomas PRM. Current radiation oncology. 1st ed. Kent 
(UK): Edward Arnold, 1994. 
4. Bourguignon MH, Gisone PA, Perez MR et al. Genetic and 
epigenetic features in radiation sensitivity. Part I: Cell signaling in 
radiation response. Eur J Nucl Med Mol Imaging 2005;32:229-246. 
5. Jackson SP. Sensing and repairing DNA double-strand breaks. 
Carcinogenesis 2002;23:687-696. 
6. Iliakis G, Wang Y, Guan J et al. DNA damage checkpoint control 
in cells exposed to ionizing radiation. Oncogene 2003;22:5834-
5847. 
7. Hoeijmakers JHJ. Genome maintenance mechanisms for 
preventing cancer. Nature 2001;411;366-374. 
8. Fleck O, Nielsen O. DNA repair. J Cell Science 2004;117:515-517. 
9. Nilsen H, Krokan HE. Base excision repair in a network of 
defence and tolerance. Carcinogenesis 2001;22:987-998. 
10. Dianov GL, Parsons JL. Co-ordination of DNA single strand 
break repair. DNA Repair 2007;6:454-460. 
11. Dip R, Camenisch U, Naegeli H. Mechanisms of DNA damage 
recognition and strand discrimination in human nucleotide 
excision repair. DNA Repair 2004;3:1409-1423.  
12. Cohen-Jonathan E, Bernhard EJ, McKenna WG. How does 
radiation kills cells? Curr Opin Chem Biol 1999;3:77-83. 
13. Dent P, Yacoub A, Contessa J et al. Stress and radiation-induced 
activation of multiple intracellular signaling pathways. Radiat 
Res 2003;159:283-300. 
14. Snyder AR, Morgan WF. Gene expression profiling after 
irradiation: Clues to understand acute and persistent responses? 
Cancer Metastasis Rev 2004;23:259-268. 
 28
15. Hallahan DE. Radiation-mediated gene expression in the 
pathogenesis of the clinical radiation response. Sem Radiat Oncol 
1996;6:250-267. 
16. Johansson S, Svensson H, Denekamp J. Timescale of evolution of 
late radiation injury after postoperative radiotherapy of breast 
cancer patients. Int J Radiat Oncol Biol Phys 2000;48:745-750. 
17. Denham JW, Hauer-Jensen M, Peters LJ. Is it time for a new 
formalism to categorize normal tissue radiation injury? Int J 
Radiat Oncol Biol Phys 2001;50:1105-1106. 
18. Stone HB, Coleman CN, Anscher MS et al. Effects of radiation on 
normal tissue: consequences and mechanisms. Lancet Oncol 
2003;4:529-536. 
19. Denham JW, Hauer-Jensen M. The radiotherapeutic injury - a 
complex wound. Radiother Oncol 2002;63:129-145. 
20. Travis EL. Organizational response of normal tissues to 
irradiation. Sem Radiat Oncol 2001;11:184-196. 
21. Barcellos-Hoff MH. How do tissues respond to damage at the 
cellular level? The role of cytokines in irradiated tissues. Radiat 
Res 1998;150:109-120. 
22. Rubin P, Johnston CJ, Williams JP et al. A perpetual cascade of 
cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat 
Oncol Biol Phys 1995;33:99-109. 
23. Fajardo LF. Morphology of radiation effects on normal tissues. In: 
Perez CA, Brady LW (Eds). Principles and practice of radiation 
oncology. 3rd ed. Philadelphia (NY): Lippincott-Raven,1997:143-
155. 
24. Bentzen SM. Preventing or reducing late side effects of radiation 
therapy: radiobiology meets molecular pathology. Nat Rev 
Cancer 2006;6:702-713. 
25. Vujaskovic Z, Anscher MS, Feng QF et al. Radiation-induced 
hypoxia may perpetuate late normal tissue injury. Int J Radiat 
Oncol Biol Phys 2001;50:851-855. 
26. Martin M, Lefaix JL, Delanian S. TGF-β1 and radiation fibrosis: a 
master switch and a specific therapeutic target? Int J Radiat Oncol 
Biol Phys 2000;47:277-290. 
 29
27. Dörr W, Hendry JH. Consequential late effects in normal tissues. 
Radiother Oncol 2001;61:223-231. 
28. Heemsbergen WD, Peeters STH, Koper PCM, et al. Acute and late 
gastrointestinal toxicity after radiotherapy in prostate cancer 
patients: Consequential late damage. Int J Radiat Oncol Biol Phys 
2006;66:3-10. 
29. Thames HD, Withers HR, Peters LJ et al. Changes in early and late 
radiation responses with altered dose fractionation: implications 
for dose-survival relationships. Int J Radiat Oncol Biol Phys 
1982;8:219-226. 
30. Fowler JF. The first James Kirk memorial lecture. What next in 
fractionated radiotherapy? Br J Can 1984;6 (suppl):285-300. 
31. Rubin P, Constine LS, Williams JP. Late effects of cancer 
treatment: radiation and drug toxicity. In: Perez CA, Brady LW 
(Eds). Principles and practice of radiation oncology. 3rd ed. 
Philadelphia (NY): Lippincott-Raven,1997:155-211. 
32. Hopewell JW, Trott KR. Volume effects in radiobiology as 
applied to radiotherapy. Radiother Oncol 2000;56:283–88. 
33. Withers HR, Taylor JM, Maciejewski B. Treatment volume and 
tissue tolerance. Int J Radiat Oncol Biol Phys 1988;14:751–59. 
34. Chon BH, Loeffler JS. The effect of nonmalignant systemic disease 
on tolerance to radiation therapy. Oncologist 2002;7:136–43. 
35. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor 
for late radiation morbidity. Int J Radiat Oncol Biol Phys 
1999;43:475–79. 
36. Bentzen SM, Overgaard J. Patient to patient variability in the 
expression of radiation induced normal tissue injury. Semin 
Radiat Oncol 1994;4:68-80. 
37. Safwat A, Bentzen SM, Turesson I et al. Deterministic rather than 
stochastic factors explain most of the variation in the expression 
of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol 
Phys 2002;52:198-204. 
 
 
 30
38. Bentzen SM, Overgaard M, Overgaard J. Clinical correlations 
between late normal tissue end-points after radiotherapy – 
implications for predictive assays of radiosensitivity. Eur J Cancer 
1993;29A:1373-1376. 
39. Tucker SL, Turesson I, Thames HD. Evidence for individual 
differences in the radiosensitivity of human skin. Eur J Cancer 
1992;28A:1783-1791. 
40. Bentzen SM, Overgaard M. Relationship between early and late 
normal tissue injury after postmastectomy radiotherapy. 
Radiother Oncol 1991;20:159-165. 
41. Gatti RA. The inherited basis of human radiosensitivity. Acta 
Oncol 2001;40:702–711. 
42. Appleby JM, Barber JBP, Levine E et al. Absence of mutations in 
the ATM gene in breast cancer patients with severe responses to 
radiotherapy. British J Cancer 1997;76:1546-1549. 
43. Ramsay J, Birrell G, Lavin M. Testing for mutations of the ataxia 
telangiectasia gene in radiosensitive breast cancer patients. 
Radiother Oncol 1998;47:125-128. 
44. Shayeghi M, Seal S, Regan J et al. Heterozygosity for mutations in 
the ataxia telangiectasia gene is not a major cause of radiotherapy 
complications in breast cancer patients. Br J Cancer 1998;78:922-
927. 
45. Haston CK, Zhou X, Gumbiner-Russo L et al. Universal and 
radiation-specific loci influence murine susceptibility to 
radiation-induced pulmonary fibrosis. Cancer Res 2002;62:3782-
3788. 
46. Laug WE, DeClerck YA, Jones PA. Degradation of the 
subendothelial matrix by tumor cells. Cancer Res 1983;43:1827-
1834. 
47. Stone HB, Milas L. Enhancement of radiation-induced normal 
tissue damage by a fibrosarcoma. Int J Radiat Oncol Biol Phys 
1987;13:1721-1724. 
48. Stamenkovic I. Matrix metalloproteinases in tumor invasion and 
metastasis. Semin Cancer Biol 2000;10:415-433. 
 
 31
49. Dvorak HF. Tumors: wounds that do not heal. Similarities 
between tumor stroma generation and wound healing. N Engl J 
Med 1986;315:1650-1659. 
50. Försti A, Louhelainen J, Söderberg M et al. Loss of heterozygosity 
in tumour-adjacent normal tissue of breast and bladder cancer. 
Eur J Cancer 2001;37:1372-1380. 
51. Kong FM, Anscher MS, Sporn TA et al. Loss of heterozygosity at 
the mannose 6-phosphate insulin-like growth factor 2 receptor 
(M6P/IGF2R) locus predisposes patients to radiation-induced 
lung injury. Int J Radiat Oncol Biol Phys 2001;49:35-41. 
52. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation 
Therapy Oncology Group (RTOG) and the European 
Organization for Research and Treatment of Cancer (EORTC). Int 
J Radiat Oncol Biol Phys 1995;31:1341-1346. 
53. Rubin P, Constine LS, Fajardo LF et al. Overview of late effects 
normal tissues (LENT) scoring system. Radiother Oncol 1995:35:9-
10. 
54. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 
2.0. An improved reference for grading the acute effects of cancer 
treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 
2000;47:13-47. 
55. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of 
a comprehensive grading system for the adverse effects of cancer 
treatment. Semin Radiat Oncol 2003;13:176-181. 
56. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. 
Accessed December 12,2003. 
57. Begg AC. Cell proliferation in tumors. In: Steel GG (Ed). Basic 
clinical radiobiology. 1st ed. Great Britain: Edward Arnold 
Publishers,1993:14-22. 
58. Steel GG. The radiobiology of tumors. In: Steel GG (Ed). Basic 
clinical radiobiology. 1st ed. Great Britain: Edward Arnold 
Publishers,1993:108-119. 
59. Pries R, Nitsch S,  Wollenberg B. Role of cytokines in head and 
neck squamous cell carcinoma. Expert Rev Anticancer Ther 
2006;6:1195-1203. 
 32
60. Withers HR. Biology of radiation oncology. In: Tobias JS, Thomas 
PRM (Eds). Current radiation oncology. 1st ed. Great Britain: 
Edward Arnold Publishers,1994:5-23. 
61. Bomford CK, Kunkler IH, Sheriff SB. Walter and Miller’s textbook 
of radiotherapy. 5th ed. Edinburgh (UK): Churchill Livingstone, 
1993. 
62. Steel GG. The dose-rate effect: brachytherapy. In: Steel GG (Ed). 
Basic clinical radiobiology. 1st ed. Great Britain: Edward Arnold 
Publishers,1993:120-129. 
63. Dale RG, Jones B. The clinical radiobiology of brachytherapy. Brit 
J Radiol 1998;71:465-483. 
64. Sankaranarayanan R, Ferlay J. Worldwide burden of 
gynecological cancer: the size of the problem. Best Pract Res Clin 
Obstet Gynaecol 2006;20:207-225. 
65. Haverkos HW. Multifactorial etiology of cervical cancer: a 
hypothesis. Medscape Gen Med 2005;7:57-69. 
66. Perez CA. Uterine cervix. In: Perez CA, Brady LW (Eds). 
Principles and practice of radiation oncology. 3rd ed. 
Philadelphia (NY): Lippincott-Raven,1997:1733-1834. 
67. Lowy DR, Schiller JT. Prophylactic human papillomavirus 
vaccines. J Clin Invest 2006;116:1167-1173. 
68. Ostapovicz DM, Keit J, Brady LW. Ovary. In: Perez CA, Brady 
LW (Eds). Principles and practice of radiation oncology. 3rd ed. 
Philadelphia (NY): Lippincott-Raven,1997:1853-1879. 
69. Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res 
Clin Obstet Gynaecol 2006;20:339-362. 
70. Elmasry K, Gayther SA. Ovarian cancer aetiology: facts and 
fiction. J Fam Plann Reprod Health Care 2006;32:82-86. 
71. Glassburn JR, Brady LW, Grigsby PW. Endometrium. In: Perez 
CA, Brady LW (Eds). Principles and practice of radiation 
oncology. 3rd ed. Philadelphia (NY): Lippincott-Raven,1997:1835-
1852. 
 33
72. Tiffen JM, Mahon SM. Educating women regarding the early 
detection of endometrial cancer- What is the evidence? Clin J 
Oncol Nurs 2006;10:102-104. 
73. Ryan AJ, Susil B, Jobling TW et al. Endometrial cancer. Cell Tissue 
Res 2005;322:53-61. 
74. Perez CA, Grigsby PW, Chao KSC. Vulva. In: Perez CA, Brady 
LW (Eds). Principles and practice of radiation oncology. 3rd ed. 
Philadelphia (NY): Lippincott-Raven,1997:1915-1942. 
75. Perez CA, Garipagaoglu M. Vagina. In: Perez CA, Brady LW 
(Eds). Principles and practice of radiation oncology. 3rd ed. 
Philadelphia (NY): Lippincott-Raven,1997:1891-1914. 
76. Ahamad A, Jhingran A. New radiation techniques in 
gynecological cancer. Int J Gynecol Cancer 2004;14:569-579.  
77. Tewari KS, Disaia PJ. Radiation therapy for gynecologic cancer. J 
Obstet Gynaecol Res 2002;28:123-140. 
78. Nag S, Clifford C, Erickson B et al. The American brachytherapy 
society recommendations for low dose rate brachytherapy for 
carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;52:33-
48. 
79. Sundar S, Symonds P, Deehan C. Tolerance of pelvic organs to 
radiation treatment for carcinoma of cervix. Clin Oncol 
2003;15:240-247. 
80. O’Brien PC. Radiation injury of the rectum. Radiother Oncol 
2001;60:1-14. 
81. Feltl D, Vosmik M, Jirasek M et al. Symptomatic 
osteoradionecrosis of pelvic bones in patients with gynecological 
malignancies - result of a long-term follow-up. Int J Gynecol Can 
2006;16:478-483. 
82. Yeung AR, Amdur RJ, Morris CG et al. Long-term outcome after 
radiotherapy for FIGO stage IIIB and IVA carcinoma of the 
cervix. Int J Radiat Oncol Biol Phys 2007;67:1445-50. 
83. Iraha S, Ogawa K, Moromizato H et al. Radiation enterocolitis 
requiring surgery in patients with gynecological malignancies. Int 
J Radiat Oncol Biol Phys 2007;67:article in press. 
 34
84. Kasibhatla M, Clough RW, Montana GS et al. Predictors of severe 
gastrointestinal toxicity after external beam radiotherapy and 
interstitial brachytherapy for advanced or recurrent gynecologic 
malignancies. Int J Radiat Oncol Biol Phys 2006;65:398-403. 
85. Tucker SL, Geara FB, Peters LJ et al. How much could the 
radiotherapy dose be altered for individual patients based on a 
predictive assay of normal tissue radiosensitivity? Radiother 
Oncol 1996;38:103-118. 
86. Mackay RI, Hendry JH. The modeled benefits of individualizing 
radiotherapy patients’ dose using cellular radiosensitivity assays 
with inherent variability. Radiother Oncol 1999;50:67-75. 
87. Bourguignon MH, Gisone PA, Perez MR et al. Genetic and 
epigenetic features in radiation sensitivity. Part II: Implications 
for clinical practice and radiation protection. Eur J Nucl Med Mol 
Imaging 2005;32:351-368. 
88. Alapetite C, Cosset JM, Bourguignon MH et al. Genetic 
susceptibility to radiations - Which impact on medical practice? 
Quart J Nucl Med 2000;44:347-354. 
89. Brock WA, Tucker SL, Geara FB et al. Fibroblast radiosensitivity 
versus acute and late normal skin-responses in patients treated 
for breast cancer. Int J Radiat Oncol Biol Phys 1995;32:1371-1379. 
90. Burnet NG, Nyman J, Turesson I et al. Prediction of normal tissue 
tolerance to radiotherapy from in vitro cellular radiation 
sensitivity. Lancet 1992; 339:1570-1571. 
91. Geara FB, Peters LJ, Ang KK et al. Prospective comparison of in 
vitro normal cell radiosensitivity and normal tissue reactions in 
radiotherapy patients. Int J Radiat Oncol Biol Phys 1993;27:1173-
1179. 
92. Johansen J, Bentzen SM, Overgaard J et al. Evidence for a positive 
correlation between in vitro radiosensitivity of normal human 
skin fibroblasts and the occurrence of subcutaneous fibrosis after 
radiotherapy. Int J Radiat Biol 1994;66:407-412. 
93. Peacock J, Ashton A, Bliss J et al. Cellular radiosensitivity and 
complication risk after curative radiotherapy. Radiother Oncol 
2000;55:173-178. 
 35
94. Russell NS, Grummels A, Hart AAM et al. Low predictive value 
of intrinsic fibroblast radiosensitivity for fibrosis development 
following radiotherapy for breast cancer. Int J Radiat Biol 
1998;73:661-670. 
95. West CML, Davidson SE, Elyan SAG, et al. Lymphocyte 
radiosensitivity is a significant prognostic factor for morbidity in 
carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2001;51:10-
15. 
96. Bryant PE, Gray L, Riches AC et al. The G2 chromosomal 
radiosensitivity assay. Int J Radiat Biol 2002;78:863-866. 
97. Fenech M. The in vitro micronucleus technique. Mutat Res 
2000;455:81-95. 
98. Barber JBP, Burrill W, Spreadborough AR et al. Relationship 
between in vitro chromosomal radiosensitivity of peripheral 
blood lymphocytes and the expression of normal tissue damage 
following radiotherapy for breast cancer. Radiother Oncol 
2000;55:179-186. 
99. Lisowska H, Lankoff A, Wieczorek A et al. Enhanced 
chromosomal radiosensitivity in peripheral blood lymphocytes of 
larynx cancer patients. Int J Radiat Oncol Biol Phys 2006;66:1245-
1252. 
100. Rached E, Schindler R, Beer KT et al. No predictive value of the 
micronucleus assay for patients with severe acute reaction of 
normal tissue after radiotherapy. Eur J Cancer 1998;34:378-383. 
101. Slonina D, Klimek M, Szpytma K et al. Comparison of the 
radiosensitive of normal-tissue cells with normal-tissue reactions 
after radiotherapy. Int J Radiat Biol 2000;76:1255-1264. 
102. Widel M, Jedrus S, Lukaszczyk B et al. Radiation-induced 
micronucleus frequency in peripheral blood lymphocytes is 
correlated with normal tissue damage in patients with cervical 
carcinoma undergoing radiotherapy. Radiat Res. 2003;159:713-
721. 
103. Lee TK, Allison RR, O'Brien KF et al. Lymphocyte radiosensitivity 
correlated with pelvic radiotherapy morbidity. Int J Radiat Oncol 
Biol Phys 2003;57:222-229. 
 36
104. Hoeller U, Borgmann K, Bonacker M et al. Individual 
radiosensitivity measured with lymphocytes may be used to 
predict the risk of fibrosis after radiotherapy for breast cancer. 
Radiother Oncol 2003;69:137-144. 
105. Borgmann K, Roper B, El-Awady R et al. Indicators of late normal 
tissue response after radiotherapy for head and neck cancer: 
fibroblasts, lymphocytes, genetics, DNA repair, and chromosome 
aberrations. Radiother Oncol 2002;64:141-152. 
106. Jones LA, Scott D, Cowan R et al. Abnormal radiosensitivity of 
lymphocytes from breast cancer patients with excessive normal 
tissue damage after radiotherapy: chromosome aberrations after 
low dose rate irradiation. Int J Radiat Biol 1995;67:519-528. 
107. Collins AR. The comet assay for DNA damage and repair - 
Principles, applications, and limitations. Mol Biotech 2004;26:249-
261. 
108. Oppitz U, Schulte S, Stopper H et al. In vitro radiosensitivity 
measured in lymphocytes and fibroblasts by colony formation 
and comet assay: Comparison with clinical acute reactions to 
radiotherapy in breast cancer patients. Int J Radiat Biol 
2002;78:611– 616. 
109. Alapetite C, Thirion P, de la Rochefordière A et al. Analysis by 
alkaline comet assay of cancer patients with severe reactions to 
radiotherapy: defective rejoining of radioinduced DNA strand 
breaks in lymphocytes of breast cancer patients. Int J Cancer 
1999;83:83–90. 
110. Popanda O, Ebbeler R, Twardella D et al. Radiation-induced DNA 
damage and repair in lymphocytes from breast cancer patients 
and their correlation with acute skin reactions to radiotherapy. Int 
J Radiat Oncol Biol Phys 2003;55:1216–1225. 
111. Maule J. Pulsed-field Gel electrophoresis. Mol Biotech 1998;9:107-
126. 
112. Kiltie AE, Ryan AJ, Swindell R et al. A correlation between 
residual radiation-induced DNA double-strand breaks in 
cultured fibroblasts and late radiotherapy reactions in breast 
cancer patients. Radiother Oncol 1999;51:55-65. 
 37
113. Kiltie AE, Barber JB, Swindell R et al. Lack of correlation between 
residual radiation-induced DNA damage, in keratinocytes 
assayed directly from skin, and late radiotherapy reactions in 
breast cancer patients. Int J Radiat Oncol Biol Phys 1999;43:481-
487. 
114. Wang WD, Chen ZT, Li DZ et al. Detecting normal cell 
radiosensitivity via assay of DNA damage in lymphocytes for 
individualizing radiotherapy in head and neck cancer patients. 
Oncol 2005;69:208-213. 
115. Lopez E, Guerrero R, Nunez MI et al. Early and late skin reactions 
to radiotherapy for breast cancer and their correlation with 
radiation-induced DNA damage in lymphocytes. Breast Cancer 
Res 2005;7:R690-R698. 
116. Ozsahin M, Crompton NEA, Gourgou S et al. CD4 and CD8 T-
lymphocyte apoptosis can predict radiation-induced late toxicity: 
A prospective study in 399 patients. Clin Cancer Res 
2005;11:7426-7433. 
117. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI 
database of genetic variation. Nucleic Acids Res 2001;29:308-311. 
118. Wheeler DL, Barrett T, Benson DA et al. Database resources of the 
National Center for Biotechnology Information. Nucleic Acids 
Res 2005;33:D39-D45. 
119. Wjst M. Target SNP selection in complex disease association 
studies. BMC Bioinformatics 2004;5:92-97. 
120. Suh Y, Vijg J. SNP discovery in associating genetic variation with 
human disease phenotypes. Mutat Res 2005;573:41-53. 
121. De La Vega FA, Lazaruk KD, Rhodes MD et al. Assessment of two 
flexible and compatible SNP genotyping platforms: TaqMan® 
SNP genotyping assays and the SNPlexTM genotyping system. 
Mut Res 2005;573:111-135. 
122. West M, Ginsburg GS, Huang AT et al. Embracing the complexity 
of genomic data for personalized medicine. Genome Res 
2006;16:559-566. 
 
 
 38
123. West CML, McKay MJ, Holscher T et al. Molecular markers 
predicting radiotherapy response: Report and recommendations 
from an international atomic energy agency technical meeting. Int 
J Radiat Oncol Biol Phys 2005;62:1264-1273. 
124. Quarmby S, West C, Magee B et al. Differential expression of 
cytokine genes in fibroblasts derived from skin biopsies of 
patients who developed minimal or severe normal tissue damage 
after radiotherapy. Radiat Res 2002;157:243-248. 
125. Kruse JJCM, Te Poele JAM, Russell NS et al. Microarray analysis 
to identify molecular mechanisms of radiation-induced 
microvascular damage in normal tissues. Int J Radiat Oncol Biol 
Phys 2004;58:420-426. 
126. Strup-Perrot C, Mathe D, Linard C et al. Global gene expression 
profiles reveal an increase in mRNA levels of collagens, MMPs, 
and TIMPs in late radiation enteritis. Am J Physiol-Gastroint 
Liver Physiol 2004;287:G875-G885. 
127. Vozenin-Brotons MC, Milliat F, Linard C et al. Gene expression 
profile in human late radiation enteritis obtained by high-density 
cDNA array hybridization. Radiat Res 2004;161:299-311. 
128. Rodningen AK, Overgaard J, Alsner J et al. Microarray analysis of 
the transcriptional response to single or multiple doses of 
ionizing radiation in human subcutaneous fibroblasts. Radiother 
Oncol 2005;77:231-240. 
129. Leong T, Chao M, Bassal S et al. Radiation-hypersensitive cancer 
patients do not manifest protein expression abnormalities in 
components of the nonhomologous end-joining (NHEJ) pathway. 
Brit J Can 2003;88:1251-1255. 
130. Noguchi T, Shibata T, Fumoto S et al. DNA-PKcs expression in 
esophageal cancer as a predictor for chemoradiation therapeutic 
sensitivity. Annals Surg Oncol 2002;9:1017-1022. 
131. Anscher MS, Murase T, Prescott DM et al. Changes in plasma TGF 
beta levels during pulmonary radiotherapy as a predictor of the 
risk of developing radiation pneumonitis. Int J Radiat Oncol Biol 
Phys 1994;30:671– 676. 
 39
132. Li C, Wilson PB, Levine E et al. TGFβ1 levels in pretreatment 
plasma identify breast cancer patients at risk of developing post-
radiotherapy fibrosis. Int J Cancer 1999;84:155–159. 
133. Novakova-Jiresova A, Van Gameren MM, Coppes RP, et al. 
Transforming growth factor-β dynamics and post-irradiation 
lung injury in lung cancer patients. Radiat Oncol 2004;71:183–189. 
134. Feltl D, Zavadova E, Pala M et al. Posttreatment plasma 
transforming growth factor beta 1 (TGF-beta1) level predicts for 
late morbidity in patients with advanced head and neck cancer. 
Neoplasma 2005;52:393–397. 
  
 41
Chapter  2  
Aim and outline of the thesis 
2.1 Aim 
During the past few decades, numerous in vitro radiosensitivity assays 
have been developed in order to predict normal tissue reactions after 
radiotherapy. One of the most promising assays is the cytogenetic G2 
assay (1,2). As it was shown previously that the number of chromatid 
breaks after in vitro irradiation, determined by this assay, is highly 
correlative with the occurrence of acute radiotherapy reactions (3), the 
first aim of this thesis was to assess the value of the G2 assay in 
predicting late clinical radiosensitivity after radiotherapy. 
Today, normal tissue radiosensitivity is considered to be a complex trait 
dependent on the interaction of multiple genes or gene products. As a 
result, it is assumed that the development of normal tissue reactions 
could be predicted from individual genetic profiles (4,5). Because of the 
importance of DNA repair in cell and tissue response to radiation, genetic 
variants in genes responsible for DNA damage detection and repair are 
suitable candidates to study normal tissue radiosensitivity (6,7). 
Therefore, the second aim of this thesis was to investigate the association 
between single nucleotide polymorphisms (SNPs) in the DNA repair 
genes XRCC1, XRCC3 and OGG1 and the development of late 
radiotherapy reactions. In addition, as suggested by literature data, the 
involvement of microsatellite polymorphisms in the DNA repair genes 
XRCC1, XRCC3 and XRCC5 in late clinical radiosensitivity was also 
examined. 
Over the years, it has become clear that normal tissue radiosensitivity is 
not exclusively caused by cell killing, but is the result of multicellular 
interactions between various cell types within a specific organ (8). The 
early activation of cytokine cascades after radiation exposure strongly 
affects the normal tissue response (9). Since the multifunctional 
 42
profibrotic cytokine TGFβ1 plays an important role in radiation induced 
normal tissue reactions (8,10,11), the last aim of this thesis was to study 
the association between TGFβ1 polymorphisms and late clinical 
radiosensitivity. 
2.2 Outline 
Gynecologic cancers account for an important percentage of cancers in 
women worldwide (12). Most gynecologic malignancies, particularly 
cervical and endometrial cancers, are treated surgically followed by 
radiotherapy (13). Although the irradiation techniques have improved 
considerably, normal tissue reactions in the pelvic area still occur and 
vary widely from patient to patient (14). Therefore, the occurrence of late 
clinical radiotherapy reactions was studied within the framework of the 
present thesis using a patient group consisting of women with cervical or 
endometrial cancer. 
In the first study described in chapter three (part I, p 45), the correlation 
between in vitro chromosomal radiosensitivity and clinical 
radiosensitivity was assessed using the G2 assay. To this end, whole 
blood cultures were irradiated in vitro and the mean number of radiation 
induced chromatid breaks was compared between non-radiosensitive 
and radiosensitive patients. 
Based on the hypothesis that normal tissue radiosensitivity is the result of 
multiple subtle genomic alterations, and based on the positive results of 
our initial cytogenetic study, the involvement of single nucleotide 
polymorphisms (SNPs) in the DNA repair genes XRCC1, XRCC3, and 
OGG1 in clinical radiosensitivity was studied in part I (p 45). For this 
study, genomic DNA was extracted from isolated lymphocytes and the 
polymorphic sites were analyzed by polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) assays. 
As polymorphic microsatellites within the XRCC1 and XRCC3 genes have 
previously been suggested to be associated with clinical radiosensitivity 
(15), the association of these microsatellite polymorphisms in the 
development of late pelvic radiotherapy reactions was studied in part II 
(p 67). A microsatellite in the XRCC5 gene was included based on the 
involvement of this gene in DNA repair. The number of tandem repeat 
units at each locus was determined by PCR on lymphocyte DNA 
followed by automated fragment analysis. 
 43
In radiogenomics, genetic polymorphisms in DNA repair genes are not 
the only interesting candidates to study. In fact, as the cytokine TGFβ1 
plays a significant role in the cell and tissue response to radiation, genetic 
variations in this gene can also be important to study in relation to 
clinical radiosensitivity (11). Therefore, in part III (p 83), the association 
between TGFβ1 polymorphisms and the occurrence of late normal tissue 
reactions was investigated. The polymorphic sites were examined by 
PCR-RFLP, single base extension and genotyping assays on lymphocyte 
DNA. Furthermore, TGFβ1 haplotypes were determined and linkage 
disequilibrium between the different polymorphisms was calculated. 
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Chapter  3  
Original research: results 
3.1 Part I  
Radiation-induced damage to normal tissues after radiotherapy in 
patients treated for gynecologic tumors: association with single 
nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes 
and in vitro chromosomal radiosensitivity in lymphocytes 
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Abstract 
Purpose: To examine the association of polymorphisms in XRCC1 (194Arg/Trp, 280Arg/His, 
399Arg/Gln, 632Gln/Gln), XRCC3 (5’ UTR 4.541A>G, IVS5-14 17.893A>G, 241Thr/Met), and 
OGG1 (326Ser/Cys) with the development of late radiotherapy (RT) reactions and to assess the 
correlation between in vitro chromosomal radiosensitivity and clinical radiosensitivity. 
Methods and Materials: Sixty-two women with cervical or endometrial cancer treated with RT 
were included in the study. According to the Common Terminology Criteria for Adverse 
Events, version 3.0, scale, 22 patients showed late adverse RT reactions. Polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) assays were performed to 
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examine polymorphic sites, the G2 assay was used to measure chromosomal radiosensitivity, 
and patient groups were compared using actuarial methods. 
Results: The XRCC3 IVS5-14 polymorphic allele was significantly associated with the risk of 
developing late RT reactions (odds ratio 3.98, p = 0.025), and the XRCC1 codon 194 variant 
showed a significant protective effect (p = 0.028). Patients with three or more risk alleles in 
XRCC1 and XRCC3 had a significantly increased risk of developing normal tissue reactions 
(odds ratio 10.10, p = 0.001). The mean number of chromatid breaks per cell was significantly 
greater in patients with normal tissue reactions than in patients with no reactions (1.16 and 1.34, 
respectively; p = 0.002). Patients with high chromosomal radiosensitivity showed a 9.2-fold 
greater annual risk of complications than patients with intermediate chromosomal 
radiosensitivity. Combining the G2 analysis with the risk allele model allowed us to identify 
23% of the patients with late normal tissue reactions, without false-positive results.  
Conclusion: The results of the present study showed that clinical radiosensitivity is associated 
with an enhanced G2 chromosomal radiosensitivity and is significantly associated with a 
combination of different polymorphisms in DNA repair genes. 
 
Introduction 
The ultimate goal of curative radiotherapy (RT) is to achieve tumor 
control without producing complications due to damage to surrounding 
normal tissues. With respect to normal tissue reactions, RT dose 
fractionation schemes are based on α/β values and other parameters such 
as the TD5/5, the tolerance dose producing 5% of a specific, either acute or 
late, radiotoxic effect within 5 years after treatment in a patient 
population (1). Evidence is now emerging that normal tissue radiation 
effects are also due to a patient-related variability in response, which is 
determined mainly by genetic factors (2). The first indications for an 
inherited basis for clinical radiosensitivity came from patients with rare 
genetic syndromes such as ataxia telangiectasia, Nijmegen breakage 
syndrome, Fanconi anemia, and Bloom syndrome. These patients exhibit, 
not only an enhanced clinical, but also an enhanced in vitro cellular 
radiosensitivity. All these syndromes are associated with germline 
mutations in genes involved in the detection of DNA damage and DNA 
repair (3). Mutations in repair genes have also been detected in very 
radiosensitive cancer patients who do not have these syndromes (4). The 
importance of genetic factors in clinical radiosensitivity has been further 
supported by the results of controlled animal studies showing that some 
strains of mice have a greater genetic predisposition to develop typical 
late reactions such as fibrosis (5).  
Except for patients with rare genetic syndromes, the data available today 
have indicated that clinical normal tissue radiosensitivity should be 
regarded as a complex phenotype dependent on the interplay of several 
gene products (6). This is supported by the observation that in 
overreacting patients no association has been found between the different 
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radiotoxic effects: the genetic determinants exhibit differential expression 
in different cell types and tissues (7, 8). At the interindividual level, single 
nucleotide polymorphisms (SNPs) represent approximately 90% of the 
naturally occurring sequence variation (9). Complex diseases, such as the 
considered radiopathologic effects, are determined most likely by genetic 
variants with a relatively high allelic frequency. This leads to the idea that 
common SNPs in a limited number of genes could be the inherited basis 
of clinical radiosensitivity.  
In view of the importance of DNA repair in cell and tissue response to 
radiation, SNPs in the genes responsible for DNA damage signalling and 
repair pathways are suitable candidates in the search for the genetic basis 
of clinical normal tissue radiosensitivity. The XRCC1 and the OGG1 
genes, involved in base excision repair, have a key role in the efficient 
repair of DNA damage caused by ionizing radiation and oxidative stress. 
Mutations in XRCC1 result in an increased sensitivity and an increased 
number of chromosomal aberrations (10). The 194Arg/Trp and 
399Arg/Gln polymorphisms in XRCC1 were associated with an increased 
risk of developing an adverse response to RT in breast cancer patients 
(11). The XRCC1 280Arg/His polymorphism appeared to be correlated 
with in vitro bleomycin hypersensitivity (12). The 241Thr/Met SNP in the 
XRCC3 gene, involved in the homologous recombination pathway, as 
well as the XRCC1 399Arg/Gln SNP, has been associated with increasing 
chromosome deletions after in vitro irradiation (13).  
In the past decade, numerous in vitro radiosensitivity assays have been 
developed aimed at prediction of individual radiosensitivity and 
individualizing treatment schedules. Studies correlating in vitro 
radiosensitivity using different biologic endpoints and cells have led to 
contradictory results (14–16). Although initially encouraging results were 
obtained with the alkaline comet assay (15, 17), larger scale studies did 
not support the comet assay as a valuable prediction test for individual 
clinical radiosensitivity (18). Among the cytogenetic test systems on 
peripheral blood lymphocytes, the G2 chromatid break assay can be 
considered as the standard measure of chromosomal radiosensitivity (19). 
The study performed by Barber et al. (20) showed that highly 
radiosensitive patients with respect to acute effects had significantly 
greater G2 scores than patients with reactions considered to be normal. 
The value of the G2 assay has, up to now, never been confirmed for 
clinical radiosensitivity prediction.  
In the present study we investigated whether eight SNPs selected in 
XRCC1 (194Arg/Trp, 280Arg/His, 399Arg/Gln, 632Gln/Gln), XRCC3 
(5’UTR 4.541A>G, IVS5-14 17.893A>G, 241Thr/Met), and OGG1 
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(326Ser/Cys) genes are associated with an increased risk of adverse 
reactions to RT in patients treated for gynecologic tumors. Furthermore, 
the reliability of the G2 assay in the prediction of late reactions within the 
studied population was investigated. 
 
Methods and Materials 
Population 
The study population consisted of 62 women with cancer of the cervix (n 
= 30) or endometrium (n = 32). All patients were treated at the Ghent 
University Hospital between December 1993 and May 2002. They 
received fractionated external beam RT to the pelvis (one anterior and 
two lateral fields, 25-MV photons), followed by a brachytherapy boost. Of 
the 62 patients, 15 received a tumor dose of 45 Gy in 25 fractions of 1.8 Gy 
within 5 weeks, 22 received a tumor dose of 46 Gy in 23 fractions of 2 Gy 
within 4.6 weeks, 22 received a tumor dose of 50 Gy in 25 fractions of 2 
Gy within 5 weeks, 2 received 46 Gy supplemented with a 14-Gy (7 
fractions of 2 Gy) parametrial boost within 6 weeks, and 1 received a total 
tumor dose of 66 Gy in 33 fractions of 2 Gy, with the final 20 Gy given by 
three-dimensional conformal therapy within 6.4 weeks. Except for 2 
patients, all patients additionally underwent brachytherapy using vaginal 
ovoids (after hysterectomy), Fletcher-type applications, or perineal 
implants. All brachytherapy was performed using a pulsed-dose-rate 
technique with 192I. The dose rate was between 0.5 and 0.65 Gy/h at 0.5 
cm from the applicator surface for ovoids and perineal implants and to 
point A for the Fletcher-type application. The total doses from 
brachytherapy ranged from 15 to 35 Gy. Of the 30 patients with cervical 
cancer, 18 received combined radiochemotherapy and were treated with 
40 mg/m2 cisplatinum weekly during the external beam RT period. 
Forty-six patients underwent Wertheim Meigs hysterectomy. The mean 
patient age at treatment was 59 years (range, 24–80 years).  
The reactions of all patients were scored with respect to several different 
normal tissue reactions according the Common Terminology Criteria for 
Adverse Events scale, version 3.0, of the National Cancer Institute (21). Of 
the 62 patients, 40 had no or very light adverse reactions to RT and were 
classified as CTC0-1, and 14 experienced side effects according to CTC2 
(radiation enteritis with diarrhea and secondary hemorrhoidal bleeding, 
miction problems with pollakisuria and incontinence, radiocolitis and 
radiation rectitis, and vaginal atrophy with telangiectases and synechia). 
Six patients experienced side effects classified as CTC3 (dehydration as a 
 49
consequence of extreme diarrhea, anemia caused by rectal blood loss, 
vaginal atrophy, pelvis fibrosis, edema of the upper leg, sacrum fracture 
and osteoradionecrosis, and hemorrhagic radiocystitis). Finally, 1 patient 
experienced side effects classified as CTC4 (radiation enteritis with pelvic 
fibrosis, anal blood loss, and rectal ulcus leading to intestinal resection), 
and 1 patient died as a consequence of RT (perforation of the small 
intestine) and was classified as CTC5. All normal tissue reactions 
appeared between 6 months and 5.7 years after RT and could be 
considered as late normal tissue reactions. The mean time of follow-up 
was 4.8 years (range, 0.7–10.6 years).  
From each patient in the study, a heparinized blood sample was taken at 
least 6 months after the last therapy session. Part of the blood sample was 
used on the sampling day to perform the G2 assay. Lymphocytes were 
isolated from the remaining blood and frozen for genotyping analysis. To 
determine the frequency of the considered SNPs in a Belgian control 
population, a blood sample was taken of 150 healthy individuals, 
working at the Ghent University Hospital, at their annual occupational 
medical examination. Lymphocytes were isolated and used for the SNP 
analysis. Patient samples were collected from January 2003 to July 2004 
and control samples from October 2003 to July 2004. The local ethical 
committee approved the study, including the genotyping analysis on 
DNA of all individuals. All participants provided written informed 
consent. 
G2 assay 
The G2 assay procedure (Paterson Institute, Manchester, UK) was 
followed with some minor changes. In brief, heparinized blood was kept 
at room temperature before culturing within 4 h after blood sampling. To 
a tissue culture flask (25 cm2), 0.5 mL of blood was added to 4.5 mL of 
complete RPMI-1640 culture medium supplemented with 10% fetal calf 
serum (Life Technologies), 1% L-glutamine, 50 U/mL penicillin, and 50 
µg/mL streptomycin. The lymphocytes were stimulated to divide with 
1% phytohemagglutinin (Life Technologies). Two cultures were started 
per donor, one served as the control, the other for irradiation. After 70-h 
incubation in a CO2 incubator at 37°C, the cultures were irradiated with a 
dose of 0.4 Gy 60Co rays at 37°C. At 30-min after irradiation, 75 µL of 
colcemid (final concentration 0.15 µg/mL, Sigma-Aldrich) was added to 
block the cells at metaphase; 90 min after irradiation, the cultures were 
arrested by putting them on ice for 5 min. The cells were harvested by 
centrifugation of the samples, and the cell pellets were resuspended in 5 
mL of 0.075 M KCl for 15 min on ice. After the hypotonic shock, the cells 
were fixed three times in 5 mL of cold methanol acetic acid (3:1). Finally, 
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the cells were dropped on clean slides and stained with 4% Azur B SCN 
solution (Serva Polylab). Fifty well spread metaphases were analyzed by 
two independent scorers on coded slides for the appearance of chromatid 
breaks. All types of single chromatid breaks in which a clear 
discontinuity was present were scored (22). 
 Genotyping analysis 
Polymorphic sites in XRCC1 (194Arg/Trp, 280Arg/His, 399Arg/Gln, 
632Gln/Gln), XRCC3 (5’UTR 4.541A>G, IVS5-14 17.893A>G, 
241Thr/Met), and OGG1 (326Ser/Cys) were examined by polymerase 
chain reaction (PCR)-restriction length fragment polymorphism analysis. 
Genomic DNA was extracted from the isolated lymphocytes using a 
commercially available kit (QIAamp DNA Blood Mini Kit, Qiagen). PCR-
restriction fragment length polymorphism (RFLP) assays were performed 
on each DNA sample using the primer sequences, annealing 
temperatures, and restriction enzymes detailed in Table 1. The PCR 
reactions contained 0.2 mM dNTPs (Amersham Biosciences), 1X PCR 
buffer (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 1 µM forward and 
reverse primer, 0.6 U Platinum taq DNA Polymerase (Invitrogen), and 
200 ng DNA in a 25-µL reaction volume. The PCR amplification 
conditions for the SNPs in XRCC3 and OGG1 consisted of an initial 
denaturation step at 95°C for 5 min, followed by 35 cycles of 1 min at 
95°C, 1 min at the appropriate annealing temperature Ta (Table 1), 1 min 
at 72°C, and a final extension step at 72°C for 10 min. For the 
amplification of the DNA regions containing the polymorphic sites for 
XRCC1, the following touchdown program was used: an initial 
denaturation step at 95°C for 2 min, 12 cycles of 20 s at 95°C, 15 s at the 
initial annealing temperature Ta (Table 1), 1 min at 72°C, followed by 24 
cycles of 40 s at 95°C, 40 s at Ta-12, 30 s at 72°C, and a final extension step 
of 10 min at 72°C. The amplified fragments were digested with the 
appropriate restriction endonucleases listed in Table 1. After 3 h of 
incubation (2 h for FokI and Fnu4HI) at 37°C, 20 µL of digested product 
was analyzed by gel electrophoresis on a 2% agarose gel and visualized 
under ultraviolet light after staining with ethidiumbromide. Table 1 lists 
the polymorphic variants found at each site and the fragment 
combinations identifying the different genotypes. 
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Table 1. Technical details of PCR-RFLP analysis 
Gene SNP Primers 
PCR 
product 
size (bp) 
Restriction 
enzyme Variant 
Fragments 
identifying 
genotypes (bp) 
XRCC1 194 Arg/Trp F=GTTCCGTGTGAAGGAGGAG 504 PvuII C → T CC=431 
  R=CTTGGAGGTGCTGCCTATG    CT=368+431 
  Ta=67°C    TT=368 
 280 Arg/His F=CTGGACTGCTGGGTCTGAG 849 RsaI G → A GG=153+597 
  R=CTCCAGATTCCTGGCATTGC    GA=153+597+696 
  Ta=69°C    AA=153+696 
 399 Arg/Gln F=CTGGACTGCTGGGTCTGAG 849 HpaII G → A GG=321+461 
  R=CTCCAGATTCCTGGCATTGC    GA=321+461+528 
  Ta=69°C    AA=321+528 
 632 Gln/Gln F=AGTTACTTCCTCACCAGCTC 333 HaeIII G → A GG=195 
  R=AAGATACAGGTGTGGCTCAG    GA=195+234 
  Ta=67°C    AA=234 
XRCC3 5’ UTR 4.541 F=TGAGGCGCCTAATCAGCTG 293 FokI A → G AA=111+182 
  R=TGGACTGTGTCAAGCAGCG    AG=111+182+293 
  Ta=58°C    GG=293 
 IVS5-14 17.893 F=GACACCTCTACAGAGGACG 650 PvuII A → G AA=283+367 
  R=TTCTCGATGGTTAGGCACAG    AG=283+367+650 
  Ta=58°C    GG=650 
 241 Thr/Met F=GACACCTCTACAGAGGACG 650 NlaIII C → T CC=281+298 
  R=TTCTCGATGGTTAGGCACAG    CT=193+281+298 
  Ta=58°C    TT=193+281 
OGG1 326 Ser/Cys F=GTGGATTCTCATTGCCTTCG 672 Fnu4HI C → G CC =553 
  R=CTGTTGCTGTCGAGACTGC    CG=154+399+553 
  Ta=58°C    GG=154+399 
Abbreviations: PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism;  
F = forward; R = reverse; Ta = annealing temperature. 
 
Statistical analysis 
Statistical analysis was performed using MedCalc, version 4.0, and 
Statistical Package for Social Sciences, version 10.0, software (SPSS Inc., 
Chicago, IL). For the comparison of the G2 scores between different 
groups, the Mann-Whitney U test was applied. Differences in the 
proportions of sensitive patients and nonsensitive patients were 
compared using the chi-square test. Actuarial fibrosis rates were obtained 
from Kaplan-Meier analysis. The rate of complications in the different 
groups was analyzed with the log–rank test. The annual incidence of 
radiation-induced complications was estimated according to Jung et al. 
(23) using the actuarial Kaplan-Meier data. Genotype and allele 
frequencies were calculated by direct counting. Allele frequencies were 
examined by calculating the odds ratios (OR), with 95% confidence 
 52
intervals (95% CIs) using the Fisher exact test, with the wild-type alleles 
used as the reference group. 
 
Results 
G2 assay 
Chromosomal radiosensitivity G2 data were collected for 58 patients. 
Stimulation of the cultures of blood samples of 4 patients failed. The 
average yield of chromatid breaks per cell for patients in the CTC0-1, 
CTC2, and CTC3-4-5 group was 1.16, 1.33 (p = 0.012), and 1.37 breaks/cell 
(p = 0.022), respectively. Of the 20 patients with reactions to RT (CTC2+), 
9 could be judged as highly radiosensitive with respect to chromosomal 
radiosensitivity on the basis of the 90th percentile cutoff value of the 
patient group with no severe normal tissue radiation effects (1.39 
breaks/cell, p = 0.001). An overview of the results is given in Table 2.  
 
Table 2. Overview of G2 data of different CTC groups 
 CTC 0-1 CTC 2 CTC 3-4-5 CTC 2-3-4-5 
Population size* 38 14 6 20 
Mean ± SD† 1.16 ± 0.18 1.33 ± 0.19 1.37 ± 0.19 1.34 ± 0.19 
p value (Mann-Whitney U test)  0.012 0.022 0.002 
Cut off value‡ 1.39    
% > cut off value 5 43 50 45 
p value (χ²)  0.004 0.011 0.001 
* Number of successful blood samples, † Number of chromatid breaks per cell, ‡ Ninetieth percentile of 
nonradiosensitive patients. 
 
Fig. 1. Correlation of G2 data and clinical response according to Common Terminology 
Criteria for Adverse Events scale. 
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Figure 1 sketches the spread of the G2 data for the CTC groups, CTC0-1, 
CTC2, and CTC3-4-5. 
The G2 data of all patients were normally distributed with a mean (µ) of 
1.22 breaks/cell and standard deviation (SD) of 0.20 breaks/cell. In view 
of this distribution, three patient groups were defined: patients with low 
chromosomal radiosensitivity (≤µ-SD or ≤1.02 breaks/cell), patients with 
high chromosomal radiosensitivity (≥µ+SD or ≥1.42 breaks/cell), and 
patients with intermediate chromosomal radiosensitivity (>µ-SD but 
<µ+SD or >1.02 but <1.42 breaks/cell). The Kaplan-Meier plot analysis 
for the three groups showed that for patients with high chromosomal 
radiosensitivity, the probability of complication-free survival at 3 years 
was 0.20 versus 0.73 for patients with intermediate chromosomal 
radiosensitivity (p = 0.007; Fig. 2). Except for the group with low 
chromosomal radiosensitivity, the proportion of complication-free 
patients decreased exponentionally with the time after RT. The annual 
rate of complications was 9.2-fold greater in patients with high 
chromosomal radiosensitivity compared with patients with intermediate 
chromosomal radiosensitivity (55%/y vs. 6%/y). For all patients, the 
annual risk was 8%/y. 
 
Fig. 2. Kaplan-Meier plot showing relationship between chromosomal radiosensitivity and 
occurrence of complications after radiotherapy. Actuarial rate of complication-free patients 
showing low, intermediate, or high chromosomal radiosensitivity plotted versus time after 
radiotherapy. 
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Genotyping analysis 
The allele frequencies for the eight polymorphisms in the control group 
of healthy individuals were similar to those reported previously in white 
control subjects from Europe and America. Except for the XRCC1 
632Gln/Gln polymorphism in the control group, all the genotype 
distributions in all groups considered were in Hardy-Weinberg 
equilibrium. Tables 3 and 4 show the genotype and allele frequencies 
obtained for each polymorphic site in the cancer patients with (CTC2+) 
and without (CTC0-1) reactions to RT and in the control population. The 
results of a comparative statistical analysis of these data are presented in 
Table 5.  
In a first analysis, patients with and without normal tissue reactions were 
compared. A significant negative association (p = 0.028) was found 
between the XRCC1 194Arg/Trp polymorphism and the risk of normal 
tissue reactions after RT. Variant alleles of this polymorphism occurred 
only in patients without normal tissue reactions (allele frequency 14%). 
This observation indicates a radioprotective effect for the Trp allele. A 
greater number of patients with adverse reactions to RT possessed one 
variant XRCC1 280His allele, one variant XRCC1 399Gln allele, and two 
variant XRCC1 632Gln alleles. Variant alleles at these sites correlated 
positively with radiosensitivity (OR 2.65, 1.58, and 1.78, respectively). 
However, none of these results were statistically significant (Table 5). 
The subgroup of patients with adverse reactions to RT had a greater 
percentage of individuals who were heterozygous for the polymorphic 
allele at IVS5-14 in XRCC3 (54% vs. 30%) and a lower percentage who 
were homozygous for the normal alleles (32% vs. 65%). Individuals in the 
radiosensitive group had an OR of 3.98 (p = 0.025) for carrying this 
variant allele. No direct significant association was found between the 
polymorphic genotypes in XRCC3 5’UTR and the XRCC3 241 codon and 
normal tissue reaction risk. Variant alleles at these sites correlated 
negatively with an increased risk of normal tissue reactions (OR, 0.42 and 
0.87, respectively). Furthermore, no major differences in OGG1 
326Ser/Cys genotype distributions could be found between 
radiosensitive patients and patients with no adverse reactions. Slightly 
more homozygous mutants were found among radiosensitive patients, 
but, in contrast, radiosensitive patients included fewer heterozygous 
mutant allele carriers (Table 4). 
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Table 3. Genotype and allele frequencies of XRCC1 polymorphisms in cancer patients with and without reactions to radiotherapy and healthy controls 
 Position of the polymorphic site in the XRCC1 gene (%) 
 194 Arg/Trp C>T 280 Arg/His G>A 399 Arg/Gln G>A 632Gln/Gln G>A 
 Cancer patients  Cancer patients  Cancer patients  Cancer patients  
 CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls 
Genotype and allele frequencies n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 
Genotype             
    Homozygous normal alleles 75 (30) 100 (22) 83 (124) 90 (36) 77 (17) 90 (135) 42 (17) 32 (7) 39 (58) 40 (16) 27 (6) 31 (46) 
    Heterozygous 22 (9) 0 (0) 17 (25) 10 (4) 23 (5) 10 (15) 40 (16) 55 (12) 46 (69) 50 (20) 50 (11) 58 (88) 
    Homozygous polymorphic 3 (1) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 18 (7) 13 (3) 15 (23) 10 (4) 23 (5) 11 (16) 
Allele frequency             
    Normal allele 86 100 91 95 89 95 63 59 62 65 52 60 
    Polymorphic allele 14 0 9 5 11 5 37 41 38 35 48 40 
Data in parentheses are numbers of individuals with each genotype. 
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Table 4. Genotype and allele frequencies of XRCC3 and OGG1 polymorphisms in cancer patients with and without reactions to radiotherapy and healthy 
controls 
 Position of the polymorphic site in the XRCC3 gene Position of the polymorphic site in the OGG1 gene 
 5’ UTR 4.541 A>G IVS5-14 17.893 A>G 241 Thr/Met C>T 326 Ser/Cys C>G 
 Cancer patients  Cancer patients  Cancer patients  Cancer patients  
 CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls CTC 0-1 CTC 2+ Controls 
Genotype and allele frequencies n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 n = 40 n = 22 n = 150 
Genotype             
Homozygous normal alleles 48 (19) 68 (15) 72 (108) 65 (26) 32 (7) 51 (76) 38 (15) 41 (9) 37 (56) 60 (24) 68 (15) 62 (93) 
Heterozygous 42 (17) 27 (6) 27 (40) 30 (12) 54 (12) 39 (58) 50 (20) 50 (11) 42 (63) 38 (15) 23 (5) 34 (51) 
Homozygous polymorphic alleles 10 (4) 5 (1) 1 (2) 5 (2) 14 (3) 10 (16) 12 (5) 9 (2) 21 (31) 2 (1) 9 (2) 4 (6) 
Allele frequency             
Normal allele 69 82 85 80 59 70 63 66 58 79 80 79 
Polymorphic allele 31 18 15 20 41 30 37 34 42 21 20 21 
Data in parentheses are numbers of individuals with each genotype. 
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Table 5. Statistical comparison of data for cancer patients with and without reactions to 
radiotherapy and for cancer patients vs. healthy controls 
   CTC 0-1 vs. CTC 2+ Controls vs. patients 
Gene SNP Genotype OR 95% CI p OR 95% CI p 
XRCC1 194 Arg/Trp 0 / 0.039* 0.86 [0.38 – 1.96] 0.877 
  Trp/Trp 0 / 0.862 2.38 [0.15 – 38.85] 0.882 
  Arg/Trp + Trp/Trp 0 / 0.028* 0.92 [0.41 – 2.04] 0.991 
 280 Arg/His 2.65 [0.63 – 11.13] 0.325 1.53 [0.63 – 3.70] 0.480 
  His/His 0 / / / / / 
  Arg/His + His/His 2.65 [0.63 – 11.13] 0.325 1.53 [0.63 – 3.70] 0.480 
 399 Arg/Gln 1.82 [0.57 – 5.78] 0.463 0.98 [0.51 – 1.87] 0.915 
  Gln/Gln 1.04 [0.21 – 5.23] 0.716 1.05 [0.44 – 2.54] 0.908 
  Arg/Gln + Gln/Gln 1.58 [0.53 – 4.73] 0.580 1.00 [0.54 – 1.83] 0.883 
 632 GA 1.47 [0.45 – 4.83] 0.740 0.74 [0.38 – 1.41] 0.452 
  AA 3.33 [0.66 – 16.76] 0.280 1.18 [0.45 – 3.08] 0.934 
  GA + AA 1.78 [0.57 – 5.51] 0.469 0.80 [0.43 – 1.50] 0.602 
XRCC3 5’ UTR AG 0.45 [0.14 – 1.41] 0.269 1.83 [0.96 – 3.47] 0.092 
  GG 0.32 [0.03 – 3.14] 0.591 7.94* [1.47 – 42.80] 0.019* 
  AG + GG 0.42 [0.14 – 1.26] 0.194 2.12* [1.15 – 3.91] 0.024* 
 IVS5-14 AG 3.71* [1.17 – 11.80] 0.046* 0.95 [0.51 – 1.78] 0.993 
  GG 5.57 [0.77 – 40.12] 0.197 0.72 [0.24 – 2.13] 0.738 
  AG + GG 3.98* [1.31 – 12.05] 0.025* 0.90 [0.50 – 1.63] 0.851 
 241 Thr/Met 0.92 [0.30 – 2.77] 0.898 1.15 [0.60 – 2.18] 0.797 
  Met/Met 0.67 [0.11 – 4.18] 0.988 0.53 [0.20 – 1.36] 0.266 
  Thr/Met + Met/Met 0.87 [0.30 – 2.51] 0.993 0.94 [0.51 – 1.73] 0.974 
OGG1 326 Ser/Cys 0.53 [0.16 – 1.77] 0.457 0.94 [0.49 – 1.77] 0.965 
  Cys/Cys 3.20 [0.27 – 38.43] 0.727 1.19 [0.28 – 5.01] 0.892 
  Ser/Cys + Cys/Cys 0.70 [0.23 – 2.10] 0.716 0.96 [0.52 – 1.77] 0.974 
Abbreviations: OR = odds ratio; calculated to homozygous normal genotype; 95% CI = 95% confidence 
interval.  
* Statistically significant. 
 
The data in Table 6 show the distribution of patients with and without 
adverse reactions to RT for the XRCC1 (280Arg/Trp, 399Arg/His, 
632Gln/Gln) genotypes, XRCC3 (IVS5-14A>G) genotypes, and combined 
XRCC1 (280Arg/Trp, 399Arg/His, 632Gln/Gln) and XRCC3 (IVS5-
14A>G) genotypes. For these polymorphisms, ORs >1 were found, which 
points to a positive correlation between their presence and the 
appearance of RT reactions. An analysis of the patient population 
according to these risk alleles showed that clinical radiosensitivity is 
significantly associated with the number of risk alleles in XRCC1 (OR, 
12.60; p = 0.011, for two or more risk alleles) and with the number of risk 
alleles in XRCC1 combined with XRCC3 (OR, 10.10; p = 0.001, for three or 
more risk alleles). Patients with one or no risk allele and with two or less 
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risk alleles served as a reference group, respectively, for XRCC1 and 
combined XRCC1 and XRCC3 analysis. 
 
Table 6. Association between XRCC1 risk alleles and XRCC1 and XRCC3 risk alleles and 
clinical radiosensitivity 
Gene(s) Risk alleles* (n) CTC 0-1 CTC 2+ OR 95% CI p 
XRCC1 ≤1 37.5† 4.5‡ Ref   
 2 62.5 90.9 12.00 [1.46 – 98.78] 0.014 
 ≥2 62.5 95.4 12.60 [1.53 – 103.49] 0.011 
XRCC1 & XRCC3 ≤2 82.5§ 31.8║ ref   
 3 15.0 54.5 9.43 [2.63 – 33.74] 0.001 
 ≥3 17.5 68.1 10.10 [3.00– 33.96] 0.001 
Abbreviations: OR = odds ratio; 95% CI = 95% confidence interval; Ref = reference. Patient percentages in 
the CTC0-1 group and the CTC2+ group for the different number of risk alleles given. * Risk allele: OR > 1 
for CTC2+ group compared with CTC0-1 group, calculated to reference alleles. † Three patients with 0 risk 
alleles. ‡ No patients with no risk alleles. § Nine patients with 0 or 1 risk allele. ║ No patients with 0 or 1 
risk allele. 
 
In a second analysis of the SNP data, all cancer patients were compared 
with the cohort of healthy individuals. Except for one polymorphism, no 
association was found between the presence of mutant alleles and the risk 
of cancer. Individuals with one or two mutant alleles of the XRCC3 5’UTR 
polymorphism had a twofold increased risk of developing a gynecologic 
tumor compared with individuals with only the wild-type allele (p = 
0.024). Furthermore, homozygous carriers of the mutant 5’UTR G allele 
had an eightfold increased risk of developing a gynecologic tumor (p = 
0.019). 
 
Combined G2 and genotyping analysis 
To investigate the correlation between the genotype and chromosomal 
data, a combined analysis between the G2 score and the number of risk 
alleles in XRCC1 and XRCC3 was performed. This combined G2/risk 
allele analysis is presented in Figure 3. The 90th percentile of the patient 
group without radiation reactions was used as the cutoff value for the 
number of chromatid breaks, and more than two risk alleles was adopted 
as the limit for the number of risk alleles pointing to enhanced 
radiosensitivity. Five patients, possessing three or more risk alleles in 
XRCC1 and XRCC3 and a G2 score greater than the cutoff value of 1.39 
breaks/cell, all showed severe RT reactions. None of the patients without 
normal tissue reactions (CTC0-1) were found in this quartile. Of the 38 
patients without reactions to RT and 20 patients with reactions to RT, 30 
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and 3, respectively, were located in the third quartile (two or less risk 
alleles and <1.39 chromatid breaks/cells). The latter indicates that a 
normal G2 score, together with a low number of XRCC1 and XRCC3 risk 
alleles, is predictive of no adverse reactions to RT. 
 
Fig. 3. Combined G2/risk alleles analysis. Vertical line represents 90th percentile cutoff value 
of number of chromatid breaks of patient group without radiation reactions (CTC0-1); 
horizontal line represents criterion for radiosensitivity with respect to number of risk alleles 
(>2). 
 
Discussion 
The aim of this study was to investigate the association between in vitro 
individual  radiosensitivity using the G2 chromosomal assay and late 
normal tissue reactions. Furthermore, the involvement of four XRCC1 
(194Arg/Trp, 280Arg/His, 399Arg/Gln, 632Gln/Gln) polymorphisms, 
three XRCC3 (5’UTR 4.541A>G, IVS5-14 17.893A>G, 241Thr/Met) 
polymorphisms, and one OGG1 (326Ser/Cys) polymorphism in clinical 
radiosensitivity was studied. 
 
Clinical endpoint and patient population 
Late reactions in the pelvic area were used as the clinical endpoint. 
Because the scoring of these side effects is subjective, one staff oncologist 
was responsible for the follow-up of all patients in the study. The patients 
underwent a physical examination every 6 months for the first 2 years, 
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followed by an annual examination for up to 10 years after treatment. 
Normal tissue reactions were scored according to the Common 
Terminology Criteria for Adverse Events scale (21, 24). Various patient- 
and treatment-related factors may contribute to the development of 
adverse reactions to RT. For the patient group under study, age at 
treatment, follow-up period, total dose, and dose per fraction were 
largely uniform. The mean age at the end of the last RT session for the 
patients without adverse reactions (CTC0-1) was 57 years and for the 
patients with adverse reactions (CTC2+) was 62 years; the mean follow-
up for both groups was, respectively, 5.0 and 4.5 years. Normal tissue 
reactions occurred 0.5–5.7 years (mean, 1.7 years) after the last treatment. 
For 8 patients without normal tissue reactions, the follow-up period was 
<1.7 years. This may constitute a shortcoming in the analysis when 
addressing normal tissue reactions that develop gradually after a latency 
period. However, excluding these patients from the data set did not result 
in a significant divergence for any of the conclusions. Different treatment 
schedules may also act as a confounding factor and affect the 
development of adverse normal tissue reactions. To investigate this, the 
patient population was sorted according to the treatment and CTC 
grading. The chi-square analysis showed no significant differences in 
CTC classification between patients with or without chemotherapy (p = 
0.270) or between patients with or without surgery (p = 0.914). 
 
Relationship between clinical and chromosomal radiosensitivity 
To date, studies correlating cellular radiosensitivity (comet, micronucleus 
or colony-forming assays) and radiation toxicity have produced 
contradictory findings with some showing a relationship (15,26,27) and 
others not (18,25). In the present study, individual chromosomal 
radiosensitivity was determined by scoring chromatid breaks in 
lymphocytes irradiated in vitro. Our results confirm the findings of Barber 
et al. (20) that the number of in vitro radiation-induced G2 chromatid 
aberrations is greater for patients with complications after RT, but for a 
patient group treated for gynecologic tumors with late radiopathologic 
reactions. Of our patients with enhanced clinical radiosensitivity, 45% 
also showed a significantly increased chromosomal radiosensitivity based 
on the 90th percentile cutoff value. Actuarial analysis was used because of 
the time dependence of the late RT reactions and showed that patients 
with high chromosomal radiosensitivity (≥µ+SD) had a 9.2-fold greater 
annual risk of complications than patients with intermediate 
chromosomal radiosensitivity (<µ+SD). This is in agreement with the 
study of Hoeller et al. (28), in which patients were classified according to 
their cellular sensitivity. Although the sensitivity of the G2 assay (45%) is 
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not sufficient for individual tailoring of RT schedules, the technique can 
have a limited usefulness in patients in whom the clinician expects 
radiation hypersensitivity because of family history or associated medical 
conditions. The incomplete association between the chromosomal and 
clinical radiosensitivity can be explained by the existence of other 
susceptibility factors such as inflammatory reactions or cytokine 
production, in addition to a possible defect in DNA repair. 
 
Relationship between clinical radiosensitivity and SNPs in DNA repair 
genes 
Single nucleotide polymorphisms represent a very abundant type of 
genetic variation, and hundreds of genes can potentially participate in the 
response to RT (9). The selection of candidate genes and polymorphisms 
remains a crucial step in the search for an association with normal tissue 
radiosensitivity. For this study, we decided to screen for polymorphisms 
that have been shown to be involved in cancer predisposition and 
radiosensitivity according to the literature. In our first selection, we opted 
for functional polymorphisms in biologic processes. Later, this selection 
was expanded with (1) polymorphisms without amino acid change 
(XRCC1 632Gln/Gln), (2) polymorphisms located in regulatory regions 
(XRCC3 5’UTR), and (3) polymorphisms in noncoding sequences (XRCC3 
IVS5-14). Furthermore, we decided to examine different polymorphisms 
within one gene to study intragenic associations.  
Analysis of the individual polymorphism data showed that the strongest 
association with clinical radiosensitivity was observed for the XRCC3 
IVS5-14G variant (OR 3.98, p = 0.025). Because the XRCC3 IVS5-14 17.893 
polymorphism is located in a noncoding sequence region of the gene, the 
functional effect of this polymorphism is still incomprehensible. Apart 
from Kuschel et al. (29), who showed a protective effect of the variant G 
allele for developing breast cancer, no positive linkage studies have been 
reported with respect to this polymorphism (30, 31). The functional 
relevance could be associated with an alternative splicing variant or be 
involved in RNA instability. Another possibility is that the 
polymorphism is in linkage disequilibrium with other functional variants 
not tested here.  
Recently, Moullan et al. (11) reported a positive association of the XRCC1 
194Trp polymorphic allele, as well as the XRCC1 399Gln polymorphic 
allele, and the risk of developing normal tissue reactions after RT for the 
breast. In present study, we also established a positive association for the 
399Gln polymorphic allele and clinical radiosensitivity, but a statistically 
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significant opposite association for the XRCC1 194Trp variant allele (p = 
0.028) and clinical radiosensitivity was found. The latter could have been 
because individuals with the CT genotype were underrepresented in the 
patient group with reactions. Alternatively, it might be that different 
polymorphisms predispose different tissues to fibrosis-like reactions. 
Another explanation for the discrepancy may be that Moullan et al. (11) 
did not make a distinction between acute and late RT reactions. 
Although the XRCC3 IVS5-14G polymorphic allele was significantly 
associated with the occurrence of late normal tissue reactions, one-third 
of the radiosensitive patients were homozygous for the normal alleles. 
This reflects the possible role of additional genes and polymorphisms 
participating in the development of late normal tissue reactions. 
Combined analysis of positively correlated polymorphisms in XRCC1 
and XRCC3 genes with late normal tissue reactions confirmed this 
hypothesis. In the present study, the His and Gln amino acids, the A and 
G alleles in XRCC1 codon 280, codon 399, codon 632, and XRCC3 IVS5-14 
position, respectively, appeared to be risk factors for radiation-induced 
normal tissue reactions. These four alleles were defined as “risk alleles,” 
and the patients were classified according to the total number of risk 
alleles they harbored. Patients with three and more risk alleles had a 
significantly increased risk of developing late normal tissue reactions (OR 
10.10, p = 0.001). Of the 40 patients without reactions to RT, 17.5% 
possessed three or more risk alleles and could be considered as false 
positives. In an additional analysis, the risk allele model was combined 
with the G2 chromosomal data. Using the 90th percentile of the patient 
group without radiation reactions as the cutoff value for the number of 
chromatid breaks and more than two risk alleles as the criterion for 
radiosensitivity with respect to risk alleles, 23% of the patients with late 
normal tissue reactions could be identified without false-positive results. 
Likewise, 79% of the patients without normal tissue reactions could be 
identified, with 15% false-negative findings. 
The positive association found in our study between the number of risk 
alleles and the clinical radiosensitivity supports the assumption that 
normal tissue radiosensitivity is determined by the combined effect of 
different genetic variations. Furthermore, Quarmby et al. (32) and 
Andreassen et al. (33) demonstrated in their studies of radiation-induced 
fibrosis that supplemental genes in the development of late normal tissue 
reactions could be located outside DNA repair genes. 
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Relationship between gynecologic cancer and SNPs in DNA repair genes 
A lot of research has already been done on the association between 
polymorphisms in DNA repair genes and cancer risk (34). The primary 
goal of this study with respect to SNPs was the association with clinical 
radiosensitivity. Taking into account genotype data of a healthy control 
population, the obtained data also allowed us to study possible 
associations between polymorphisms and cervical and/or endometrial 
cancer risk. Except for the XRCC3 5’UTR 4.541 A>G polymorphism, no 
association of the selected SNPs with an increased risk of gynecologic 
tumors was found. Subdividing the patient group into cervical (n = 30) 
and endometrial (n = 32) cancer cases, it became clear that the XRCC3 
5’UTR G variant allele is associated with the risk of cervical cancer 
exclusively (AA vs. GG, OR 15.43, p = 0.001; AA vs. AG + GG, OR 2.57, p 
= 0.038). Although our patient group was relatively small, our data 
support the results obtained in a recent study by Wu et al. (35) that did 
not find any correlation between polymorphisms in XRCC1 (194, 280, 
399) and the risk of cervical cancer. To date, only one study has examined 
the association between genetic variations in XRCC3 (5’UTR 4.541, IVS5-
14 17.893, 241) and endometrial cancer risk (31). That study could not 
provide evidence that women with polymorphisms at these sites had an 
altered risk of endometrial cancer, which is in agreement with our data 
set. 
 
Conclusion 
The data analysis of the present study showed that clinical 
radiosensitivity is related to an enhanced G2 chromosomal 
radiosensitivity and is significantly associated with a combination of 
different polymorphisms in DNA repair genes. Additional association 
studies of well-characterized large cohorts analyzing genes involved in 
the different mechanisms of the cellular response to radiation, not only 
DNA damage detection and repair, but also cytokines promoting fibrosis, 
could prove a promising approach to identify the genes associated with 
the adverse response to RT. 
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Abstract 
This study investigates the association of microsatellite polymorphisms in XRCC1, XRCC3 and 
XRCC5 with the development of late radiation-induced radiotherapy reactions and examines 
the correlation between these microsatellites and cancer incidence. 
Sixty-two women with cervical or endometrial cancer treated with radiotherapy were included 
in the study. According to the CTCAEv3.0 scale, 22 patients showed late adverse radiotherapy 
reactions (grade 2 or more). PCR on lymphocyte DNA followed by automated fragment 
analysis was performed to examine the number of tandem repeat units at each locus.  
No significant association was found between the repeat length at any of the microsatellites in 
XRCC1, XRCC3 or XRCC5 and the incidence of late radiotherapy complications. Since higher 
odds ratios (ORs) were found for the rare XRCC1 [AC]11 and [AC]21 repeats (OR = 2.65, p = 0.325 
and OR = 8.67, p = 0.093, respectively), the possible involvement of these small and large 
repeats in clinical radiosensitivity cannot be completely ruled out. When specific numbers of 
repeats were examined, no significant correlation was found between the microsatellite repeat 
length in XRCC1 and XRCC5 and cancer incidence. A weak correlation between XRCC3 [AC]16 
homozygotes and cancer incidence was found (OR = 2.56, p = 0.055).  
A large-scale multicenter study of cancer patients with a high number of radiosensitive 
individuals is needed to clarify the value of rare polymorphic microsatellite repeats in XRCC1 
and XRCC3 as a biomarker of clinical radiosensitivity or increased cancer risk. 
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Introduction 
In radiation oncology, radiation dose protocols are dependent on both the 
tolerance of healthy tissue and the tumor control probability. In a small 
percentage of patients, radiation doses that are usually well tolerated by 
the healthy tissues within the irradiation field result in unexpected acute 
and/or late radiotoxic effects. The development of predictive methods to 
determine the degree of radiosensitivity of both tumor and healthy tissue 
has become of major interest in radiobiological research (1). 
Several observations indicate that normal tissue hypersensitivity may be 
related to genetic factors (2, 3). Several studies have reported a possible 
correlation between genetic polymorphisms and adverse radiotherapy 
reactions in patients (4–12). Although most studies have not detected a 
conclusive correlation between genotype and clinical radiosensitivity, 
Price et al. have reported a highly significant association between clinical 
radiosensitivity and rare microsatellites (unusually large or unusually 
small alleles) in the DNA repair genes XRCC1 and XRCC3 (13). 
Microsatellites are tandemly repeated highly polymorphic sequences and 
are common throughout the human genome. Repeat units are gained and 
lost by DNA replication slippage, a mutation mechanism that results 
from the transient dissociation of the replicating DNA strands followed 
by misaligned reassociation (14, 15). Expansions of triplet repeats are the 
underlying cause of several genetic diseases such as myotonic dystrophy, 
Huntington’s disease and fragile X syndrome (16–18). Furthermore, 
microsatellites are the molecular targets for malfunctioning repair and 
replication proteins in diseases such as hereditary non-polyposis 
colorectal carcinoma (HNPCC), where there is a defect in mismatch 
repair, and Bloom’s syndrome, where a DNA helicase homologue is 
defective (19, 20).  
XRCC1 plays an important role in the base excision repair pathway (BER) 
and participates as a scaffolding intermediate by interacting with ligase 
III, DNA polymerase β and poly(ADP-ribose) polymerase (21). XRCC3 
functions in the homologous recombination repair pathway (HHR) by 
repairing double-strand breaks. XRCC5 or Ku80 is involved in the non-
homologous end-joining repair pathway (NHEJ), and encodes, together 
with the G22P1 (KU70) and PRKDC genes, components of a DNA-
dependent protein kinase (DNA-PK) (22). 
In the present study we investigated whether polymorphic microsatellites 
in three DNA repair genes, XRCC1, XRCC3 and XRCC5, are associated 
with clinical radiosensitivity and cancer incidence. To this end we have 
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screened for these microsatellites in patients with cervical or endometrial 
cancer who received radiotherapy and in a control population of healthy 
individuals. 
 
Methods and Materials  
Participants 
The patient group has been described previously (12). Sixty-two women 
with cancer of the cervix (n = 30) or endometrium (n = 32) were treated 
with fractionated external-beam radiotherapy to the pelvis (one anterior 
and two lateral fields, 25 MV photons) followed by a brachytherapy boost 
at the Ghent University Hospital. Fifteen patients received a tumor dose 
of 45 Gy (25 x 1.8 Gy), 22 patients received a tumor dose of 46 Gy (23 x 2 
Gy), and 22 patients received a tumor dose of 50 Gy (25 x 2 Gy). Three 
patients received 46 Gy supplemented with a parametrial boost up to 60 
Gy. Except for two patients, all patients were additionally treated by 
brachytherapy using either vaginal ovoids, Fletcher-type applications, or 
perineal implants. All brachytherapy was performed using a pulsed dose-
rate technique with iridium-192. Total doses from brachytherapy ranged 
from 15 to 35 Gy (dose rate 0.5 to 0.65 Gy/h). Eighteen patients with 
cancer of the cervix received combined radiochemotherapy and were 
treated with 40 mg/m2 cisplatinum per week during the period of the 
external radiotherapy. Forty-six patients were operatively treated with a 
Wertheim Meigs hysterectomy. Nine premenopausal patients received 
hormone replacement therapy (estrogen). The mean age of the patients at 
the time of treatment was 59 years (range 24–80 years). 
All patients have been scored with respect to several different normal 
tissue reactions by the same oncologist according to the Common 
Terminology Criteria for Adverse Events (CTCAE) scale version3.0 of the 
National Cancer Institute (23). Forty patients showed no or very light 
reactions to radiotherapy (CTC0–1), 14 patients experienced intermediate 
but distinct radiotherapy reactions (CTC2), six patients showed severe 
radiotherapy reactions (CTC3), one patient experienced life-threatening 
radiotherapy reactions (CTC4), and one patient died as a consequence of 
the radiotherapy (CTC5). Complication specifications are described in 
more detail by De Ruyck et al. (12). All normal tissue reactions appeared 6 
months to 5.7 years after radiotherapy and can be considered as late 
reactions. The mean time of follow-up was 4.8 years (range 0.7–10.6 
years). Patients classified in CTC0–1 are indicated as nonradiosensitive 
patients, while patients classified in CTC2, CTC3, CTC4 and CTC5 
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(CTC2+) are indicated as radiosensitive patients. For these two patient 
groups under study, age at time of treatment and follow-up period were 
very similar. Mean age at the end of the last radiation treatment for the 
patients without adverse reactions (CTC0–1) was 57 years and for the 
patients with adverse reactions (CTC2+) 62 years, while the mean follow-
up time for the two groups was 5.0 and 4.5 years, respectively. 
A Caucasian control population of 118 cancer-free individuals was used 
to determine the overall population microsatellite frequency and allows 
association analysis of microsatellite genotype with cancer incidence. The 
control individuals were employees of the Ghent University Hospital and 
were recruited during the annual occupational medical examination. The 
mean age of controls was 38 years (range 22–62 years). The patient and 
the control populations were ethnically matched. All individuals were 
Belgian. The mean age of the patients was higher in comparison with the 
healthy controls, 59 years and 38 years, respectively. However, there are 
no indications that microsatellite frequencies at the loci considered vary 
with age. The healthy control population consisted of 53 men and 65 
women, while the patients are all women. This lack of sex matching 
should not cause a problem since the loci studied are located on 
autosomes. Moreover, χ2 tests on the control population verified that 
there are no differences between microsatellite frequencies in men and 
women (0.16 < p < 0.96 for all repeats tested separately in the three XRCC 
genes). 
A heparinized blood sample was taken from each individual in the study, 
and lymphocytes were isolated and frozen for genotyping analysis. The 
study was approved by the Ghent University Hospital Ethical 
Committee. All participants received oral and written information 
concerning the study and signed the informed consent form. 
Genotyping Analysis 
Genomic DNA was extracted from isolated lymphocytes, and DNA 
analysis was successful on all samples. A [AC]n microsatellite repeat 
region in the 3’ untranslated region (3’ UTR) of XRCC1 (accession number 
L34079), a [AC]n microsatellite repeat located in intron 3 of XRCC3 
(accession number AF000735), and a [GAPyA]n repeat located 120kb 5’ of 
XRCC5 (accession number AF000736) were analyzed. The repeat regions 
were amplified by PCR, and sizes were analyzed using an ABI Prism 310 
Genetic Analyser (PE Applied Biosystems). The XRCC1 3’ UTR 
microsatellite tandem [AC]n repeat region was amplified using the 
following primers (MWG Biotech): XRCC1F 5’-CCC GAT GGA TCT ACA 
GTT GC-3’ and XRCC1R 5’-CCC AGG GAG CCT CTT AGA GT-3’. The 
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forward primer was labeled with the fluorophore FAM-6. The intron 
tandem [AC]n repeat region in XRCC3 was amplified with XRCC3F 5’-
GAC AAT ATG CAT GTA TTA CTT TG-3’ and XRCC3R 5’-GTG TGC 
AGT TTA TAT AAG GCA GG-3’. The XRCC5 [GAPyA]n repeat region 
was amplified using XRCC5F 5’-TGT TGC TAT TGT TGT CTA GC-3’ and 
XRCC5R 5’-AAG TCA CTC ACA TGT AAT CC-3’. Both XRCC3R and 
XRCC5R were labeled with the fluorophore TET. Multiplex PCR was 
undertaken in 12.5-µl volumes on an ABI9700 thermal cycler with 
conditions of 95°C for 15 min followed by 25 cycles of 94°C for 30 s, 57°C 
for 90 s and 72°C for 60 s, with a final 60°C hold for 30 min. PCR was 
undertaken using a multiplex PCR mix (Qiagen). Each reaction contained 
1x Qiagen Multiplex PCR mix, 0.2 µM of each primer, and 0.5 µl template 
DNA. After PCR, fragment analysis was undertaken on an ABI Prism 310 
Genetic Analyser. One microliter of PCR sample was mixed with 12 µl of 
deionized formamide and 0.5 µl of Genescan-500 TAMRA size standard 
(Applied Biosystems) and denatured for 3 min at 94°C. Capillary 
electrophoresis used POP-4 polymer with a 5-s injection time and 27 min 
electrophoresis at 60°C. Microsatellite allele sizes were converted to 
repeat lengths based on allele size as described by Price et al. (13). All 
genotyping was performed in duplicate. 
Statistical analysis 
Statistical analysis was performed by MedCalc 4.0. Allele frequencies of 
the different patient groups and the control population were determined 
and displayed graphically. Heterozygosities were calculated by dividing 
the number of heterozygotes by the total number of individuals. Odds 
ratios (ORs) with 95% confidence intervals (95% CI) were calculated for 
each microsatellite repeat length to evaluate the association of XRCC1, 
XRCC3 and XRCC5 microsatellite genotypes with both clinical 
radiosensitivity and cancer incidence. Corresponding p values were 
obtained using the χ2 test. The reference genotype was a pooled sample of 
individuals with all repeat numbers, except the one examined. For clinical 
radiosensitivity, genotypes were compared between radiosensitive 
patients (CTC2+) and nonradiosensitive patients (CTC0–1). For cancer 
incidence, genotypes were compared between patients (total population) 
and control individuals. Impact of the different external radiotherapy 
doses, brachytherapy doses and total doses was evaluated with the 
Mann-Whitney test. Influence of chemotherapy, surgery and hormone 
therapy in the patient population and influence of gender in the control 
population was tested using the χ2 test. 
 
 72
Table 1. Overview of cancer type, treatment protocols and clinical radiosensitivity according 
to the CTCAE Scale 
Patient 
no. 
Cancer 
type 
Hormone 
therapy 
External 
radiotherapy 
dose (Gy) 
Brachytherapy 
dose  
(Gy) 
Clinical 
radiosensitivity 
CTCAE 
1 Cervix yes 45 15 0 
2 Cervix yes 45 30 0 
3 Cervix no 45 20 0 
4 Cervix yes 45 19 0 
5 Cervix no 45 20 0 
6 Cervix no 45 30 0 
7 Endometrium no 45 30 0 
8 Cervix no 45 20 0 
9 Cervix no 45 20 0 
10 Endometrium no 45 27 0 
11 Endometrium no 45 22 0 
12 Cervix no 45 15 2 
13 Cervix no 45 25 0 
14 Endometrium no 45 20 0 
15 Cervix no 45 35 2 
16 Cervix no 46 30 3 
17 Cervix no 46 19 0 
18 Cervix no 46 15 3 
19 Cervix no 46 34 3 
20 Endometrium no 46 19 2 
21 Cervix no 46 24 0 
22 Endometrium no 46 34 3 
23 Cervix yes 46 30 0 
24 Cervix yes 46 20 0 
25 Endometrium no 46 19 0 
26 Endometrium no 46 19 1 
27 Cervix no 46 34 0 
28 Endometrium no 46 19 0 
29 Endometrium no 46 19 0 
30 Cervix no 46 19 3 
31 Endometrium yes 46 19 0 
32 Cervix no 46 35 3 
33 Cervix yes 46 19 0 
34 Endometrium no 46 19 0 
35 Endometrium no 46 19 0 
36 Endometrium no 46 24 2 
37 Endometrium no 46 19 2 
38 Endometrium no 50 / 5 
39 Endometrium no 50 15 2 
40 Cervix yes 50 19 4 
41 Endometrium no 50 15 2 
42 Endometrium no 50 15 1 
43 Endometrium no 50 15 0 
44 Endometrium no 50 15 0 
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Table 1. Overview of cancer type, treatment protocols and clinical radiosensitivity according 
to the CTCAE Scale (continued) 
Patient 
no. 
Cancer 
type 
Hormone 
therapy 
External 
radiotherapy 
dose (Gy) 
Brachytherapy 
dose 
(Gy) 
Clinical 
radiosensitivity 
CTCAE 
45 Cervix no 50 19 0 
46 Cervix no 50 15 0 
47 Endometrium no 50 15 2 
48 Endometrium no 50 15 2 
49 Cervix no 50 15 2 
50 Endometrium no 50 / 0 
51 Endometrium no 50 30 1 
52 Endometrium no 50 15 2 
53 Cervix yes 50 14 0 
54 Endometrium no 50 19 0 
55 Endometrium no 50 15 0 
56 Endometrium no 50 15 0 
57 Endometrium no 50 15 2 
58 Endometrium no 50 20 2 
59 Endometrium no 50 15 0 
60 Cervix no 60 19 0 
61 Cervix no 60 20 2 
62 Cervix no 60 15 0 
 
Results 
An overview of the radiotherapy treatment protocols and the 
radiotherapy reactions is given in Table 1. To investigate a possible bias 
of the treatment protocols, the delivered radiation doses of both the 
CTC2+ and the CTC3+ groups were compared with the CTC0–1 patient 
group using a two-tailed Mann-Whitney test. For the CTC0–1 and CTC2+ 
groups, no significant difference could be shown with respect to the 
external radiotherapy dose (p = 0.13), the dose delivered by 
brachytherapy (p = 0.74), and the summation of both doses (p = 0.72). The 
comparison of the CTC0–1 and CTC3+ groups resulted in nonsignificant 
p values of 0.58, 0.10 and 0.28, respectively. The impact of the 
chemotherapy treatment, surgery and hormone therapy on the clinical 
radiosensitivity in the population was evaluated by χ2 analysis. 
Therefore, the patient population was sorted according to the treatment 
and the CTC grading. This analysis showed no significant differences in 
CTC classification between patients with or without chemotherapy (p = 
0.27), with or without surgery (p = 0.91), and with or without hormone 
therapy (p = 0.20).  
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Figures 1, 2 and 3 show the allele frequencies of the different 
microsatellite repeats in XRCC1, XRCC3 and XRCC5, respectively, for 
healthy controls, all cancer patients, nonradiosensitive cancer patients 
(CTC0–1), and radiosensitive cancer patients (CTC2+). The data on the 
association between the number of microsatellite repeats in XRCC1, 
XRCC3 and XRCC5 and clinical radiosensitivity are given in Table 2, 
while the data on the association between the microsatellites and cancer 
incidence are given in Table 3. 
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Fig. 1. Allele frequencies of the [AC]n microsatellite in the 3’ untranslated region of XRCC1. 
Number of healthy controls = 118; number of nonradiosensitive cancer patients = 40; number 
of clinically radiosensitive cancer patients = 22. 
 
The XRCC1 [AC]n microsatellite was highly polymorphic, with between 
11 and 22 repeat units and an observed heterozygosity of 0.74. The most 
frequently occurring alleles were in the range [AC]17 to [AC]19. Allele 
frequencies for these repeats were similar in all groups considered. The 
smallest observed allele size ([AC]11) had a frequency of 0.047 in healthy 
controls, 0.073 in all patients, 0.050 in nonradiosensitive patients, and 
0.114 in radiosensitive patients. Patients with one [AC]11 repeat had a 2.65 
times higher risk of developing adverse radiotherapy reactions. This 
result, however, is not statistically significant (p = 0.325). With this 
obtained OR of 2.65, a sample size of 160 individuals is needed to reach 
statistical significance. Allele frequencies for [AC]21 repeats were 0.034, 
0.040, 0.013 and 0.091 for healthy controls, all cancer patients, 
nonradiosensitive cancer patients, and radiosensitive cancer patients, 
respectively. Four patients with one [AC]21 repeat were found among the 
22 clinically radiosensitive patients, while only one [AC]21 heterozygote 
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was found in the 40 nonradiosensitive patients (OR = 8.67, p = 0.093). 
With this very high OR of 8.67, an increase of the sample size to 80 
individuals would be needed to reach statistical significance. None of the 
patients were homozygous for [AC]11 and [AC]21 microsatellite copy 
numbers; thus we were unable to determine whether these alleles act in a 
recessive fashion. Comparison of cancer incidence with the presence of 
any number of microsatellite repeats in XRCC1 did not show any distinct 
association (Table 3). 
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Fig. 2. Allele frequencies of the [AC]n microsatellite in intron 3 of the XRCC3 gene. Number 
of healthy controls = 118; number of nonradiosensitive cancer patients = 40; number of 
clinically radiosensitive cancer patients = 22. 
 
The XRCC3 [AC]n microsatellite exhibited between 9 and 21 repeat units. 
The observed heterozygosity for this repeat was 0.63. The most frequently 
occurring alleles were [AC]14 and [AC]16. The largest allele, [AC]21, was 
found at a frequency of 0.034 in controls, 0.024 in all cancer patients, 0.038 
in nonradiosensitive cancer patients, and 0 in clinically radiosensitive 
cancer patients. Accordingly, no measure of association with 
radiosensitivity could be undertaken. Patients carrying one [AC]17 repeat 
had a three times higher risk of developing normal tissue reactions after 
radiotherapy in comparison with patients having any other number of 
repeats, although this is not statistically significant (p = 0.479). None of 
the patients were homozygous for the [AC]17 repeat (Table 2). A 
borderline significant positive association was found between the 
presence of two [AC]16 repeats and cancer incidence (OR = 2.56, p = 
0.055). Other [AC] repeats did not show any significant association with 
cancer incidence. 
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Fig. 3. Allele frequencies of the [GAPyA]n microsatellite 120 kb from the XRCC5 gene. A 
small proportion of the alleles were extended by two nucleotides, resulting in [GAPyA]14+2,  
[GAPyA]15+2, [GAPyA]16+2, [GAPyA]17+2 and [GAPyA]19+2 repeats. Number of healthy controls 
= 118; number of nonradiosensitive cancer patients = 40; number of clinically radiosensitive 
cancer patients = 22. 
 
The XRCC5 [GAPyA]n tetranucleotide microsatellite was polymorphic, 
with repeat units from 14 to 19. The observed heterozygosity for this 
repeat was 0.63. A small proportion of the alleles were extended by two 
nucleotides, resulting in [GAPyA]14+2, [GAPyA]15+2, [GAPyA]16+2, 
[GAPyA]17+2 and [GAPyA]19+2 repeats. The most frequent alleles were 
[GAPyA]15 and [GAPyA]16. The rarest alleles were the smallest and the 
largest ([GAPyA]14+2, [GAPyA]17+2, [GAPyA]18, [GAPyA]19, [GAPyA]19+2), 
representing together 0.8, 4, 6.3 and 0% in healthy controls, all cancer 
patients, nonradiosensitive cancer patients, and radiosensitive cancer 
patients, respectively (Fig. 3). Statistical analysis of clinical 
radiosensitivity or cancer incidence with the presence of any number of 
microsatellite repeats in XRCC5 did not show any significant association. 
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Table 2. Association between microsatellite repeat number in XRCC1, XRCC3 and XRCC5 
and clinical radiosensitivity 
 Number of repeats 
XRCC1a 11 17 18 19 20 21 
   NRS patients 4 (4/0) 18 (13/5) 20 (11/9) 17 (14/3) 3 (3/0) 1 (1/0) 
   RS patients 5 (5/0) 11 (10/1) 12 (10/2) 8 (8/0) 1 (1/0) 4 (4/0) 
   Odds ratio 2.65 1.22 1.20 0.77 0.59 8.67 
   95% CI 0.63 - 11.13 0.43 - 3.47 0.42 - 3.41 0.26 - 2.26 0.06 - 6.01 0.90 - 83.17 
       
XRCC3b 14 15 16 17 20 21 
   NRS patients 24 (20/4) 3 (3/0) 29 (18/11) 2 (2/0) 3 (3/0) 3 (3/0) 
   RS patients 13 (11/2) 1 (1/0) 17 (10/7) 3 (3/0) 1 (1/0) 0 
   Odds ratio 0.96 0.59 1.29 3.00 0.59 / 
   95% CI 0.33 - 2.78 0.06 - 6.01 0.38 - 4.35 0.46 - 19.51 0.06 - 6.01 / 
       
XRCC5c 14+2 15 15+2 16 16+2 17 
   NRS patients 1 (1/0) 22 (17/5) 4 (3/1) 24 (19/5) 1 (0/1) 12 (12/0) 
   RS patients 0 12 (9/3) 4 (3/1) 12 (8/4) 1 (1/0) 6 (5/1) 
   Odds ratio / 0.98 2.00 0.80 1.86 0.88 
   95% CI / 0.35 - 2.79 0.45 - 8.94 0.28 - 2.29 0.11 - 31.22 0.28 - 2.78 
Notes. The number of individuals carrying at least one allele is given (with number of 
heterozygous/homozygous individuals indicated in parentheses). Odds ratios, with 95% CI, for risk of 
radiosensitivity are  shown for  nonradiosensitive (NRS) patients (n = 40)  compared  to  radiosensitive 
(RS) patients (n = 22). 
a Does not include [AC]22 repeats for which only one individual was seen. 
b Does not include [AC]9, [AC]13, [AC]18, [AC]19 repeats for which only one individual each was seen. 
c Does not include [GAPyA]17 + 2, [GAPyA]19, [GAPyA]19 + 2 for which only one individual each was seen 
and [GAPyA]18 for which only two individuals were seen. 
 
Discussion 
This study investigated the association between polymorphic 
microsatellites in the DNA repair genes XRCC1, XRCC3 and XRCC5 and 
the risk of developing normal tissue reactions after radiotherapy 
treatment. Therefore, we have screened for these microsatellites in 
patients with cancer of the cervix or endometrium who received 
radiotherapy. To determine the overall microsatellite frequency in a 
Belgian population and to assess the correlation of these microsatellites 
with gynecological tumors, a control population consisting of healthy 
individuals was also screened. The microsatellites examined are located 
in different genomic contexts: the XRCC1 microsatellite occurs in the 
3’UTR of the gene, the XRCC3 microsatellite is intronic, and the XRCC5 
microsatellite is located 120 kb from the gene. The microsatellites within 
XRCC1 and XRCC3 have previously been suggested to be associated with 
radiosensitivity and cancer incidence (13). The microsatellite in XRCC5 
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was included based on the involvement of the XRCC5 gene in the NHEJ 
repair pathway. 
 
Table 3. Association between microsatellite repeat number in XRCC1, XRCC3 and XRCC5 
and cancer incidence 
 Number of repeats 
XRCC1a 11 17 18 19 20 21 
   Controls 11 (11/0) 67 (60/7) 74 (59/15) 36 (31/5) 12 (12/0) 8 (8/0) 
   Patients 9 (9/0) 29 (23/6) 32 (21/11) 25 (22/3) 4 (4/0) 5 (5/0) 
   Odds ratio 1.65 0.67 0.63 1.54 0.61 1.21 
   95% CI 0.64 - 4.23 0.36 - 1.24 0.34 - 1.18 0.81 - 2.92 0.19 - 1.97 0.38 - 3.86 
       
XRCC3b 14 15 16 17 20 21 
   Controls 76 (54/22) 11 (9/2) 77 (59/18) 5 (4/1) 13 (13/0) 8 (8/0) 
   Patients 37 (31/6) 4 (4/0) 46 (28/18) 5 (5/0) 4 (4/0) 3 (3/0) 
   Odds ratio 0.82 0.67 1.53 1.98 0.56 0.70 
   95% CI 0.43 - 1.54 0.20 - 2.20 0.77 - 3.03 0.55 - 7.13 0.17 - 1.79 0.18 - 2.74 
       
XRCC5c 14+2 15 15+2 16 16+2 17 
   Controls 1 (1/0) 80 (64/16) 10 (6/4) 72 (64/8) 12 (12/0) 31 (30/1) 
   Patients 1 (1/0) 34 (26/8) 8 (6/2) 36 (27/9) 2 (1/1) 18 (17/1) 
   Odds ratio 1.92 0.58 1.60 0.88 0.29 1.17 
   95% CI 0.12 - 31.20 0.31 - 1.09 0.60 - 4.29 0.47 - 1.65 0.06 - 1.36 0.59 - 2.33 
Notes. The number of individuals carrying at least one allele is given (with number of 
heterozygous/homozygous individuals indicated in parentheses). Odds ratios, with 95% CI, for risk of 
cancer are shown for healthy controls (n = 118) compared to cancer patients (n = 62). 
a Does not include [AC]22 repeats for which only one individual was seen. 
b Does not include [AC]9, [AC]13, [AC]18, [AC]19  repeats for which only one individual each was seen. 
c Does not include [GAPyA]17 + 2, [GAPyA]19, [GAPyA]19 + 2 for which only one individual each was seen 
and [GAPyA]18 for which only two individuals were seen. 
 
The overall microsatellite frequencies and distribution of repeat lengths 
in a healthy Belgian population were similar to those reported previously 
in studies of UK newborns and retired UK radiation workers (25, 26) and 
in an Australian twin study for XRCC3 and XRCC5 (27).  
In 1997, Price et al. (13) reported a highly significant association between 
clinical radiosensitivity and rare microsatellites in XRCC1 and XRCC3 in 
a population of 19 cancer patients. In their study, rare microsatellites 
were alleles with less than 12 or more than 23 repeats for XRCC1, alleles 
with more than 20 repeats for XRCC3, and alleles with less than 14 or 
more than 18 repeats for XRCC5. All other microsatellite allele sizes were 
classified as common repeats. In this study we found a positive 
correlation between patients with [AC]11 repeats and patients with [AC]21 
repeats in XRCC1 and the risk of developing adverse radiotherapy 
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reactions, but these results were not statistically significant for both 
repeat numbers (p = 0.325 and p = 0.093, respectively). Alleles with more 
than 23 [AC] repeats were not present in the patient population or in the 
control population. Large XRCC3 alleles ([AC]20 and [AC]21 repeats) did 
not correlate with clinical radiosensitivity, while XRCC3 [AC]17 repeats 
were slightly more common in patients with adverse radiotherapy 
reactions (p = 0.479). For XRCC5, no examples of rare (≤14 or ≥18) repeat 
lengths were identified in the clinically radiosensitive patient group. 
Accordingly, no measure of association with radiosensitivity could be 
undertaken. For the other more common repeat lengths, we found no 
association with clinical radiosensitivity. 
Furthermore, we could not demonstrate an association between the rare 
microsatellite alleles considered and cancer incidence. However, a weak 
correlation was found between XRCC3 [AC]16 homozygotes and cancer 
incidence (p = 0.055). Subdividing the patient group into cervical and 
endometrial cancer cases, the positive association with the XRCC3 [AC]16 
repeat is retrieved only for endometrial cancer (p = 0.057). 
Although we found no significant association between the rare 
microsatellite alleles considered and clinical radiosensitivity or cancer 
incidence, the microsatellites could affect radiosensitivity or cancer in a 
recessive manner. Because of the small numbers of individuals 
homozygous for the rare microsatellite repeats, we are unable to test this 
hypothesis. For other microsatellite repeat lengths where sufficient 
variant homozygotes were detected, we found (XRCC3 [AC]16 excluded) 
no evidence for a recessive action of these polymorphisms. We have 
consequently assumed dominance and treated the data accordingly.  
For this study, radiosensitivity classification of the patients is based on 
grading of the normal tissue reactions to the radiotherapy according to 
the CTCAE scale (23). Patients with intermediate but distinct 
radiotherapy reactions (CTC2) were pooled with patients with severe 
(CTC3) to life-threatening (CTC4/5) radiotherapy reactions. To assess 
possible differences in genotypes between the more severe radiosensitive 
individuals (CTC3/4/5), the intermediate radiosensitive patients (CTC2) 
and the nonradiosensitive patients (CTC0–1), we performed analyses of 
CTC3/4/5 (n = 8) compared to CTC0–1 (n = 40) and CTC2 (n = 14) 
compared to CTC0–1 (n = 40) analysis. The outcome of these analyses 
showed similar associations with the initial analysis (results not shown). 
Furthermore, the supplemental analysis showed that the XRCC1 [AC]11 
repeat occurred 2.3 times more frequently in the CTC2 patient group than 
in the CTC3/4/5 patient group. On the other hand, the XRCC1 [AC]21 
repeat was present more often in the CTC3/4/5 patient group, resulting 
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in an odds ratio of 13 compared the nonradiosensitive patient group 
(CTC0–1). Due to the low frequency of this microsatellite repeat and the 
small number of patients with very severe radiotherapy reactions, no 
statistical significance for this effect was reached (p = 0.110).  
Although not statistically significant, higher odds ratios were obtained 
for XRCC1 [AC]11 and XRCC1 [AC]21 alleles in radiosensitive patients. 
Therefore, we are not able to completely reject the hypothesis that these 
small and large rare alleles may be associated with adverse radiotherapy 
outcome. The strongly positive associations found by Price et al. between 
XRCC1 [AC]24 and XRCC3 [AC]20 repeats and clinical radiosensitivity 
were not found in this study, nor could we show significant associations 
between rare microsatellite repeats and cancer incidence. These 
discrepancies could be due to the fact that the two studies are based on 
different cancer populations and studied different radiosensitivity end 
points. The fact that both studies could not demonstrate an association 
between the XRCC5 microsatellite, clinical radiosensitivity and cancer 
incidence could be explained by the distant location of the microsatellite 
considered from the gene.  
Due to the highly polymorphic nature of the loci considered, in the 
future, larger studies with larger numbers radiosensitive cases in a 
multicenter setting are needed to clarify the involvement of rare 
polymorphic microsatellites in XRCC1 and XRCC3 DNA repair genes in 
either clinical radiosensitivity or cancer incidence. 
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Abstract 
Purpose: To investigate the association between six transforming growth factor-β1 gene 
(TGFβ1) polymorphisms (-1.552delAGG, -800G>A, -509C>T, Leu10Pro, Arg25Pro, Thr263Ile) 
and the occurrence of late normal tissue reactions after gynecologic radiotherapy (RT). 
Methods and Materials: Seventy-eight women with cervical or endometrial cancer and 140 
control individuals were included in the study. According to the Common Terminology Criteria 
for Adverse Events version 3.0 (CTCAEv3.0) scale, 25 patients showed late adverse RT reactions 
(CTC2+), of whom 11 had severe complications (CTC3+). Polymerase chain reaction–restriction 
fragment length polymorphism (PCR-RFLP), single base extension and genotyping assays were 
performed to examine the polymorphic sites in TGFβ1. 
Results: Homozygous variant -1.552delAGG, -509TT, and 10Pro genotypes were associated with 
the risk of developing late severe RT reactions. Triple (variant) homozygous patients had a 3.6 
times increased risk to develop severe RT reactions (p = 0.26). Neither the -800A allele, nor the 
25Pro allele or the 263Ile allele were associated with clinical radiosensitivity. There was perfect 
linkage disequilibrium (LD) between the -1.552delAGG and the -509C>T polymorphisms, and 
tight LD between the -1.552/-509 and the Leu10Pro polymorphisms. Haplotype analysis 
revealed two major haplotypes but could not distinguish radiosensitive from nonradiosensitive 
patients. 
Conclusions: The present study shows that homozygous variant TGFβ1 -1.552delAGG, -509TT, 
and 10Pro genotypes may be associated with severe clinical radiosensitivity after gynecologic 
RT.  
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Introduction 
Late normal tissue complications in cancer radiotherapy (RT) are 
becoming of increasing concern as the number of long-term cancer 
survivors increases. For the radiation oncologist, a better understanding 
of the molecular events underlying normal tissue injury will allow a more 
rational approach to the prevention and treatment of normal tissue injury 
(1).  
Late RT effects develop months or years after treatment through complex 
interacting processes and result in diverse pathologic lesions, including 
fibrosis, necrosis, atrophy, and vascular damage. Important in this 
response is the production of cytokines (2). Among them, the 
multifunctional, autoinducible transforming growth factor-β1 (TGFβ1) is 
considered as a master switch for fibrosis, contributing to both the influx 
and activation of inflammatory cells, as well as to the activation of 
fibroblasts to produce extracellular matrix. TGFβ1 is implicated in the 
development and continuation of postirradiation injury in various tissues 
(3). The cytokine is known to be upregulated in normal tissues damaged 
by radiation as well as to be overproduced by tumors (4–6). Circulating 
TGFβ1 levels are also linked to the development of fibrosis in irradiated 
normal tissues. Associations between radiation pneumonitis after RT for 
lung cancer and TGFβ1 plasma levels have been reported (7–9). For RT of 
breast cancer and head-and-neck tumors, similar associations have been 
observed with respect to late radiation-induced fibrosis (10, 11). Out of 
the three known isoforms, TGFβ1 is predominant in human plasma, 
whereas TGFβ2 and TGFβ3 account for less than 5% of its total plasma 
concentration (12). 
Transforming growth factor-beta-1, located on chromosome 19q13.1, is 
synthesized as a large immature precursor molecule composed of a signal 
peptide, a latency-associated peptide, and active TGFβ1. The mature 
peptide contains two latency-associated peptide dimers with two 
disulfide cysteine bonds, bound to an active TGFβ1 dimer. In humans, 
mutations in the latency-associated peptide encoding sequence of the 
gene lead to the Camurati-Engelman syndrome (13).  
Several polymorphisms in the TGFβ1 gene have been detected (14–19). 
Grainger et al. have demonstrated that the TGFβ1 promoter genotype is 
responsible for 54% of the variation in circulating levels of TGFβ1. They 
studied the -800G>A and the -509C>T polymorphisms and found that the 
-509TT genotype was significantly associated with increased serum levels 
of TGFβ1 (17). The Leu10Pro and the Arg25Pro polymorphisms in exon 1 
of the TGFβ1 gene are located in the signal peptide sequence that is 
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cleaved from the TGFβ1 precursor at codon 29. Whereas both leucine and 
proline are apolar, the Arg25Pro polymorphism leads to a change of the 
big polar amino acid arginine for the small apolar proline closely to the 3’ 
end of the hydrophobic core of the signal sequence (20). Dunning et al. 
showed in in vitro experiments that the allele encoding 10Pro is associated 
with increased rates of TGFβ1 secretion (21). Yokota et al. reported that 
the amount of TGFβ1 in serum is higher for 10Pro homozygotes than for 
10Leu homozygotes (22). In addition, three independent studies showed 
a significant association of -509TT and 10Pro homozygotes and the 
occurrence of late fibrosis in breast cancer patients after RT treatment (23–
25). For the Arg25Pro polymorphism, however, homozygosity for the 
normal 25Arg allele is associated with higher TGFβ1 production in vitro 
and with fibrosis in lung allografts (26, 27). The Thr263Ile polymorphism 
is located in exon 5 and codes for that part of the TGFβ1 proprotein that is 
cleaved from the active part at codon 278 (20). Substitution of the polar 
amino acid threonine by the apolar isoleucine could affect the stability 
and the activation process of TGFβ1, leading to reduced concentrations of 
latent and subsequently active TGFβ1 (19).  
These observations indicate that TGFβ1 could be involved in the 
pathogenesis of radiation-induced normal tissue damage and that 
polymorphisms in TGFβ1 may predispose individuals to severe normal 
tissue morbidity after RT. To investigate this association, we performed 
genotyping for the -1.552delAGG, -800G>A, -509C>T, Leu10Pro (T>C), 
Arg25Pro (G>C), and Thr263Ile (C>T) polymorphisms in patients with 
cervix or endometrial cancer treated previously by RT. 
 
Methods and Materials 
Participants 
The study population consisted of 78 women, of whom 62 were also 
included in previous studies (28, 29). The patients with cancer of the 
cervix (n = 35) or endometrium (n = 43) were treated at the Ghent 
University Hospital with fractionated external beam RT to the pelvis (1 
anterior and 2 lateral fields, 25-MV photons) followed by a brachytherapy 
boost. Eighteen patients received a tumor dose of 45 Gy (25 x 1.8 Gy), 33 
patients received a tumor dose of 46 Gy (23 x 2 Gy), and 23 patients 
received a tumor dose of 50 Gy (25 x 2 Gy). Four patients received 46 Gy 
supplemented with a parametrial boost up to 60 Gy. Except for 2 patients, 
all patients were additionally treated by brachytherapy using either 
vaginal ovoids, Fletcher type applications, or perineal implants. All 
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brachytherapy was performed using a pulsed dose rate technique with 
iridium-192. Total doses from brachytherapy ranged from 15 to 35 Gy 
(dose rate, 0.5 to 0.65 Gy/h) at 0.5 cm from the applicator surface for 
ovoids and perineal implants and to point A for the Fletcher type 
application. Twenty-one patients with cancer of the cervix received 
combined radio-chemotherapy and were treated with 40 mg/m2 
cisplatinum per week during the period of the external RT. Sixty-one 
patients were operatively treated with a Wertheim-Meigs hysterectomy. 
Nine premenopausal patients received hormone replacement therapy 
(estrogen). The mean age of the patients at time of treatment was 59 years 
(range, 24–80 years). 
All patients have been scored with respect to several different normal 
tissue reactions by the same oncologist according to the Common 
Terminology Criteria for Adverse Events (CTCAE) scale version 3.0 of the 
National Cancer Institute (30). Fifty-three patients showed no or very 
light reactions to RT (CTC0–1), 14 patients experienced intermediate but 
distinct RT reactions (CTC2), 7 patients showed severe RT reactions 
(CTC3), 3 patients experienced life-threatening RT reactions (CTC4), and 
1 patient died as a consequence of the RT (CTC5). All normal tissue 
reactions appeared 6 months to 5.7 years after RT treatment and can be 
considered as late reactions. Of the 14 patients classified as CTC2, 13 
patients suffered from rectal problems including radiation enteritis with 
diarrhea, rectal blood loss, and ulcus formation. Three patients had 
additional urinary problems, 1 patient additional urinary and vaginal 
side effects, and 1 patient had additional bone problems 
(osteoradionecrosis). One CTC2 patient had only bone problems (pubis 
fracture). Of the 7 patients classified as CTC3, 6 patients had rectal injury 
comprising radiation enteritis with extreme diarrhea, rectal blood loss, 
ulceration, and intestinal obstruction. One CTC3 patient had exclusively 
bone problems (pelvis fibrosis, sacrum fracture, and osteoradionecrosis). 
All the patients classified as CTC4 suffered from severe rectal problems 
including radiation enteritis with anal blood loss and rectal ulceration 
leading to intestinal resection. The CTC5 patient suffered from a 
perforation of the small intestine. This overview shows that, except for 2 
patients, all adverse reactions scored comprise rectal injury.  
To investigate a possible bias of the treatment protocols on the clinical 
radiosensitivity, the delivered radiation doses of the CTC2+ group were 
compared with the CTC0–1 group using a two-tailed Mann-Whitney test. 
No significant differences could be shown with respect to the external RT 
dose (p = 0.224) and the dose delivered by brachytherapy (p = 0.549). The 
impact of the chemotherapy treatment, surgery, and hormone therapy on 
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the clinical radiosensitivity was evaluated by chi-square analysis. 
Therefore, the patient population was sorted according to the treatment 
and the CTC grading. This analysis showed no significant differences in 
CTC classification between patients with or without chemotherapy (p = 
0.900), with or without surgery (p = 0.976), and with or without hormone 
therapy (p = 0.293). An overview of the RT protocols according to cancer 
type and CTC classification is given in Table 1. 
 
Table 1. Overview of the treatment protocol data according to cancer type and CTC 
classification 
 n 
Mean 
external 
RT dose 
(Gy)* 
Mean 
brachytherapy 
dose (Gy)* 
% 
Chemotherapy 
treatment 
% 
Surgery 
% 
Hormone 
therapy 
Cervical cancer 35 47.4 (4.2) 21.8 (6.4) 51.4 71.4 22.9 
CTC 0-1 23 47.3 (4.3) 21.3 (5.4) 47.8 73.9 30.4 
CTC 2+ 12 47.5 (4.3) 22.7 (8.3) 58.3 66.7 8.3 
Endometrial cancer 43 47.9 (2.8) 19.4 (4.7) 7.0 83.7 2.3 
CTC 0-1 30 47.6 (3.1) 19.6 (4.4) 10.0 83.3 3.3 
CTC 2+ 13 48.5 (2.0) 18.8 (5.6) 0 84.6 0 
Abbreviations: CTC = Common Terminology Criteria; RT = radiotherapy. 
* Standard deviation is in parenthesis. 
 
The patients were subjected to a physical examination every 6 months for 
the first 2 years followed by an annual examination up to 11 years after 
treatment. The mean time of follow-up was 5.2 years (range, 0.9 –11.6 
years). Patients classified in CTC0–1 are considered as nonradiosensitive 
patients. Of this category, 1 patient was lost from the follow-up as she 
died 1 year after RT treatment. In addition, 11% of the CTC0–1 patients 
left the follow-up prematurely. Patients classified in the CTC2, CTC3, 
CTC4, and CTC5 (CTC2+) groups are indicated as radiosensitive patients, 
whereas patients with the most severe RT reactions are classified in the 
CTC3+ group. For the three patient groups under study, age at time of 
treatment and follow-up period were very similar. Mean age at the end of 
the last radiation treatment for the patients without adverse reactions 
(CTC0–1) was 58 years, for the patients with adverse reactions (CTC2+) 
62 years, and for the patients with the most severe adverse reactions 
(CTC3+) 64 years. The mean follow-up time was respectively 5.3, 5.1, and 
4.4 years. To study the association of polymorphisms in TGFβ1 with 
global clinical radiosensitivity, the CTC2+ patient group was compared 
with the CTC0–1 group. To evaluate the association with severe RT 
reactions, the CTC3+ patient group was compared with the CTC0–1 
group. 
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A Caucasian control population of 140 cancer-free individuals was used 
to determine the frequency of the TGFβ1 polymorphisms. The control 
population consisted of 65 men and 75 women, and the mean age was 42 
years (range, 23–83 years). The majority of the control individuals were 
employees of Ghent University Hospital and were recruited on the 
occasion of the annual occupational medical examination. Samples of 
elderly control individuals were collected during a meeting of a local 
senior club. All patients and control individuals had Belgian nationality. 
From each individual in the study, a heparinized blood sample was taken 
and lymphocytes were isolated and frozen for genotyping analysis. The 
study was approved by the Ghent University Hospital Ethical 
Committee. All participants received oral and written information 
concerning the study and signed the informed consent form. 
Nomenclature of polymorphisms 
Publications reporting linkage or association studies often use an 
equivocal description of polymorphisms. According to the nomenclature 
of the Human Genome Variation Society (31), the correct nucleotide 
number of polymorphisms in the 5’ region of a gene is determined by 
counting back from the translation start. However, numerous studies use 
a nucleotide numbering beginning from the transcription start. 
Polymorphisms in the coding region of the gene are most often named by 
codon number. Table 2 gives an overview of the different TGFβ1 
polymorphisms, analyzed in this study, with their synonyms used in 
literature. Because most polymorphisms are already widely known by a 
certain name, this name was maintained throughout this study (bold in 
Table 2). 
 
Table 2 . Characteristics of the TGFβ1 polymorphisms analyzed in this study 
Synonyms used in literature    
nt * nt† Codon Location Substitution Reference 
- 2.391 - 1.552  5’ region AGG deletion 14 
- 1.639 - 800  5’ region G>A 15, 16, 17 
- 1.348 - 509  5’ region C>T 15, 16, 17 
29 + 869 Leu10Pro Exon 1 (SP) T>C 15, 16, 18 
74 + 915 Arg25Pro Exon 1 (SP) G>C 15, 16, 18 
788 + 1.629 Thr263Ile Exon 5 (LAP) C>T 15, 16, 19 
GenBank accession number = NT_011109 (reverse-complement); bold: nomenclature used in this study. 
* Nucleotide number, counting from translation start (in agreement with the nomenclature according to 
the Human Genome Variation Society) (31). 
† Nucleotide number, counting from transcription start.  
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Genotyping analysis 
Polymorphic sites in TGFβ1 at position -800 (G>A), -509 (C>T), codon 25 
(Arg/Pro G>C), and codon 263 (Thr/Ile C>T) were examined by 
polymerase chain reaction–restriction fragment length polymorphism 
(PCR-RFLP) analysis; the TGFβ1 Leu10Pro (T>C) polymorphism was 
determined by SNaPshot analysis and the TGFβ1 -1.552delAGG 
polymorphic site was genotyped by direct sequencing. Genomic 
deoxyribonucleic acid (DNA) was extracted from the isolated 
lymphocytes using a commercially available kit (QIAamp DNA Blood 
Mini kit; Westburg, Leusden, The Netherlands). PCR was performed on 
each DNA sample using the primer sequences detailed in Tables 3 and 4.  
 
Table 3. Technical details of PCR-RFLP analysis 
Polymorphism PCR primers PCR product size (bp) 
Restriction 
enzyme 
Fragments identifying 
genotypes (bp) 
-800 G>A F = GCAGTTGGCGAGAACAGTTG 681 HpyCh4IV GG = 195 + 486 
 R = TGGGTCACCAGAGAAAGAGG   GA = 195 + 486 + 681 
    AA = 681 
-509 C>T F = GCAGTTGGCGAGAACAGTTG 681 Bsu36I CC = 193 + 488 
 R = TGGGTCACCAGAGAAAGAGG   CT = 193 + 488 + 681 
    TT = 681 
Arg25Pro G>C F = TGTTCGCGCTCTCGGCAG 365 BglI GG = 252 
 R = GACCTCCTTGGCGTAGTAG   GC = 252 + 312 
    CC = 312 
Thr263Ile C>T F = CTGCTCCTGTGACAGCAGG 361 FokI CC = 361 
 R = AGGCCTCCATCCAGGCTAC   CT = 116 + 245 + 361 
    TT = 116 + 245 
Abbreviation: PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism.  
 
The PCR reactions contained 0.2 mM deoxyribonucleoside triphosphates 
(Amersham Biosciences, Diegem, Belgium), 1x PCR buffer, 1.5 mM 
MgCl2, 1 µM forward and reverse primer, 0.6 units Platinum Taq DNA 
Polymerase (all Invitrogen, Merelbeke, Belgium), and 200 ng DNA in a 
25-µL reaction volume. The PCR amplification conditions for the 
polymorphisms at location -1552, -800, -509, and codon 263 consisted of 
an initial denaturation step at 95°C for 5 min, followed by 35 cycles of 1 
min at 95°C, 1 min at 60°C, 1 min at 72°C, and a final extension step at 
72°C for 10 min. For the amplification of the DNA fragment containing 
the codon 10 and codon 25 polymorphic sites, the following touchdown 
program was used: an initial denaturation step at 95°C for 2 min, 12 
cycles of 20 s at 95°C, 15 s at the initial annealing temperature (58°C), 1 
min at 72°C, followed by 24 cycles of 40 s at 95°C, 40 s at 46°C, 30 s at 
72°C, and a final extension step of 10 min at 72°C. For polymorphisms at -
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800, -509, codon 25, and codon 263, the amplified fragments were 
digested with appropriate restriction endonucleases listed in Table 3. 
After incubation at 37°C, 20 µL of digested product was analyzed by gel 
electrophoresis on a 2% agarose gel and visualized under ultraviolet light 
after staining with ethidium bromide (Sigma-Aldrich, Bornem, Belgium). 
The -1.552delAGG polymorphism was genotyped by direct sequencing 
(ABI 3730XL DNA Analyzer, Applied Biosystems) using dye terminator 
chemistry (Big Dye version 3.1, Applied Biosystems). The codon 10 
polymorphism was analyzed by single base extension using the ABI 
Prism SNaPshot Kit (Applied Biosystems, Lennik, Belgium). The DNA 
samples, containing extension products, and GeneScan-120 LIZ Size 
Standard (Applied Biosystems, Lennik, Belgium) were added to Amresco 
Capillary Electrophoresis (ACE) running buffer (Lucron Bioproducts, De 
Pinte, Belgium) and loaded onto the ABI Prism 3100 Genetic Analyzer. 
The results were analyzed using GeneMapper Software version 3.7 
(Applied Biosystems). 
 
Table 4. Technical details of PCR-single base extension and PCR-genotyping analysis 
Polymorphism PCR primers PCR product size (bp) 
Sequencing / SNaPshot 
primer 
-1552delAGG F = CCAGGTGGAAGGTGGATTAG 429 CCAGGTGGAAGGTGGATTAG 
 R = CTCCCTGATACTCACTGGAG   
    
Leu10Pro T>C F = TGTTCGCGCTCTCGGCAG 365 TAGCCACAGCAGCGGTAGCAGCAGC 
 R = GACCTCCTTGGCGTAGTAG   
    
Abbreviation: PCR = polymerase chain reaction. 
 
Statistical analysis 
Statistical analysis was performed by MedCalc 4.0 software (MedCalc, 
Mariakerke, Belgium) and SPSS 10.0 software (SPSS Inc., Chicago, IL). 
Genotype and allele frequencies were calculated by direct counting. 
Allele frequencies were examined by calculating the odds ratios (OR), 
with 95% confidence intervals using Fisher exact test, with the wild-type 
alleles used as the reference group. Haplotypes were estimated by an 
expectation-maximization algorithm using the Haploview version 3.2 
software (Haploview, Cambridge, MA) (32). This software packet was 
also used to calculate the linkage disequilibrium (LD) coefficient r2. The 
impact of the external RT and brachytherapy doses on the clinical 
radiosensitivity in the population was evaluated with the Mann-Whitney 
test. The influence of the chemotherapy treatment, surgery, and hormone 
therapy was tested using the chi-square test. 
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Results 
Linkage analysis and haplotype determination 
The allele frequencies of the TGFβ1 -1.552, -800, -509, codon 10, codon 25, 
and codon 263 polymorphisms were respectively 28%, 11%, 28%, 34%, 
6%, and 1% in the control population, and 36%, 6%, 36%, 39%, 4%, and 
4% in the total patient group. All genotype distributions in both groups 
considered were in Hardy-Weinberg equilibrium. The mutual position of 
the TGFβ1 polymorphisms and the results of the linkage analysis for the 
healthy individuals are shown in Fig. 1. The first five polymorphisms are 
located closely together in a region spanning 2.5 kb, whereas the codon 
263 polymorphism is approximately 11 kb downstream from the codon 
25 polymorphism. There was perfect LD between the -1.552 and the -509 
polymorphisms (r2 = 1 for the control and patient population) and tight 
LD between the -509/-1.552 and the codon 10 polymorphism (r2 = 0.71 for 
the control population, r2 = 0.87 for the patient group). There was no LD 
between the other polymorphisms.  
 
 
Fig. 1. Map and linkage disequilibrium coefficient (r2) of TGFβ1 polymorphisms in 140 
healthy individuals. 
 
The six polymorphisms have been used to reconstruct TGFβ1 haplotypes 
(Fig. 2). Eight haplotypes (H1–H8) were found in the patient population, 
four in the control population (H1–H3, H5). The H1 haplotype, composed 
of all wild-type alleles, and the H2 haplotype, composed of the -1.552, -
509, and codon 10 variant alleles, represented >85% of the population in 
both groups. To correlate haplotypes with clinical radiosensitivity, 
1
0.71
0.71
 92
haplotype frequencies were calculated for the CTC0–1, CTC2+, and 
CTC3+ patient groups. This analysis showed that the frequency of the H1 
and the H2 haplotypes was similar for the CTC0–1 and the CTC2+ patient 
groups as for the control group. On the other hand, the H2 haplotype was 
more frequent in the CTC3+ patient group. Taking CTC0–1 patients and 
the H1 haplotype as reference, patients with the H2 haplotype had a 2.28 
(p = 0.428) times higher risk to develop severe (CTC3+) late RT reactions. 
Three rare haplotypes (H6, H7, H8) occurred only within the 
radiosensitive patient group. Because of the low frequency of these 
haplotypes, they were restrained when calculating haplotype frequencies 
of the total patient group. 
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Fig. 2. Haplotype distribution of the control population, the total patient population, and the 
different Common Terminology Criteria (CTC) patient groups. 
 
Genotyping analysis 
The genotype numbers, frequencies, and comparative statistics of the -509 
and the codon 10 polymorphisms for the different patient groups are 
summarized in Table 5. Because there was a perfect linkage between the -
1.552 and the –509 polymorphisms, only the results for the -509 
polymorphism are displayed. The patients with adverse reactions to RT 
(CTC2+) had, compared with the nonradiosensitive patients (CTC0–1), a 
lower percentage of individuals who were heterozygous for the 
polymorphic alleles at -509 and codon 10 (32% vs. 53% and 32% vs. 58% 
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respectively), and a greater percentage who were homozygous for the 
variant alleles at these sites (20% vs. 9% and 20% vs. 11%, respectively). 
The percentage of -509 and codon 10 homozygous variant individuals 
increased up to 27% for the subgroup of patients with the most severe RT 
reactions (CTC3+). Consequently, patients in this CTC3+ radiosensitive 
group had an OR of 4.00 (p = 0.323) for carrying two variant alleles at -509 
and an OR of 2.67 (p = 0.573) for carrying two variant alleles at codon 10. 
Assuming a recessive action of both polymorphisms (the wild-type 
genotype together with the heterozygous genotype is the reference 
genotype), the association of the homozygous variant genotype with 
severe adverse RT reactions was more pronounced. Patients homozygous 
for the -509 polymorphism had a risk of severe RT reactions increased by 
3.60 times (p = 0.260), and patients homozygous for the codon 10 
polymorphism had a risk increased by 2.94 times (p = 0.364). Accordingly, 
triple (-1.552, -509, codon 10) variant homozygous patients had a 3.6 
times increased risk to develop severe RT reactions (p = 0.260). 
Approximately 50% of the patients with the -509 and the codon 10 
homozygous variant genotype are clinically radiosensitive (CTC2+), 
compared with 29% of the patients with the homozygous normal and the 
heterozygous genotype (p = 0.337). With respect to severe RT reactions 
(CTC3+), the percentages are 38% vs. 14% (p = 0.241). 
 
Table 5. Genotype numbers, genotype/allele frequencies (%) and statistics of the TGFβ1 -509 
C>T and the codon 10 T>C polymorphisms in cancer patients with and without reactions to 
radiotherapy 
 CTC0-1   (n = 53) 
CTC2+    
(n = 25) OR p 
CTC3+    
(n = 11) OR p 
- 509 C>T         
CC 20 (38%) 12 (48%) 1  3 (27%) 1  
CT 28 (53%) 8 (32%) 0.48 0.266 5 (46%) 1.19 0.868 
TT 5 (9%) 5 (20%) 1.67 0.738 3 (27%) 4.00 0.323 
CT + TT 33 (62%) 13 (52%) 0.66 0.540 8 (73%) 1.62 0.754 
CC + CT 48 (91%) 20 (80%) 1  8 (73%) 1  
TT 5 (9%) 5 (20%) 2.40 0.347 3 (27%) 3.60 0.260 
Freq T allele 36% 36%   50%   
10 T>C         
TT 16 (30%) 12 (48%) 1  3 (27%) 1  
TC 31 (58%) 8 (32%) 0.34 0.089 5 (46%) 0.86 0.832 
CC 6 (11%) 5 (20%) 1.11 0.832 3 (27%) 2.67 0.573 
TC + CC 37 (70%) 13 (52%) 0.47 0.201 8 (73%) 1.15 0.865 
TT + TC 47 (89%) 20 (80%) 1  8 (73%) 1  
CC 6 (11%) 5 (20%) 1.96 0.497 3 (27%) 2.94 0.364 
Freq C allele 41% 36%   50%   
Abbreviations: CTC = Common Toxicity Criteria; OR = odds ratio. 
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For the polymorphisms at location -800, codon 25, and codon 263, the 
genotype numbers, frequencies, and statistics for the different patient 
groups are summarized in Table 6. No major differences in genotype 
distributions could be found between radiosensitive patients and patients 
without adverse RT reactions. The number of patients heterozygous for 
the codon 263 polymorphism increased from 8% for the CTC0–1 patient 
group to 18% for the CTC3+ patient group, resulting in an OR of 2.72 for 
the patients with severe RT reactions. On the other hand, the number of -
800 variant allele carriers decreased slightly in the CTC2+ patient group 
and dropped to zero in the CTC3+ patient group. None of these results 
were, however, statistically significant. 
 
Table 6. Genotype numbers, genotype/allele frequencies (%) and statistics of the TGFβ1 -800 
G>A, the codon 25 G>C and the codon 263 C>T polymorphisms in cancer patients with and 
without reactions to radiotherapy 
 CTC0-1  (n = 53) 
CTC2+    
(n = 25) OR p 
CTC3+    
(n = 11) OR p 
- 800 G>A         
GG 47 (89%) 23 (92%) 1  11 (100%) 1  
GA 5 (9%) 2 (8%) 0.82 0.847 0 (0%)   
AA 1 (2%)  0 (0%)   0 (0%)   
GA + AA 6 (11%) 2 (8%) 0.68 0.959 0 (0%)   
Freq A allele 7% 4%   0%   
25 G>C         
GG 48 (91%) 24 (96%) 1  10 (91%) 1  
GC 5 (9%) 1 (4%) 0.40 0.700 1 (9%) 0.96 0.594 
CC 0 (0%) 0 (0%)   0 (0%)   
GG + GC 5 (9%) 1 (4%) 0.40 0.700 1 (9%) 0.96 0.594 
Freq C allele 5% 2%   5%   
263 C>T        
CC 49 (92%) 22 (88%) 1  9 (82%) 1  
CT 4 (8%) 3 (12%) 1.67 0.828 2 (18%) 2.72 0.594 
TT 0 (0%) 0 (0%)   0 (0%)   
CT + TT 4 (8%) 3 (12%) 1.67 0.828 2 (18%) 2.72 0.594 
Freq T allele 4% 6%   9%   
Abbreviations: CTC = Common Toxicity Criteria; OR = odds ratio. 
 
Discussion 
The reaction of normal tissues to radiation is very similar to tissue wound 
healing. In case of irradiation, however, the tissue enters into a cycle 
involving hypoxia, angiogenesis, cell death, proliferation, and 
macrophage infiltration. Ultimately, this spiral leads to total replacement 
of the tissue by collagen, leaving few cellular elements (33). In 
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gynecologic RT, the rectum is the area most often affected by pelvic 
irradiation. The most common late effects include increased stool 
frequency, spotting of blood, and partial incontinence. Less common are 
ulceration, severe bleeding, pain, stricture, severe incontinence, and 
fistula. Fibrosis and ischemia in the submucosa and muscularis are 
largely responsible for these effects, accompanied by telangiectasia and 
other vascular abnormalities, mucosal congestion, collagen deposition, 
and abnormal fibroblasts (2, 34). The cytokine TGFβ has been 
demonstrated to be a key mediator of fibrogenesis in a number of 
pathologic conditions, including tissue reactions postirradiation (4, 35). 
Moreover, rectum radiation injury is associated with significant 
downregulation of the endothelial cell surface protein, thrombomodulin. 
Reduced thrombomodulin levels may contribute to hypercoagulation 
with increased fibrin formation, platelet aggregation, and subsequent 
upregulation or release of inflammatory and fibrogenic cytokines, such as 
TGFβ (36). 
Numerous studies reporting the association between high TGFβ1 plasma 
levels, both before and after RT, in cancer patients and the development 
of severe radiation-induced fibrosis demonstrate the involvement of 
TGFβ1 and its functional polymorphisms in clinical radiosensitivity (7–
11). To analyze the involvement of TGFβ1 in the pathobiology of 
radiation-induced damage to normal tissues, we studied six TGFβ1 
polymorphisms in a patient group treated with RT for cervix or 
endometrium cancer. Therefore, we decided to screen for variations that 
possibly contribute to the genetic control of TGFβ1 plasma levels. The -
1.552delAGG, the -800G>A, and the -509C>T polymorphisms are located 
in the 5’ and promoter region of the gene and could affect the production 
of the cytokine. Both Leu10Pro and Arg25Pro polymorphisms are located 
in the signal sequence, which is responsible for the export of the newly 
synthesized protein across the membranes of the endoplasmic reticulum. 
The Thr263Ile polymorphism is situated in the latency associated protein 
and thus is possibly involved in the stability and activity of the protein. 
Whereas proven functional information for the -1.552delAGG, the -
800G>A, and the Thr263Ile polymorphisms is lacking, both -509C>T and 
Leu10Pro homozygous variant genotypes have been shown to be 
associated with increased serum levels of TGFβ1 (17, 22, 37). Previously 
published studies addressing the influence of TGFβ1 polymorphisms on 
clinical radiosensitivity established significant associations between the 
Leu10Pro as well as the -509C>T polymorphisms and increased risk of 
radiation-induced late complications after RT for breast cancer (23–25). 
This association was most pronounced (23) or retrieved only (24) when 
the mutant homozygous genotype was compared with the wild-type 
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genotype. In this study we could also only demonstrate an increased 
normal tissue complication risk for -509TT and 10Pro homozygotes when 
recessivity was assumed. Double (variant) homozygous patients had a 2.4 
(p = 0.347) times increased risk for developing moderate or severe RT 
reactions and a 3.6 (p = 0.260) times increased risk to develop severe RT 
reactions. 
For the remaining polymorphisms, the study did not provide any 
valuable associations with the risk of RT complications. Variant alleles at 
codon 263 correlated slightly positively with radiosensitivity, whereas 
variant alleles at -800 and codon 25 had a minor protective effect. This 
protective effect of the codon 25 Pro allele was expected to be higher 
because several investigations have previously reported a reduced 
production of TGFβ1 in vitro and a decreased risk of different fibro-
proliferative conditions for this variant Pro allele (26, 27, 38, 39).  
Linkage analysis of the six considered polymorphisms showed a strong 
linkage between the -509C>T and the Leu10Pro polymorphisms and a 
perfect linkage between the -1.552delAGG and the -509C>T 
polymorphisms. The effect on radiosensitivity and TGFβ1 serum levels 
reported in the literature could thus be caused as well by the Leu10Pro 
polymorphism by its influence on the intracellular trafficking or export 
efficiency of the propeptide, as by the -1.552delAGG or the -509C>T 
polymorphism, through their effect on the production of the proprotein. 
Kim et al. characterized the 5’ region of the TGFβ1 gene down to 1.362 bp 
from the transcription start and demonstrated that this promoter region 
consists of several transcriptional binding sites (40). As the -1.552delAGG 
polymorphism is located outside this screened region, it is unknown 
whether this deletion polymorphism is situated in or near a 
transcriptional binding site. Because the last regulatory element was 
found at position -1.232, the possibility exists that another upstream 
regulatory region is present. The -509C>T polymorphism lies several 
bases from nuclear hormone receptor binding sites (41). In this way, the 
polymorphism could influence transcription, because it has been shown 
that ligands for nuclear hormone receptors regulate TGFβ1 production in 
vitro and in vivo (42, 43). 
Haplotypes are becoming important tools in genetic studies because they 
are theoretically more informative than single polymorphisms. In our 
patient group, eight haplotypes were identified by six polymorphisms 
with two major haplotypes that contained 86% of the haplotype 
distribution. The H2 haplotype, consisting of the -1.552, the -509, and the 
codon 10 variant alleles, was overrepresented in the CTC3+ patient 
subgroup (Fig. 2). Because analysis of the individual polymorphisms 
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showed that homozygous variant genotypes in the -1.552, -509, or codon 
10 polymorphisms are required for an association with radiosensitivity, 
haplotype analysis using these polymorphisms is not ideal for 
interpretation of the results. On the other hand, the haplotype with the -
1.552delAGG, the -800G>A, the -509C>T, and the Leu10Pro variant alleles 
(H6), the haplotype with the Arg25Pro variant allele (H7), and the 
haplotype with the Thr263Ile variant allele (H8) occurred only within the 
radiosensitive patient group. 
For this study we evaluated the association between global clinical 
radiosensitivity and polymorphisms in TGFβ1 by performing a CTC2+ vs. 
CTC0–1 analysis. To assess possible differences in genotypes between the 
more severe radiosensitive individuals, a CTC3+ vs. CTC0–1 analysis was 
performed. The outcome of both analyses showed that the strongest 
associations for the -1.592, the -509, and the codon 10 polymorphisms 
were found for the CTC3+ patient group. Moreover, supplemental CTC2 
vs. CTC0–1 analysis revealed a further loss of the associations for the 
CTC2 radiosensitivity group (results not shown). This indicates that the 
CTC3+ patients were responsible for the positive odds ratios when 
comparing the CTC2+ group with the CTC0–1 group. In conclusion, 
homozygous variant -1.552, -509, and codon 10 individuals are at a higher 
risk to develop severe or life-threatening reactions after RT treatment. 
Although the -1.552delAGG, the -509C>T, and the Leu10Pro homozygous 
variant genotypes were at higher risk to develop late RT reactions, this 
higher risk was not statistically significant (p < 0.05) in our study using 
late reactions in the pelvis region as endpoint. Possible explanations for 
the lack of statistical significance are the relatively small sample size, 
especially with respect to the CTC3+ patient group, and the uncompleted 
follow-up for 11% of the nonradiosensitive patients. Forty-eight percent 
of the patients with moderate and severe radiosensitivity (CTC2+) and 
27% of the patients with severe radiosensitivity (CTC3+) were 
homozygous for the normal alleles. This is in accordance with the study 
of Quarmby et al. where over one-third of the patients with fibrosis in the 
breast after RT treatment were homozygous for the normal alleles (23). 
This finding indicates that other factors influencing TGFβ1 levels 
contribute to the differences in response. Examples are given by Roberts 
et al. and Flanders et al. demonstrating that disruption of the signal 
transduction pathway for TGFβ using transgenic mice deficient in Smad3, 
results in resistance to the development of radiation-induced fibrosis (44, 
45). In addition, gene therapy with an adenoviral vector in rats, which 
results in increased expression of the type 2 TGFβ receptor (TGFβRII), 
reduces tissue levels of TGFβ and protects against radiation-induced 
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injury in the lung (46). Kang et al. showed that overexpression of 
extracellular superoxide dismutase in transgenic mice appears to be 
protective against radiation-induced lung injury. TGFβ is here also 
involved because latent TGFβ is activated in part by reactive oxygen 
species (47). 
 
Conclusion 
The present study shows that late severe clinical radiosensitivity may be 
associated with TGFβ1 polymorphisms. The association holds only for 
patients with homozygous genotypes for the polymorphic alleles. The 
results encourage further investigation of the involvement of TGFβ1 
polymorphisms and TGFβ1 plasma levels in late fibrosis–associated RT 
complications. 
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Chapter  4  
General discussion and conclusions 
4.1 Normal tissue toxicity 
Radiation therapy remains a cornerstone of cancer management, with 
approximately half of all newly diagnosed cancer patients receiving 
radiotherapy at some point in the treatment of their disease (1). 
Compared with surgery, radiation therapy has the advantage of being 
non-invasive and potentially organ preserving. Unfortunately, early and 
late normal tissue toxicity limit the radiation dose, and may affect the 
long-term health-related quality of life of the patients. As the number of 
long-term cancer survivors increases, preventing or reducing late side 
effects has increasingly become a priority. The development of an in vitro 
assay capable of predicting individual radiosensitivity prior to 
radiotherapy would enable the identification of radiosensitive patients, 
modification of their therapy and consequently minimalisation of 
radiation induced normal tissue toxicity. Furthermore, individualized 
radiotherapy protocols would also allow intensification of therapy in 
relatively radioresistant patients. 
The classical framework for discussing early and late radiation induced 
side effects is the “target-cell hypothesis”. Following this theory, the main 
effect of ionizing radiation on tissues and organs is thought to be a direct 
consequence of cell killing, resulting in the depopulation of crucial cell 
populations and subsequent functional deficiency. Direct loss of 
parenchymal cells and loss of vascular endothelial cells were considered 
to be responsible for the clinical expression of radiation damage. The long 
latency period of late side effects was thought to be a silent interval, 
during which the irreversible cellular damage was expressed at the time 
when cells attempting mitosis died following mitotic cell death (2). 
Recent research in radiobiology and molecular pathology has caused a 
change of paradigm, particularly in the understanding of late effects. 
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According to the “orchestrated response hypothesis”, radiation induced 
side effects are the result of a biological response at the cell and tissue 
level effected by the early activation of cytokine cascades which remain 
active until clinical expression of late normal tissue injury (3,4). In 
general, the “target cell hypothesis” remains a useful frame for discussing 
early radiotherapy effects. On the other hand, for late side effects, 
radiation induced cell killing is considered to be a triggering event 
followed by an orchestrated biological response induced by the early 
release of cytokines. 
4.2 Cellular radiosensitivity assays 
In the past, several cellular radiosensitivity assays have been developed 
in order to predict normal tissue response after radiotherapy treatment. 
These assays have mainly focused on colony forming assays, cytogenetic 
assays, and assays of residual DNA damage after in vitro irradiation. 
Although some authors found associations between clinical 
radiosensitivity and in vitro radiosensitivity, the observed correlations 
have been difficult to reproduce between studies (5-26). In this thesis, 
individual cellular radiosensitivity was determined by the G2 assay (27). 
The mean number of chromatid breaks per cell was found to be 
significantly higher in patients with late normal tissue reactions than in 
patients without normal tissue reactions. Two other studies could, 
however, not find a correlation between the G2 in vitro radiosensitivity 
and late normal tissue effects after breast or larynx irradiation (11,12). 
Nonetheless, although a positive association between in vitro and clinical 
radiosensitivity was found in our study, the G2 assay lacked sensitivity to 
identify high-risk patients at the individual level. Moreover, based on the 
low reproducibility of the G2 assay which has been shown by Vral et al., 
care has to be taken when results obtained from one single measurement 
are used to assess the individual in vitro radiosensitivity (28). These 
shortcomings, which also occur in other studies using different cellular 
radiosensitivity assays, lead to the conclusion that target cell assays have 
limited use as a clinical screen for individual increased radiosensitivity. 
As a consequence, much of the research interest has moved toward 
genotypic assays. 
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4.3 Radiogenomics 
Radiogenomics is the study of genetic variations in relation to individual 
differences in radiotherapy response. Based on theoretical considerations 
and observations from the fields of molecular biology, population 
genetics and clinical radiobiology, a putative model for the allelic 
architecture underlying clinical radiosensitivity has been proposed (29). 
This model is based on the assumption that normal tissue radiosensitivity 
is dependent of the combined effect of a number common or rare genetic 
variations in several genes, and on the hypothesis that some genes (and 
their genetic alterations) are expressed selectively through certain types 
of normal tissue reactions, whereas others have a general impact on 
radiosensitivity. The model is illustrated in figure 4.1. 
 
 
Figure 4.1. Hypothetical model illustrating the influence of different genetic alterations on 
clinical radiosensitivity. Boxes A-I represent a number of sequence variants in genes of 
which the gene products are involved in the response to ionizing radiation. Boxes C-I 
represent sequence variants that are expressed selectively through certain types of normal 
tissue reactions. Boxes A and B represent sequence variants that affect radiosensitivity in a 
generalized way. Patient 1 exhibits an increased susceptibility to normal tissue reaction Z 
due to the variants H and I. Patient 2 exhibits a severe global radiosensitivity due to the 
highly penetrant sequence alteration A. From Andreassen et al. (29). 
 
Over the years, substantial work has been performed in order to identify 
radiosensitivity candidate genes as well as specific single nucleotide 
polymorphisms (SNPs) and other genetic variants associated with the 
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risk of developing normal tissue complications after radiotherapy. To this 
end, patient groups consisting of breast cancer patients, head- and neck 
cancer patients, prostate cancer patients and gynecological cancer 
patients were used. Studied candidate genes included genes coding for 
DNA damage detection and repair proteins, for endogenous anti-oxidant 
enzymes and for cytokines related to fibrogenesis and tissue remodeling. 
4.3.1 DNA damage detection and repair genes 
4.3.1.1 ATM 
The first gene that received significant attention was the ataxia 
telangiectasia mutated (ATM) gene. This gene encodes a kinase that 
amplifies the DNA damage signal induced by DNA double-strand breaks 
and initiates processes that regulate DNA repair, cell cycle checkpoints 
and apoptosis (30). Homozygosity for truncating mutations in the ATM 
gene, which results in early termination of the ATM gene product, is the 
typical genetic lesion underlying the rare syndrome ataxia telangiectasia 
(AT) (31). The in vitro radiosensitivity of cells from AT patients is three 
times higher than that of normal human cells, and these patients exhibit 
extreme normal tissue reactions to radiotherapy (32). The frequency of 
AT heterozygotes in the population has been estimated to be 
approximately 1% (33). As cells from AT heterozygous individuals 
exhibit an intermediate in vitro radiosensitivity compared to cells of AT 
patients and healthy controls (34), it has been speculated that AT 
heterozygotes may represent a significant proportion of clinically 
radiosensitive patients. However, a large number of studies did not 
support the idea that individuals with heterozygous truncating ATM 
mutations are at a higher risk for developing normal tissue complications 
after irradiation (18,35-41). Nonetheless, this still leaves the possibility 
that minor genetic variations in the ATM gene, which result in protein 
alterations other than protein truncation, influence the radiation 
response. A number of studies investigated this assumption by screening 
either the entire ATM gene for genetic alterations or by analyzing specific 
genetic variations (42-49). Iannuzzi et al. screened 46 breast cancer 
patients for ATM sequence variants and showed that all patients with 
severe late subcutaneous radiation injury carried two ATM alterations 
(42). A study including 37 prostate cancer patients treated with 
brachytherapy reported that most of the patients experiencing adverse 
radiation responses carried an ATM sequence variation (43). The 
preliminary study of Andreassen et al. comprising 41 breast cancer 
patients detected 26 ATM variations and showed a significantly increased 
risk for subcutaneous fibrosis for the Asp1853Asn polymorphism (44). In 
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a relatively large study of Angele et al., 16 ATM variants were genotyped 
in 254 breast cancer patients and the codon 1853 SNP was also found to 
be significantly associated with increased acute and/or late clinical 
radiosensitivity. In addition, this study indicated a significant association 
between two intronic polymorphisms and the risk of normal tissue 
complications (45). In spite of the strong association found between the 
Asp1853Asn SNP and normal tissue radiosensitivity, two other relatively 
small breast and prostate cancer studies and the expanded breast cancer 
study of Andreassen et al. could only find a moderate correlation between 
the codon 1853 polymorphism and late normal tissue toxicity (46-48). 
Moreover, a study including 83 prostate cancer patients treated with 
3DCRT could also not find a significant association between this ATM 
SNP and late rectal or bladder toxicity observed in 28 patients (49). 
 
4.3.1.2 BRCA1/2 
Among the downstream targets of ATM are the tumor suppressor genes 
BRCA1 and BRCA2 (breast cancer 1/2). The encoded proteins are 
involved in genome stabilization and repair of DNA double-strand 
breaks. Heterozygous germline mutations in the BRCA1/2 genes account 
for a large proportion of hereditary breast cancer (50,51). As these 
pathogenic and mostly protein truncation mutations appear to be 
associated with an increased in vitro radiosensitivity (52), it has been 
thought that patients with BRCA1/2 mutations may constitute a 
radiosensitive subpopulation. However, two small scale studies (53,54) 
and a large case-control study, which matched 71 breast cancer patients 
with a BRCA1/2 mutation with 213 sporadic breast cancer patients (55), 
did not find an increased risk for early or late radiation toxicity in 
patients carrying highly penetrant BRCA1/2 mutations. The involvement 
of minor BRCA1/2 variations in relation to radiation response has up to 
now only been investigated in one study addressing late toxicity after 
prostate irradiation. In this study, no association with radiation toxicity 
was found for 9 SNPs in BRCA1 and 7 SNPs in BRCA2 (49). 
 
4.3.1.3 Other DNA repair genes 
The DNA double-strand break repair genes NBS, MRE11, RAD50, DNA 
ligase4 and hHR21 have also been screened for genomic alterations in 
groups of patients showing acute and/or late normal tissue reactions. A 
DNA ligase4 single nucleotide deletion was detected in one of five chronic 
radiosensitive patients (18), and in hHR21, a T>C and a G>A substitution 
was found in, respectively, six and one of 19 radiosensitive patients (56). 
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Damaraju et al. found a significant association between the DNA ligase4 
Asp568Asp polymorphism and late toxicity after prostate irradiation. No 
association was found for the NBS1 Glu185Gln polymorphism (49). 
The XRCC3 protein participates in the repair of DNA double-strand 
breaks through the homologous recombination pathway. Up to now, four 
studies have evaluated the influence of the XRCC3 Thr241Met 
polymorphism on the risk of developing late normal tissue damage. In 
the study based on 41 breast cancer patients from Andreassen et al., 
significant associations were found between the codon 241 Met allele and 
a decreased risk of subcutaneous fibrosis and telangiectasia (57). 
However, in two other studies including the one conducted by the same 
research group in order to confirm the initial results, no significant 
association between this SNP and risk for late toxicity was found (47,48). 
Moreover, our first study performed in this thesis in which 62 women 
with cervical or endometrial cancer were screened for three XRCC3 
polymorphisms, could also not demonstrate an association between the 
codon 241 SNP and the risk of developing late toxicity after pelvic 
irradiation. Yet, our study showed that heterozygosity for the intronic 
XRCC3 IVS5-14 A>G polymorphism significantly increases the risk of late 
radiation injury (27). Because this polymorphism is located in a non-
coding sequence region of the gene, the functional effect of the 
polymorphism is still incomprehensive. The functional relevance could 
be associated with an alternative splicing variant or be involved in RNA 
stability. Another possibility is that the polymorphism is in linkage 
disequilibrium with other functional variants not tested in this study. 
Nonetheless, the positive association between this intronic polymorphism 
and late clinical radiosensitivity could not be confirmed in the prostate 
cancer study of Damaraju et al. Moreover, in contrast to our study, the 
XRCC3 5’UTR 4.541 SNP was shown to be significantly associated with 
late radiation toxicity. In the same study, no associations with radiation 
toxicity were found for one XRCC2, one Rad52 and two Rad51 SNPs (49). 
The XRCC1 protein plays a critical role in base excision repair. Several 
SNPs which have been associated with an altered cellular response to 
ionizing radiation have been documented in the XRCC1 gene. A total of 
six studies have investigated the influence of the relatively common 
XRCC1 Arg399Gln polymorphism on normal tissue radiosensitivity. In 
the previously mentioned study with 41 breast cancer patients, the codon 
399 Gln allele was significantly associated with a decreased risk of 
subcutaneous fibrosis (57). Accordingly, the study of Chang-Claude et al. 
including 446 patients, also found a significantly decreased risk for acute 
skin toxicity after breast irradiation for codon 399 Gln carriers (58). In the 
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first study performed in this thesis, the impact of the XRCC1 Arg399Gln 
polymorphism on radiation induced toxicity was also investigated. In this 
study, no significant association was found between the codon 399 
polymorphism and the occurrence of late radiation toxicity (27). A study 
conducted in breast cancer patients, did also not demonstrate significant 
associations between the XRCC1 Arg399Gln SNP and risk of altered late 
breast toxicity (47). Neither did the expanded breast cancer study of 
Andreassen et al. provide a significant association between this 
polymorphism and the risk of radiation induced subcutaneous fibrosis 
(48). Finally, in a study addressing various acute and/or late adverse 
reactions in 254 breast cancer patients, the codon 399 Gln allele was also 
not associated with an altered risk for normal tissue complications (59). 
Most of the aforementioned studies also investigated the association 
between other XRCC1 polymorphisms and clinical radiosensitivity. In 
our study, the variant Trp allele of the Arg194Trp polymorphism was 
found to exhibit a significant protective effect for the development of late 
radiation injury (27). As a similar association has not been reported in any 
of the other studies (48,49,58,59), and as this polymorphism has a low 
allele frequency, it was thought that our result could be caused by an 
underrepresentation of heterozygous individuals in the patient group 
with radiotherapy reactions. Indeed, none of the 22 patients with adverse 
radiotherapy reactions possessed the variant 194Trp allele. In our study, 
no significant association with late clinical radiosensitivity was found for 
the XRCC1 Arg280His and Gln632Gln polymorphisms and for the OGG1 
Ser326Cys polymorphism (27). For the codon 280 SNP, this is in 
accordance with the results of the other published studies (48,49,58,59). 
No additional data concerning clinical radiosensitivity are available for 
the XRCC1 codon 632 and the OGG1 codon 326 polymorphisms. On the 
other hand, Chang-Claude et al. and Brem et al. studied the association of, 
respectively, the XRCC1 -77 polymorphism and the APE1 Asp148Glu 
polymorphism. Only for the latter SNP, a significant association with 
radiation toxicity was found (58,60). 
In 1997, Price et al. reported highly significant associations between the 
risk of various normal tissue reactions and rare microsatellite 
polymorphisms in XRCC1 and XRCC3 in a population of 19 cancer 
patients (61). In their study, rare microsatellites were alleles with less than 
12 or more than 23 [AC] repeats for XRCC1 and alleles with more than 20 
[AC] repeats for XRCC3. In the second study performed in this thesis, the 
association of microsatellite polymorphisms in XRCC1 and XRCC3 with 
the development of late radiotherapy reactions was investigated in 62 
women treated for gynecological tumors. In this study, a positive 
association with late radiotherapy reactions was found for patients with 
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11 and 21 [AC] repeats in XRCC1 (62). Although these results were not 
statistically significant, patients with XRCC1 [AC]11 and [AC]21 repeats 
were clearly overrepresented in the radiosensitive patient group. Alleles 
with more than 23 [AC] repeats in XRCC1 were not present in the patient 
population and large XRCC3 alleles ([AC]20 and [AC]21 repeats) did not 
correlate with clinical radiosensitivity. Both studies also investigated the 
influence of an XRCC5 (Ku80) microsatellite polymorphism but could not 
demonstrate an association between any of the repeats and clinical 
radiosensitivity (61,62). 
XPD (ERCC2) and XPF (ERCC4) are two proteins involved in nucleotide 
excision repair. In two studies, no associations between XPD SNPs and 
radiation toxicity after breast or prostate irradiation were found (49,58). 
One study investigating the influence of two XPF SNPs on normal tissue 
toxicity in 130 head- and neck cancer patients, found a significant 
association between the Ser835Ser polymorphism and radiation toxicity 
(63). Damaraju et al. could, however, not link this polymorphism to an 
enhanced rectal or bladder toxicity (49). Apart from the above mentioned 
genes and SNPs, this study also examined one polymorphism in the BCL2 
apoptosis gene, three polymorphisms in two mismatch repair genes, 10 
polymorphisms in 9 steroid metabolism genes and two polymorphisms 
in two genes coding for cell signalling proteins. Variant alleles of the 
mismatch repair gene polymorphism MLH1 Val219Ile were found to 
exhibit a protective effect, and variant alleles of the CYP2D6*4 G>A 
polymorphism were positively associated with increased late rectal and 
bladder toxicity (49). 
 
4.3.2 Endogenous anti-oxidant genes 
The generation of reactive oxygen species (ROS) is the major mechanism 
by which the cytotoxic effect of ionizing radiation is induced. Moreover, 
sustained oxidative stress may be responsible for the development of late 
radiation reactions (64). Manganese superoxide dismutase (MnSOD) 
encoded by SOD2 is an important scavenger of ROS and plays thereby a 
major role in the defense against oxidative damage (65). Four studies 
have investigated possible associations between clinical radiosensitivity 
and SNPs in SOD2. The study of Green et al. including 80 breast cancer 
patients could not find a significant association between the Ala16Val 
polymorphism and late skin reactions after radiotherapy. Moreover, no 
novel sequence variations were detected in any of the patients (66). The 
other studies considering the involvement of genetic variations in SOD2 
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were all performed by the research group of Andreassen et al. In their 
study considering 41 breast cancer patients, it was shown that the SOD2 
Val16Ala polymorphism was significantly associated with radiation 
induced subcutaneous fibrosis (57). However, this positive association 
could not be confirmed in their study with 120 breast cancer patients, nor 
in their study considering 52 breast cancer patients (47,48). 
 
4.3.3 Fibrogenesis and tissue remodeling cytokine genes 
A number of different cytokines and growth factors are involved in the 
acute and late response of normal tissues to ionizing radiation (67). 
Especially the multifunctional cytokine TGFβ1 plays a crucial role in the 
development of radiation induced fibrosis (68). A number of SNPs have 
been described in TGFβ1. Three of these SNPs (-509C>T, Leu10Pro, 
Arg25Pro) have gathered particular interest as they are located in the 
promoter or starting sequence of the gene, and as they have been 
demonstrated to affect TGFβ1 secretion and the risk of various pathologic 
conditions (69-72). Six studies have been performed to investigate the 
influence of TGFβ1 SNPs on the risk of developing late normal tissue 
complications after radiotherapy. Quarmby et al. were the first to 
demonstrate significant associations between the -509C>T and the 
Leu10Pro polymorphisms and the risk of severe fibrosis after 
radiotherapy in 103 breast cancer patients (73). Two other studies in 
which the involvement of TGFβ1 SNPs in, respectively, 41 and 52 breast 
cancer patients was investigated in relation to radiation induced 
subcutaneous fibrosis, also reported significant associations between 
these SNPs and the occurrence of skin fibrosis (47,57). These associations 
were most pronounced (73) or retrieved only (57) for variant homozygous 
genotypes. In the third study in this thesis, the association between six 
TGFβ1 polymorphisms and the risk of late radiotherapy reactions was 
investigated in a group of 78 women treated for gynecological cancers. In 
this study, we could also demonstrate an increased, however not 
statistically significant, normal tissue complication risk for -509TT and 
10Pro homozygotes (74). Moreover, as we showed the existence of a tight 
linkage disequilibrium between the -509C>T, the Leu10Pro and the -
1.552delAGG polymorphisms, the effect on radiosensitivity and on 
TGFβ1 secretion could be caused by any of the three polymorphisms. In 
contrast to the above findings, the larger study of Andreassen et al. could 
not confirm the significant associations between these SNPs and the risk 
of radiation induced subcutaneous fibrosis (48). Given the very consistent 
results obtained in all four other conducted investigations, this finding 
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was very unexpected and the authors could not find any explanation for 
the observed inconsistency. Another very recent study including 83 
prostate cancer patients, could not find an association between the TGFβ1 
-509C>T polymorphism and the occurrence of late rectal damage. The 
Leu10Pro polymorphism was not studied (49). None of the six studies 
could indicate a significant association between the Arg25Pro 
polymorphism and late normal tissue reactions. In our study, variant 
alleles at codon 25 had a minor protective effect which was expected to be 
higher since several investigations reported a reduced production of 
TGFβ1 for this variant Pro allele (74). Furthermore, our study could not 
provide valuable associations for the -800G>A and the Thr263Ile 
polymorphisms. For the -800 SNP, this is in accordance with the study of 
Quarmby et al. (73,74). No other data are available for the codon 263 
polymorphism. 
 
4.3.4 Methodological issues 
From the overview of previous section it is clear that the associations 
between the studied genetic polymorphisms and normal tissue 
complications are not always entirely straightforward. The 
inconsistencies can be explained largely by a number of methodological 
issues since the performed studies differ from each other in several 
aspects. This makes a direct comparison of the results difficult. 
First of all, a variety of different normal tissue damage endpoints were 
used to evaluate radiosensitivity. These ranged from basic endpoints such 
as telangiectasia, subcutaneous fibrosis and skin erythema to more 
complex endpoints as erectile dysfunction and rectal injury (27,43,49). In 
a number of studies, different types of normal tissue reactions were 
studied separately whereas in other studies, various acute and late effects 
were considered together (45,59,60). The latter approach may represent a 
problem as a number of genes (and their genetic alterations) are 
expressed only through separate types of normal tissue reactions. 
In most of the studies, individual SNPs were analyzed with respect to 
clinical radiosensitivity. A few studies examined the influence of multiple 
SNPs based on the concept of risk alleles, which were defined as those 
being individually associated with increased radiosensitivity (27,44,57). 
Given the hypothesis that normal tissue radiosensitivity is determined by 
the combined effect of multiple genetic alterations, this approach seems 
to be very useful. In the first study in this thesis, two risk allele models 
based on SNPs in DNA repair genes have been proposed. According to 
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these models, patients with two or more risk alleles in XRCC1, and 
patients with three or more risk alleles in XRCC1 and XRCC3 have a 
significantly increased risk for developing late normal tissue reactions 
(27). Andreassen et al. also reported two risk allele models which could, 
however, not be confirmed in their larger scaled study (44,48,57). 
Although the risk allele approach allows to study the combined effect of 
different SNPs, this methodology does not consider possible interactions 
between SNPs. Up to now, the interaction between SNPs, which could be 
studied by multivariate analysis, has not been analyzed in any of the 
investigations. A number of studies considered haplotypes to investigate 
normal tissue radiosensitivity, thereby taking into account the existence 
of genetic linkage (45,58-60,74). As the haplotype is the basic unit that is 
inherited, it is interesting to investigate haplotypes rather than individual 
SNPs (75). The importance of evaluating haplotypes has been described 
in the study of Brem et al. that showed that the same allele of a specific 
polymorphism can be found on two haplotypes which are differently 
associated with radiation toxicity (60). On the other hand, in the case of a 
recessive action of a certain polymorphism, haplotype analysis is less 
suitable as was illustrated in the last study in this thesis considering 
TGFβ1 haplotypes (74). 
The most important factors influencing the risk, severity and type of 
normal tissue reactions are those related to radiation exposure, including 
dose, dose fractionation, volume and time. The use of concomitant 
chemotherapy and patient related factors may also affect the 
development of radiation injury (76). As a consequence, it is crucial to 
start from a homogeneous study population in which these confounding 
factors are already controlled for. In the three studies in this thesis, most 
of the patients received comparable external radiation doses. Although 
the range of the brachytherapy dose was broader, there was no significant 
difference with respect to the delivered brachytherapy dose between the 
radiosensitive and the non-radiosensitive patient groups. The external 
radiation dose and the total delivered dose did also not differ 
significantly between groups (27,62,74). However, due to the steepness of 
the dose response curves for most normal tissue reactions, small 
differences in absorbed dose can significantly influence the radiation 
response. In a group of patients apparently treated identically, differences 
in treatment characteristics may be present due to patient specific 
anatomical differences which necessitate adjusted field size and treated 
volume. If the target dose is specified at a variable depth, the dose and 
dose per fraction at the normal tissue at risk can vary considerably 
between patients. In addition, factors affecting dose build-up such as 
radiation type, varying organ anatomy, patient immobilizing and dose 
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modifying equipment can also influence the dose absorbed at the normal 
tissue at risk (29,77). In only one of the performed studies the patients 
were treated with 3DCRT, and mean doses and doses to partial volumes 
of the organs at risk were available from dose-volume histograms. In this 
study, significant associations with late rectal or bladder toxicity were 
found for mean rectal and mean bladder dose, and for dose to 30% of the 
rectum or bladder. However, no adjustments were made for these 
confounding factors when addressing the involvement of individual 
SNPs to bladder and rectal injury (49). As all patients in the other studies 
were treated by conventional external beam radiotherapy, similar 
dosimetric parameters were not available. Using the biological equivalent 
dose (BED) at a certain reference point, Chang-Claude et al. accounted for 
differences in fractionation size and treatment time (58). Andreassen et al. 
accounted for dose distributions between fields, radiation type and other 
relevant treatment parameters by calculating the BED (44,47,48,57). 
As late reactions tend to increase in frequency and severity over time, the 
length of follow-up is another important factor that needs to be taken into 
account when studying late normal tissue reactions (78). Considering our 
gynecological study population, two patients developed severe 
radiotherapy reactions after a latency period of five years (27,62,74). 
Consequently, prolonged follow-up periods are necessary in order to 
exclude false negative samples. 
The majority of the aforementioned studies are relatively small, with 
sample sizes between 5 and 446 patients. Consequently, the statistical 
power to detect associations with genetic alterations which have a minor 
impact on radiosensitivity is limited. As demonstrated in our 
microsatellite study, this is particularly pronounced for less frequent 
sequence alterations. It was calculated that in order to reach statistical 
significance for the association between late clinical radiosensitivity and 
XRCC1 [AC]11 and [AC]21 repeats, the patient group had to increase to, 
respectively, 160 and 80 individuals (62). 
4.4 Future prospects 
The next logical step in the search for genetic variations affecting normal 
tissue reactions would be to confirm the already reported associations. 
Additionally, a broad-based candidate gene approach or genome-wide 
approach may be essential in order to unravel the genetics of clinical 
normal tissue radiosensitivity. Both approaches require large patient 
cohorts with detailed information about treatment characteristics and 
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normal tissue outcome. Moreover, the patients should be subjected to a 
long follow-up in which all relevant normal tissue endpoints are 
assessed. Large scale studies of this kind demand for multicenter 
programs and international cooperation. Currently, several initiatives 
have been taken in order to enroll several thousand well-characterized 
radiotherapy patients. The European GENEPI project coordinated 
through the ESTRO is the most comprehensive in this regard (79). Others 
are the British RACE and RAPPER studies, the Japanese RadGenomics 
project and the Gene-PARE studies (80,81). 
 
4.4.1 Genome-wide approach 
All of the association studies conducted so far have been based on the 
candidate gene approach in which the investigated genes are known to be 
involved in radiation induced cellular responses. Alternatively, genome-
wide association studies could be performed in order to unravel the 
genetic background of normal tissue radiosensitivity. However, this 
approach still has a number of theoretical and practical restraints (82,83). 
It has been estimated that the human genome contains a total of 11 
million SNPs of which approximately 9 million are already available in 
public databases (84,85). Recent research, such as the HapMap project, 
has revealed that the genome contains regions with pronounced linkage 
disequilibrium in which the sequence variants are strongly associated 
with each other (75). It has been estimated that only 200.000 to 500.000 
well chosen representative SNPs, called tag SNPs, will be needed to cover 
most of the sequence variation in the genome (86). Despite recent 
advances in low-cost high-throughput genotyping, a genome-wide 
association study will still be extremely demanding, especially since 
sample sizes of at least 6.000 cases and 6.000 controls might be needed to 
ensure sufficient statistical power and stringency. Moreover, this 
approach has the disadvantage that it works less efficient in genomic 
regions with lower levels of linkage disequilibrium (82). Restricting the 
focus of genome-wide association studies to missense SNPs only would 
enable to reduce the number of SNPs needed to be genotyped to 
approximately 30.000-60.000 (83). However, this does not consider the 
possibility that non-coding regulatory variants, as one of the two TGFβ1 
SNPs which are quite consistently associated with fibrosis, might be 
involved in the response. As a consequence, the genome-wide approach 
seems less suited to study clinical radiosensitivity since, even in an 
international context, the high number of samples is unlikely to be 
collected. 
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4.4.2 Candidate gene approach 
A broad-based candidate gene approach may be the best way to proceed 
in order to identify genetic profiles associated with the risk of developing 
normal tissue complications after radiotherapy. One possible way to 
achieve this goal could consist of the analysis of for example a few 
hundred carefully selected candidate genes. Compared to the already 
performed investigations, this study design would result in a more 
extensive examination. The relatively limited number of genes would 
facilitate a meaningful statistical analysis within a realistic sample size. 
The selected genes could be screened for common SNPs, thereby 
considering the available knowledge about linkage, or the selected genes 
could be resequenced. As interactions between genetic alterations in 
different genes may complicate the attempts to unravel the genetics of 
normal tissue radiosensitivity, the analysis of interactions could be 
limited to genes that participate in the same pathway or to genes of 
proteins that are known to form complexes and interact physically with 
each other (87,88). Candidate genes could be selected according to the 
studied normal tissue endpoint. For instance, in the case of fibrosis, 
proteins that take part in the fibrogenesis processes could be valuable 
candidates. As fibrosis is the most important late normal tissue reaction 
after radiotherapy and as fibrosis is the underlying cause of the normal 
tissue reactions of the patients considered in the studies for this thesis, we 
will explore the fibrogenesis processes to identify possible new candidate 
genes. 
 
4.4.2.1 Radiation fibrogenesis 
The biologic effects of ionizing radiation begin with cell damage mainly 
due to the generated reactive oxygen and nitrogen species (ROS/RNS). 
These immediate biochemical events rapidly trigger a series of cellular 
processes including the production of a number of proinflammatory and 
profibrotic cytokines. The most important cytokine in this context is TGFβ 
which is directly activated by ionizing radiation through the dissociation 
of the latency associated peptide (LAP) from the active mature form of 
TGFβ. The perturbation of the homeostatic control of ROS and RNS also 
leads to the activation of TGFβ and directly interferes with the Smad 
signalling pathway. These extracellular events activate the TGFβ Smad 
signalling pathway, which in turn produces various transcriptional 
responses, all of which lead to increased extracellular matrix (ECM) and 
collagen deposition (4). The radiation induced vascular damage and 
uncontrolled tissue remodeling can lead to tissue hypoxia, which could 
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be one of the mechanisms perpetuating the fibrogenic response (figure 
4.2) (89). 
 
 
Figure 4.2. Key processes in radiation fibrogenesis. ROS/RNS: reactive oxygen and nitrogen 
species, LAP: latency associated protein, TGFβ: transforming growth factor β,  TGFβR:  
transforming growth factor β receptor, ECM: extracellular matrix. From Bentzen 2006. 
 
TGFβ exists in three isoforms (TGFβ1-3) of which TGFβ1 is predominant 
in human plasma. Active TGFβ binds, promoted by TGFβ receptor-3 
(TGFβR3), to pairs of two distinct transmembrane receptors TGFβR1 and 
TGFβR2, and induces transphosphorylation of TGFβR1 by TGFβR2. The 
consequently activated TGFβR1 phosphorylates receptor-activated Smads 
(R-Smads: Smad2 and Smad3) which form complexes with Smad4 
proteins. These complexes are translocated into the nucleus where they 
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regulate transcription of target genes through physical interaction and 
functional cooperation with transcription factors and co-activators or 
repressors. Two inhibitory Smads (Smad6 and Smad7) antagonize TGFβ 
signalling by preventing the activation of R-Smads. The ubiquitin ligases 
Smurf1 (Smad ubiquitination regulatory factor-1) and Smurf2 counteract 
TGFβ signalling by interacting with R-Smads and targeting them for 
degradation. Smurf1/2 can also degrade TGFβR1 through interacting 
with Smad6/7 (90). The signalling pathway is depicted in figure 4.3. 
 
 
Figure 4.3. Transforming growth factor β (TGFβ) Smad signalling pathway. R-Smad: 
receptor-activated Smad, Smurf: Smad ubiquitination regulatory factor, X: transcription 
factor, CBP: CREB binding protein. From Derynck et al. 2003. 
 
Although the Smad pathway is not the only TGFβ signalling pathway, it 
mediates most profibrotic activities (91). The involvement of TGFβ and 
Smad signalling proteins in radiation fibrosis has been showed by a 
number of studies. First of all, overexpression of  TGFβ was described in 
diverse experimental models of late radiation injury (68), and increased 
TGFβ1 plasma levels have been associated with radiation induced fibrosis 
in radiotherapy patients (92-96). In various rodent studies, it has been 
possible to reduce the development of fibrosis by TGFβ1 neutralizing 
antibodies (97), TGFβ1 antisense oligodeoxynucleotides (98) or 
recombinant TGFβ1 LAP (99). Furthermore, it was shown that disruption 
of the TGFβ signal transduction pathway, using transgenic mice deficient 
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in Smad3, prevents radiation induced fibrosis (100-102). Other rodent 
studies have established that the delivery of soluble TGFβR2 reduces the 
risk of radiation- or bleomycin induced lung injury (103,104). Finally, 
small molecule inhibitors which disrupt the TGFβ signalling pathway 
have been shown to diminish radiation induced fibrosis in mice (105). 
Apart from the observed effects of TGFβ and Smad signalling proteins on 
radiation fibrosis, it has recently been shown that loss of TGFβ signalling 
also disturbs the DNA damage response by reducing the ATM kinase 
activity (106,107). This indicates an additional role for TGFβ in regulating 
responses to genotoxic stress. Taken into account all previous indications, 
the genes coding for proteins involved in this signalling pathway could 
represent excellent candidate genes to study clinical radiosensitivity. 
Despite the fact that TGFβ is a key cytokine, the fibrotic process involves 
a complex network of interacting cytokines and growth factors including 
platelet-derived growth factor (PDGF), interleukin-1 (IL1), insulin-like 
growth factor-1 (IGF1), and tumor necrosis factor-alpha (TNFα) (68). One 
of the downstream effects of active TGFβ is that it upregulates a number 
of cytokines and growth factors, including IL1, epidermal growth factor 
(EGF), fibroblast growth factor (FGF), connective tissue growth factor 
(CTGF) and TGFβ itself (108). This mechanism of auto-induction 
contributes to the maintained level of TGFβ and to the continuous 
production of cytokines and growth factors. In many aspects, radiation 
fibrosis resembles normal wound healing which is regulated by a 
complex balance between profibrotic proteins such as TGFβ and CTGF on 
the one hand, and antifibrotic proteins such as TNFα and interferon-γ 
(IFNγ) on the other. TNFα and IFNγ are expressed during normal wound 
healing and both cytokines have been shown to inhibit the TGFβ 
signalling pathway by inducing expression of Smad7 (109). In addition, 
IFNγ was shown to decrease bleomycin induced lung fibrosis in mice, 
and TNFα was shown to be downregulated and CTGF to be upregulated 
in fibrotic bowel tissue from patients with late radiation enteritis (110-
112). Accordingly, the apparent dysfunctional homeostatic feedback 
control in radiation fibrogenesis also contributes to radiation fibrosis, and 
the genes encoding the involved cytokines and receptors could be 
appropriate candidate genes in a broad-based SNP approach. 
Radiation induced fibrosis is characterized by a progressive and excessive 
accumulation of ECM. Factors that play a role in remodeling of the ECM 
include structural ECM proteins, ECM degrading proteases (matrix 
metalloproteinases or MMPs) and inhibitors of ECM breakdown (tissue 
inhibitors of metalloproteinases or TIMPs) (113). Apart from TIMPs, 
degradation of the ECM is also inhibited by plasminogen activator 
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inhibitor-1 (PAI1) which prevents proteolytic activation of latent MMPs, 
as well as fibrin breakdown, by inhibiting the plasminogen-plasmin 
activating cascade (114-115). Many different cytokines have been 
identified that regulate the transcription of genes implicated in the 
regulation of the ECM. Of these, TGFβ has been shown to be a potent 
transcriptional activator of ECM regulators such as PAI1 and TIMP1, and 
ECM components such as collagen-1a2 (Col1a2) and ED-A fibronectin 
(ED-A FN) (116,117). Several studies provided direct evidence that PAI1 
plays a pivotal role in the pathogenesis of fibrosis: PAI1 knockout mice 
were protected from the development of bleomycin induced lung fibrosis 
and showed a rapid removal of fibrin-rich matrix compared to wild-type 
mice (118-120). Furthermore, upregulation of several collagen types, 
MMPs, TIMPs and PAI1 has been found in strictured ileum from patients 
with late radiation enteritis (112,121). Based on the above findings, it 
would be interesting to investigate if polymorphisms in ECM modulating 
genes alter the response to either radiation or TGFβ. 
Another key element in fibrogenesis is the homeostatic control of 
ROS/RNS in the cell which is altered by ionizing radiation and by 
hypoxia following tissue remodeling (64). Disturbed ROS/RNS levels 
initiate a number of cellular responses and activate TGFβ. MnSOD, 
CuZnSOD, gluthathione peroxidase and catalase are free radical 
scavenging enzymes that protect cells from oxidative stress. There is 
direct evidence that the SOD enzymes have an important role in fibrosis 
(122). Transfection with SOD2 has been shown to protect against late 
radiation induced lung damage in mice (123,124), and injection of 
MnSOD in pigs has been shown to reverse established radiation induced 
fibrosis (125). In addition, it has been demonstrated that bleomycin 
induced lung fibrosis in mice could be reduced by inhibiting inducible 
nitric oxide synthase (126). Consequently, analysis of genes coding for 
anti-oxidant enzymes or nitric oxide synthases could also contribute to 
the identification of the genetic profile associated with fibrosis. 
The renin-angiotensin system (RAS) and the Rho/ROCK pathway have 
both been shown to be involved in radiation induced fibrosis. A number 
of animal studies reported that RAS blocking reduces the level of damage 
after irradiation (127-131). Moreover, angiotensin II, which is the key 
protein in the RAS, is a potent proinflammatory agent, generates ROS, 
and has the ability to upregulate TGFβ and matrix protein synthesis, and 
to alter the regulation of ECM degradation through upregulation of PAI1 
and MMP2 (132-135). The involvement of the Rho/ROCK pathway in 
radiation induced fibrosis is based on the observation that expression of 
genes coding for proteins of this pathway is enhanced in tissues derived 
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from radiation enteritis patients, and on the finding that inhibition of the 
pathway results in decreased CTGF, TGFβ1 and Col1a2 expression levels 
in cells derived from fibrotic bowel tissue (112,136,137). 
The above overview indicates a high number of genes and pathways 
which can be studied in order to unravel the genetic background of 
radiation induced fibrosis. Although much of the emphasis has been 
placed on tissue remodeling as a crucial element in radiation fibrosis, it 
should be mentioned that the initial cellular processing of damage 
remains relevant as reduced initial cell killing will also reduce the cellular 
and tissue damage response. 
4.5 Conclusions 
In this thesis, the value of the cytogenetic G2 assay in predicting late 
clinical radiosensitivity after pelvic radiotherapy was assessed. Although 
a positive association between mean in vitro and clinical radiosensitivity 
was found, the G2 assay lacked sensitivity to identify high-risk patients at 
the individual level. This shortcoming leads to the conclusion that the G2 
assay has limited use in the clinical screening of patients for increased 
radiosensitivity. 
The main aim of this thesis was to investigate the association between 
low penetrant genetic variations and late clinical radiosensitivity. The 
studied genes included the XRCC1, XRCC3, XRCC5 and OGG1 DNA 
repair genes, and the cytokine TGFβ1. Present work showed that the 
XRCC3 IVS5-14 polymorphism is significantly associated with the risk of 
developing late radiation injury after pelvic radiotherapy. Although 
individual XRCC1 SNPs could not be associated with the risk of 
developing radiation complications, clinical radiosensitivity seems to be 
significantly associated with a combination of different SNPs in XRCC1 
and XRCC3. Moreover, despite the fact that no significant association was 
found between the repeat length at any of the microsatellites in XRCC1, 
XRCC3 or XRCC5 and the incidence of late radiotherapy complications, 
the possible involvement of small and large XRCC1 repeats could not be 
completely excluded. Finally, it was shown that the risk of fibrosis related 
late toxicity may be modulated by the TGFβ1 -509C>T and Leu10Pro 
SNPs. The fact that these associations have also been reported by other 
independent studies, supports the possible involvement of these SNPs in 
late radiotherapy toxicity. 
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To get to a comprehensive understanding of the genetic basis underlying 
clinical normal tissue radiosensitivity and in order to use genotype data 
for clinical radiosensitivity screening, large scale investigations using 
high-throughput technologies are needed. Therefore, patients should be 
subjected to a long follow-up period in which all normal tissue endpoints 
are assessed. Moreover, all relevant dosimetric parameters should be 
taken into account. In addition, in vitro studies illustrating genotype-
phenotype correlations are necessary to support the scientific background 
of the associations between genetic variations and clinical 
radiosensitivity. Currently, several initiatives are taken to establish bio-
banks and databases needed  for this purpose. 
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